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Neurotransmission is essential for neuronal communication. At the presynapse, 
synaptic vesicles (SVs) undergo exocytosis to release neurotransmitter in response to 
incoming action potentials, and endocytosis to maintain the supply of SVs needed for 
further rounds of exocytosis. A key event during SV endocytosis is the efficient 
sorting and localisation of SV proteins at the plasma membrane. This ensures that 
nascent SVs that are formed have the correct molecular composition to participate in 
subsequent exocytic events. The sorting of SV proteins at the plasma membrane is 
usually facilitated by adaptor proteins (e.g. AP-2) which recognise binding motifs 
present on key SV proteins and facilitate their internalisation during endocytosis. In 
addition to this, certain SV proteins possess the ability to chaperone each other as 
part of an endocytic transport complex throughout the SV recycling process. In 
conjunction with AP-2-facilitated sorting, the transport of complexed SV proteins 
during endocytosis provides further mechanistic insight into how SVs are generated 
with consistent high fidelity for functional viability.  
Using pHluorins as a tool to visualise SV protein trafficking in hippocampal cultures, 
the relationship between two key SV proteins, synaptic vesicle protein 2A (SV2A) 
and synaptotagmin I (SYT1), was investigated. SYT1 predominantly acts as the Ca2+ 
sensor for fast synchronous release at the presynapse, whilst the exact function of 
SV2A remains unknown to this day. In this study, the ablation of the AP-2 binding 
site in SV2A (Y46A) resulted in increased SYT1 surface expression and accelerated 
SYT1 retrieval compared to WT SV2A. No additive defects were observed when a 
second point mutation (T84A) was introduced to SV2A that disrupts the 
phosphorylation-dependent interaction between SV2A and SYT1, thus confirming 
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that SYT1 localisation and retrieval is dependent on normal SV2A retrieval by AP-2. 
The hypothesis that disruption of the SV2A-SYT1 interaction may provide an 
underlying mechanism for motor onset seizures in epilepsy was also investigated. An 
epilepsy-related mutation (R383Q) in SV2A also resulted in increased SYT1 surface 
expression and accelerated SYT1 retrieval mirroring the defects caused by the Y46A 
mutation. Introduction of Y46A or T84A mutation into SV2A R383Q resulted in no 
additive defects compared to the single mutant, suggesting that the observed defects 
in SYT1 localisation and retrieval kinetics in the epilepsy-related mutant may be 
caused by the ablation of normal SV2A internalisation. GST pulldown assays, mass 
spectrometry and western blotting data indicate that presence of the mutation disrupts 
normal binding of the SV2A cytosolic loop with actin, tubulin and certain subunits of 
V-ATPase. Finally, a link between SV2A-dependent presynaptic dysfunction and 
epilepsy was examined through studies utilising the anti-epileptic drug, levetiracetam 
(LEV). SV2A contains a binding site for LEV, suggesting that it may act as a carrier 
for the drug into the presynapse. Hippocampal neuronal cultures were treated with 
LEV at various concentrations in the presence of specific patterns of neuronal 
activity. No observed effects of the drug on synaptophysin, vesicular glutamate 
transporter 1 (VGLUT1) and SYT1 recycling were observed, suggesting that LEV is 
unlikely to function as a modulator of excitatory presynaptic activity or by 
influencing SV2A function. 
In conclusion, this work demonstrates that SV2A is essential for accurate SYT1 
trafficking and a link has been established between defective SV2A internalisation 
and subsequent downstream effects on SYT1 localisation and retrieval during SV 
recycling.   




Neurotransmission is the process by which chemicals are released by one nerve cell 
and accepted by another nerve cell to allow nerve impulses to travel through the 
body. Neurotransmission is required for different nerve cells in the body to 
communicate with each other. Inside the chemical-releasing cell, known as the 
presynaptic cell, the chemicals are packed into small fatty packages known as 
synaptic vesicles. When a neural impulse arrives at the presynaptic cell, it triggers a 
response that causes these vesicles to fuse to the cell membrane and release the 
chemicals. When all vesicles are used up in fusion, it results in a shortage of 
available vesicles for fusion when the next neural impulse arrives. In order to address 
this, the vesicles, as well as its related biological proteins, are recycled within the 
nerve cell. This recycling of vesicles and its proteins is crucial for maintaining neural 
activity. A key event during the recycling process is the efficient sorting of vesicle-
associated proteins at the cell membrane by biological machinery. This ensures that 
newly formed vesicles contain the correct number of different proteins to participate 
in the next cycle of fusion. The sorting process at the cell membrane is usually done 
by a specific family of adaptor proteins; however, this is not always the case. Certain 
vesicle-associated proteins possess the ability to sort and chaperone each other, as 
part of a unit, during the recycling process. This mutual aid between proteins during 
the sorting process helps to ensure that SVs will have the right composition to 
maintain neurotransmission. Therefore, when one of the proteins fails to sort 
accurately, it may lead to resulting defects in the sorting of the partner protein. 
The aim of this thesis is to characterise such a relationship between two specific 
vesicle proteins, synaptic vesicle protein 2A (SV2A) and synaptotagmin 1 (SYT1), 
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during synaptic vesicle recycling and establish a link to the onset of epilepsy which 
may arise from disruption to this relationship. A failure of normal SV2A function is 
thought to result in defects in the sorting and recycling of SYT1 from the cell 
membrane. In order to investigate this, the proteins were visualised in live mice 
nerve cells by genetically fusing them to a fluorescent protein. 
In this study, normal SV2A protein was subjected to a single change (amino acid 
tyrosine to alanine at position 46, Y46A) in the protein sequence that results in 
disruption of its recycling at nerve terminals. It is reported here that this change 
resulted in an increased amount of SYT1 located at the cell membrane and 
acceleration in the rate of SYT1 retrieval during vesicle recycling. This suggests that 
defects in SYT1 sorting and recycling defects could be attributed to the initial 
disruption in SV2A recycling. Previous studies have identified another key protein 
sequence change (arginine to glutamine at position 383, R383Q) which results in the 
onset of epilepsy and developmental difficulties. However, the molecular pathways 
underlying the onset of epilepsy are yet to be determined. It is hypothesised that the 
disruption of the previously described SV2A-SYT1 relationship during vesicle 
recycling may provide an underlying cause for the onset of epilepsy that was initially 
found in a human patient. In this study, the presence of the R383Q change in SV2A 
also resulted in an increased amount of SYT1 located at the cell membrane and 
acceleration in the rate of SYT1 retrieval during SV recycling. These results mirror 
the observations previously described with the Y46A change, and presents a strong 
indication that this particular form of epilepsy may be caused by dysfunction of 
SV2A recycling. Therefore, it is proposed that the disruption of normal SV2A 
function represents a major cause for the observed dysfunction in SYT1 recycling. In 
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order to determine further the mechanistic causes of these recycling defects, 
biochemical experiments were designed to investigate if interactions between SV2A 
and other unknown vesicle proteins were altered when the R383Q change was 
present. It is reported that SV2A interactions with other proteins such actin, tubulin 
and V-ATPase was altered when the R383Q change was present. 
Finally, the link between normal function of SV2A at the presynapse and epilepsy 
was investigated through use of the anti-epileptic drug levetiracetam (LEV). LEV 
has been a popular drug of choice for the treatment of partial onset epilepsy for many 
years, but the way in which it works has never been fully understood. Previous 
studies have indicated that SV2A is a carrier for the drug into the nervous system, 
however direct evidence of a therapeutic function mediated by SV2A has yet to be 
presented. In this study, the effects of various concentrations of LEV on general SV 
recycling at the presynapse were investigated. These results show that there was no 
obvious LEV-mediated effect at the presynaptic nervous system, indicating that the 
drug is unlikely to function by regulating the relationship between SV2A and SYT1 
during SV recycling. 
In conclusion, this work has established a link between abnormal SV2A retrieval and 
its resulting effects on the localisation of SYT1 at the cell surface and its retrieval 
during SV recycling. 
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1.1 – General Introduction to Neurotransmission 
The human brain is a highly flexible neural machine that is able to discriminate a 
large variety of information and stimuli from the environment. The continuous 
stream of information is organised by the brain into perceptions and memory, and 
these perceptions trigger appropriate behavioural responses in living things for 
survival and function.  Different parts of the brain are responsible for the different 
physiological functions: 1) the cerebral cortex is the largest part of the brain and is 
responsible for higher functions like interpreting touch, vision and hearing, speech, 
reasoning, emotions, learning, and fine control of movement; 2) the cerebellum 
coordinates muscle movements and plays a role in maintaining posture and balance; 
3) the brainstem is responsible for the maintenance of homeostasis functions such as 
breathing, body temperature, heart rate sleep cycles and digestion. Deeper structures 
such as hypothalamus, thalamus and hippocampus play important roles in behaviour 
control, hormonal secretion, pain sensation and long/short-term memory (Kandel and 
Hudspeth, 2012). 
The brain is a large network of interconnected nerve cells (or neurones) which share 
the same basic architecture. Neurones in the network communicate with each other 
through an intricate process known as synaptic transmission. There are two basic 
forms of synaptic transmission: electrical synaptic transmission and chemical 
synaptic transmission. Electrical synaptic transmission is rapid and is used primarily 
to send simple depolarising signals. Electrical synaptic transmission tends not to 
produce inhibitory action or make long-lasting changes in the electrical properties of 
postsynaptic cells. In contrast, chemical synapses are capable of more variable 
signalling and can therefore produce complex neuronal behaviours. Chemical 
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synapses can mediate either excitatory or inhibitory actions in postsynaptic cells and 
produce electrical changes in the postsynaptic cell that last from milliseconds to 
many minutes.  
At electrical synapses, electrical currents flow between pre- and postsynaptic 
neurones through gap junction channels, which are specialised protein structures that 
provide a low-resistance pathway for conducting the flow of ionic current from the 
presynaptic to the postsynaptic neurone. Electrical current flowing from a 
presynaptic neurone into a postsynaptic neurone deposits a positive charge on the 
inside of the membrane of the postsynaptic neurone and depolarizes the membrane. 
Excess current then flows out through resting voltage-gated ion channels in the 
postsynaptic neuronal membrane. If the depolarization exceeds threshold, voltage-
gated ion channels in the postsynaptic neurone opens and generates an action 
potential (see chapter 1.1). Thus, these voltage-gated ion channels not only have to 
depolarise the presynaptic cell above the threshold for an action potential, they must 
also generate sufficient ionic current to produce a change in potential in the 
postsynaptic cell.  
At chemical synapses, there is no direct low-resistance pathway between the pre- and 
postsynaptic neurones. Instead, the arrival of an action potential in the presynaptic 
neurone initiates the release of chemical neurotransmitter molecules, which diffuse 
across the synaptic cleft to interact with receptors on the membrane of the 
postsynaptic neurone. Receptor activation causes either depolarisation of 
hyperpolarisation of the cell membrane in the postsynaptic neurone, which acts to 
propagate further the action potential though the body or stop the propagation 
entirely (Siegelbaum and Kandel, 2012). 
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This thesis will specifically examine the process of synaptic transmission at chemical 
synapses. It will aim to provide a background on the morphology and function of 
neurones and its presynaptic features, as well as how these features play a key role in 
maintaining viable, long-term neurotransmission.  
 
1.2 – Structure and Morphology of a Neurone 
A typical neurone generally has four morphologically defined regions, namely the 
cell body, dendrites, axons and the synaptic terminals (Figure 1.2). Each of these 
regions plays a distinct role in the generation and reception of nerve signals by the 
neurone, and thus has an overarching influence on neuronal communication. 
The cell body (also known as soma) is the metabolic centre of the cell and contains 
the nucleus and endoplasmic reticulum. The nucleus stores the genes of the cell and 
the endoplasmic reticulum is the primary location of cellular protein synthesis. 
Newly synthesised proteins are transported throughout the cell by anterograde 
transport systems such as motor proteins. The cell body gives rise to two kinds of 
neuronal structures: dendrites and axons. Dendrites branch out from the cell body in 
a tree-like fashion and are responsible for receiving incoming electrical signals from 
other neurones. In contrast, axons extend away from the cell body in a tubular 
fashion along distances that may range from 0.1 mm to > 2 m (Kandel et al., 2012). 
Axons are responsible for conducting outgoing electrical and chemical signals to 
other neurones.  
The electrical signals that form the basis of neuronal communication are termed 
action potentials. Action potentials constitute the signals by which the brain receives, 
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analyses, and conveys information about the environment. These signals are highly 
regulated throughout the nervous system, even though they may be initiated by a 
great variety of stimuli such as light, mechanical contact, odours and tastes. The 
information conveyed by an action potential is determined not by the form of the 
signal but by the pathway in which the signal travels in the brain. The brain analyses 
and interprets the patterns of incoming action potentials to create our everyday 
sensations of sight, touch, taste, smell, and sound. In order to increase the speed by 
which action potentials are conducted, neuronal axons are typically wrapped in a 
fatty, insulating sheath of myelin. This myelin sheath is interrupted by regions of 
unprotected axon, known as the nodes of Ranvier, to allow regeneration of the action 
potential along the cell. 
At the terminus of the axon, the neurone splits into fine branches that form sites of 
connection with other neurones. The presynaptic neurone transmits signals from the 
presynaptic nerve terminals in the form of chemical molecules termed as 
neurotransmitters. Neurotransmitter molecules diffuse across the space between the 
presynaptic neurone and the postsynaptic neurone known as the synaptic cleft, and 
bind onto specific neurotransmitter receptors on the postsynaptic nerve terminal. This 
initiates a biochemical process to propagate the neuronal signal. 
  




Figure 1.2: Morphology of a Typical Neurone (Kandel et al., 2012). Most neurons in the vertebrate 
nervous system have several main features in common. The cell body (soma) contains the nucleus 
and endoplasmic reticulum and gives rise to two types of cell processes, axons and dendrites. 
Dendrites, both apical and basal, are responsible for receiving incoming electrical signals from other 
neurones. Axons can vary greatly in length (from 0.1 mm to > 2 m) and are responsible for 
conducting electrical signals to other neurones. Most axons in the central nervous system are very 
thin (between 0.2 and 20 μm in diameter) compared with the diameter of the cell body (50 μm or 
more). Branches of the axon of one neurone (the presynaptic neurone) transmit signals to another 
neuron (the postsynaptic neurone) at a site called the synapse. The branches of a single axon may 
form synapses with thousands of other neurones. 
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1.2.1 – Structure and Function of a Neuronal Pre/Postsynaptic Terminal 
A presynaptic terminal consists of around 200 - 300 synaptic vesicles (SVs), which 
form different vesicle pools within the synapse (See chapter 1.2). Some synaptic 
vesicles are clustered at specialised regions of the presynaptic membrane called 
active zones, and these are the primary sites of neurotransmitter release (Figure 
1.2.1). The plasma membrane of a presynaptic terminal consists of SV-related 
proteins as well voltage-gated Ca2+ channels, which open to allow Ca2+ to enter the 
presynaptic terminal resulting from an incoming action potential. The rise in 
intracellular Ca2+ concentration triggers a biochemical reaction that leads to fusion of 
SVs with the presynaptic membrane and release of neurotransmitter into the synaptic 
cleft. This process is termed SV exocytosis. Membrane is then retrieved and 
reformed back into SVs in a process termed SV endocytosis. The processes of 
exocytosis and endocytosis will be discussed in more detail in later chapters. SVs 
contain thousands of neurotransmitter molecules, and the identity of the 
neurotransmitter depends on the type of neurone and its role in neural network. A 
number of small molecules can act as a neurotransmitter in central synapses. 
Acetylcholine is present at all neuromuscular junction synapses, whilst classical 
amino acid derivatives such as glutamate (>50% of synapses) γ-aminobutyric acid 
(25-40% of synapses) and glycine. Apart from classical amino acid derivatives, a 
small percentage of synapses also use monoamine derivatives (e.g. dopamine, 
norepinephrine, epinephrine, serotonin, histamine and melatonin) as 
neurotransmitters. 
At the postsynaptic terminal, receptor proteins specific to the neurotransmitter 
released are embedded into surface of the plasma membrane.  Activation of these 
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receptors leads to the opening of gated ion channels, which changes the membrane 
conductance and membrane potential of the postsynaptic neurone and either allows 
or inhibits action potential propagation depending on whether the neurone is 
excitatory or inhibitory. Post-synaptic receptors can gate ligand channels either 
directly or indirectly. Receptors that undergo a conformation change and open the 
corresponding ion channels directly are known as ionotropic receptors e.g. 
acetylcholine receptors at the neuromuscular junction. Receptors that gate ion 
channels indirectly usually function by producing a second chemical messenger such 
as cyclic AMP or diacylglycerol upon activation and are known as metabotropic 
receptors. These second messenger molecules usually activate protein kinases that 
will phosphorylate ion channels, leading to their opening or closing (Siegelbaum and 
Kandel, 2012). 
  




Figure 1.2.1: Fine Structural Morphology of a Synaptic Terminal (Heuser and Reese, 1973). This 
electron micrograph of a frog neuromuscular junction synapse shows the presence of synaptic 
vesicles (SVs) as small round bodies and mitochondria as the larger, darker bodies. Clustering of SVs 
at the active zones along the presynaptic membrane can also be observed (black arrows). Active 
zones are specialised region that are thought to be sites for the docking and fusion of SVs. Beyond 
the presynaptic terminal, the synaptic cleft separating the pre- and postsynaptic cell membranes can 
be observed as a white extracellular space. 
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1.2.2 – Synaptic Vesicle Pools in Central Synapses 
SVs at the presynaptic terminal morphologically exist as a cluster surrounding the 
plasma membrane, but have functional differences that allow them to be framed into 
different pools based on their relevance to difference aspects of neurotransmitter 
release. The current opinion in the field is that SVs exist in three different canonical 
pools that are differentiated by the kinetics and probability of SV release: 1) the 
readily releasable pool (RRP); 2) the reserve pool (RP) and 3) the resting pool (RtP). 
The RRP and the RP together make up the total recycling pool (TRP) of vesicles that 
are mobilised upon an action potential stimulus. The mean size of the TRP directly 
correlates to synaptic release probability, and therefore many studies have tried to 
provide an accurate estimate of its size in central synapses. Differences in measuring 
approaches, sample preparation and stimulation parameters, however, have led to 
discrepancies between studies. Estimates of the TRP size may range from 15-20% 
(Marra et al., 2012) to about 50-60% (Ikeda and Bekkers, 2009) of the total vesicle 
pool at a synapse. 
The RRP consists of 5-10% of total SVs on average at a synapse (Dobrunz and 
Stevens, 1997). SVs in the RRP are docked to the active zone and are primed for 
release even at low-frequency stimulation. Depletion of the RRP can be achieved by 
1-2 s of electrical stimulation at 10-40 Hz or application of a hypertonic solution for 
1 s (Stevens and Williams, 2007). Replenishment of the RRP may be mediated by 
transitioning SVs from the RP, or by both clathrin-dependent (Cheung et al., 2010) 
and clathrin-independent modes of SV endocytosis (Watanabe et al., 2014) (see 
chapter 1.5 for detailed treatment of various endocytosis modes). 
Electrophysiological experiments in rat calyx of Held synapses have demonstrated 
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that replenishment of the RRP is regulated by Ca2+ and calmodulin, and takes place 
on a timescale of around 5-10 s (Stevens and Tsujimoto, 1995, Sakaba and Neher, 
2001). 
The RP (reserve pool) is a small body of SVs that are primed to replenish the RRP 
upon its depletion during high intensity stimulation. This means that there are extra 
transitions for the SVs to take to become fusion ready, and thus RP to RRP 
transitions often limit the rate of neurotransmitter release during persistent activity 
(Alabi and Tsien, 2012). The mean size of the RP is harder to estimate accurately, 
however it is typically approximately three times the size of the RRP in central 
synapses (Murthy and Stevens, 1999). Replenishment of the RP is Ca2+-dependent 
and takes places on a timescale of about 10 s, however in the presence of high-
frequency stimulation, the refilling rate doubles with 1-2 sec of the onset of the 
stimulus (Stevens and Wesseling, 1998). FM labelling studies in central synapses 
have demonstrated that activity-dependent bulk endocytosis, which is a specific 
mode of clathrin-independent endocytosis, selectively replenishes the reserve pool of 
SVs as compared to other modes that replenishes the RRP (Cheung et al., 2010). 
Finally, the RtP (resting pool) of SVs is defined as the subset of SVs that remain 
unreleased in even during saturation of SV turnover under extended stimulation 
(Harata et al., 2001, Li et al., 2005). Both pHluorin imaging (Fernandez-Alfonso and 
Ryan, 2008) and fluorescence dye photoconversion (Harata et al., 2001)assays have 
indicated that the mean RtP size is around 50% of total SVs at central synapses. 
Given that there are only around 200-300 SVs present at a nerve terminal, the idea 
around half of these SVs do not participate in neurotransmitter release remains 
difficult to explain. Fluorescence labelling experiments in mammalian central 
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synapses have provided evidence that SVs in the RtP participate in spontaneous 
neurotransmitter release (Sara et al., 2005, Fredj and Burrone, 2009) (see 1.2.1), 
however similar studies in various NMJ model systems have disputed this (Wilhelm 
et al., 2010). RtP SVs have also been suggested to act as a buffer for soluble 
accessory proteins involved in SV recycling, preventing loss of protein into the axon 
by acting as a depository for non-functioning SVs prior to degradation (Denker et al., 
2011). 
More recently, a novel pool classification has emerged which is functionally and 
organisationally distinct from the previous three canonical fields. The idea that each 
presynaptic terminal has its own supply and pools of SVs has now been challenged 
as increasing evidence emerges of a SV ‘superpool’ that is dynamically shared 
between multiple presynaptic terminals from fluorescence and electron microscopy 
studies (Darcy et al., 2006, Staras et al., 2010, Herzog et al., 2011).  It has been 
postulated that the superpool may be responsible for preserving presynaptic identity 
by acting as extrasynaptic resource to support changes to the properties of a host 
terminal (Staras and Branco, 2010). Several key synaptic proteins such as synapsin 
(Orenbuch et al., 2012), and α-synuclein (Scott and Roy, 2012) have been identified 
as regulators for the superpool, indicating that there may be possible connections 
between inter-synapse SV trafficking and disease-related synaptic dysfunction. 
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1.2.3 – Morphology of a Typical Synaptic Vesicle 
The typical synaptic vesicle has a diameter of about 40 nm, and they can be 
considered the basic units of membrane traffic. SV membrane is predominantly 
composed of cholesterol (40 mol %), along with a mixture of phospholipids such as 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, 
phosphatidylinositol (Takamori et al., 2006). Transport of the SV, recognition of 
active site, docking and fusion process each involve the sequential and ordered 
recruitment of specific protein complexes from the cytoplasm. The proteins 
constituents embedded in the SV membrane must therefore play a key role in the 
association of these complexes, allowing the complex to fulfil its task and then 
facilitate disassembly of the protein complex upon task completion. There have been 
a couple of elegant studies directed at identifying and quantifying the range of 
proteins on an SV. A proteomics study led by Takamori et. al. using enhanced mass 
spectrometry has identified around 80 different integral membrane proteins including 
trafficking proteins, transporter and channel proteins, cytoskeletal proteins, cell-
surface and signalling proteins (Figure 1.2.3) (Takamori et al., 2006). A 
combinatorial approach using quantitative immunoblotting, mass spectrometry and 
super-resolution microscopy has also shed light on SV protein copy numbers and 
protein localisation in synaptosomes (Wilhelm et al., 2014). For the sake of brevity, 
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1.2.3.1 – Soluble NSF Attachment Protein Receptor (SNARE) Proteins 
The SNARE proteins are a group of proteins consisting of synaptobrevin/vesicle-
associated membrane protein II (SYB2/VAMP2), syntaxin-1 and synaptosomal-
associated protein-25 kDa (SNAP-25) (Südhof and Rothman, 2009). SNARE 
proteins are the key molecular machinery responsible for the docking, priming and 
fusion of SVs during exocytosis. SYB2 is a vesicle-associated SNARE (v-SNARE) 
with approximately 70 copies per SV (Takamori et al., 2006, Wilhelm et al., 2014). 
Syntaxin-1 and SNAP-25 are target membrane-associated SNAREs (t-SNAREs) 
with approximately 6 and 2 copies per SV respectively. This is an unusually low 
number since they are plasma membrane proteins, which suggests that the sorting of 
these proteins must be efficiently regulated to maintain SV fidelity for 
neurotransmission.  SNARE proteins contain a stretch of amino acids called a 
SNARE motif. SYB2 and syntaxin-1 each contain one SNARE motif preceding the 
C-terminal transmembrane region, whereas SNAP-25 contains two SNARE motifs. 
Prior to exocytosis, the four SNARE motifs assemble into a tight SNARE complex 
that bridges both the vesicle and target cell membranes (Söllner et al., 1993). A more 
detailed treatment of the mechanisms underlying exocytosis is given in chapter 1.3. 
 
1.2.3.2 – Synaptophysin (SYP) 
Synaptophysin (SYP) is a 38-kDa glycoprotein containing four transmembrane 
domains and two intra-vesicular loops. It is the most abundant integral membrane 
protein in SVs by molecular weight, with approximately 30 copies per SV (Takamori 
et al., 2006, Wilhelm et al., 2014). The exact role of SYP in the SV cycle remains to 
be elucidated. Protein cross-linking experiments have shown that isolated pure SYP 
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has a tendency to form homo-oligomers with physophilin that contain unstable 
intramolecular disulphide bonds (Thomas and Betz, 1990). As a result, SYP was 
suggested to play a role in the formation of a putative fusion pore during SV 
exocytosis. More recently, SYP has been elegantly shown to play a key role in the 
trafficking of SYB2 in the SV cycle. Protein cross-linking experiments have shown 
that SYP and SYB2 forms a complex with each other, mediated by the 
transmembrane regions of both proteins (Calakos and Scheller, 1994, Edelmann et 
al., 1995, Washbourne et al., 1995). Immunofluorescence studies in primary neuronal 
cultures have shown that the overexpression of SYB2 resulted in increased 
expression along the axon of a neurone and mislocalisation of SYB2 at a terminal 
(Pennuto et al., 2003). This expression defect could be rescued by the co-expression 
of SYP in neurones. In agreement with this finding, genetic ablation of SYP in 
mouse hippocampal cultures demonstrate reduced expression of endogenous SYB2 
in nerve terminals as well as stranding of the genetic reporter SYB2-pHluorin on 
their plasma membrane (Gordon et al., 2011). Critically, the retrieval of SYB2-
pHluorin from the plasma membrane was greatly retarded during SV endocytosis in 
the same knockout cultures. This defect was again fully rescued by the co-expression 
of wild-type SYP (Gordon et al., 2011). Photoactivated localisation microscopy 
(PALM) studies have also shown that SYP plays a role in the release site clearance 
of SYB2 at the active zone (Rajappa et al., 2016). The intricacies between the 
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1.2.3.3 – Synaptic Vesicle Protein 2 (SV2) 
Synaptic vesicle protein 2 (SV2) is a glycoprotein which is present in the secretory 
vesicles of neural and endocrine cells, with approximately 2-12 copies per SV 
(Takamori et al., 2006, Wilhelm et al., 2014). SV2 consists of 12 transmembrane 
domains and cytoplasmic N- and C- terminus regions. The exact role of SV2A in SV 
recycling and neurotransmission remains unclear to this day, and there have been 
many possible roles for SV2A discussed in the literature. A detailed review of these 
possible roles is covered in chapter 3. 
 
1.2.3.4 – Synaptotagmin I (SYT1) 
Synaptotagmin I (SYT1) is a member of a family of proteins that are defined by a 
single transmembrane domain that is joined onto two Ca2+-binding domains (C2A 
and C2B) through a linker region. It is present on an SV with approximately 15-20 
copies per SV (Takamori et al., 2006, Wilhelm et al., 2014). SYT1 has a primary role 
in facilitating Ca2+-dependent interactions at the presynapse, in particular as the Ca2+ 
sensor in the triggering of SV fusion during exocytosis. A detailed review of these 
possible roles is covered in chapter 3. 
 
1.2.3.5 – Vesicular Glutamate Transporter 1 (VGLUT1) 
Vesicle glutamate transporter 1 (VGLUT1) is a twelve-transmembrane domain 
protein with intracellular N- and C-terminal domain regions, and is present on an SV 
with approximately 10 copies per excitatory SV (Wilhelm et al., 2014, Takamori et 
al., 2006). Biochemical studies on Xenopus oocytes and human pancreatic tumour 
   
17 
 
cells have shown that VGLUT1 is exclusively present on SVs and function as the 
vesicular glutamate transporter for excitatory synapses (Bellocchio et al., 2000, 
Takamori et al., 2000). In the mammalian brain, VGLUT1 is expressed predominant 
in the neocortex, striatum, hippocampus, thalamus and cerebellum (Liguz-Lecznar 
and Skangiel-Kramska, 2007). 
 
1.2.3.6 – Vesicular ATPase (VTP-ase) 
Vacuolar-type H+-ATPase (V-ATPase) is a highly conserved enzyme that enables 
proton transport across the cellular plasma membrane to produce a proton gradient. 
The energy required to produce this gradient derives from the hydrolysis of 
adenosine triphosphate (ATP) (Nelson and Harvey, 1999). V-ATPases are located on 
a SV with approximately 2 copies per SV (Takamori et al., 2006, Wilhelm et al., 
2014), and their primary role is the re-acidification of a SV to maintain the luminal 
pH of 5.5 for a functional SV. In experiments using hippocampal neurones 
transfected with pHluorin reporters, it was shown that V-ATPase activity allows SVs 
to re-acidify with first-order kinetics with a tau of approximately 5-15 s after 
compensatory endocytosis (Atluri and Ryan, 2006, Egashira et al., 2015). 
 
1.2.3.7 – RAB 
RAB proteins are a superfamily of small GTP-binding proteins that have been 
suggested to mediate the recognition of interacting components of the membrane 
prior to membrane fusion (Bourne, 1988). Proteomic analysis has identified more 
than 30 distinct RAB proteins to be present in highly purified SVs, however RAB3A 
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in particular was found to be present in up to 10 copies per SV (Takamori et al., 
2006, Wilhelm et al., 2014). The exact function for RAB3A at a nerve terminal has 
not been defined; however, it has been suggested to play a role in the targeting, 
docking and fusion of SVs at the active zone of the plasma membrane. Recent 
functional studies with RAB3A have revealed a binding interaction with the C2A 
domain of SYT1 during immunoprecipitation, giving credence to the argument of 
RAB3A’s role in targeting and fusion of SVs at the membrane surface (Tang et al., 
2017). Lysosomal studies in HeLa cells have shown that silencing of RAB3A 
expression changes the intracellular localisation of lysosomes and blocks repair of 
the plasma membrane (Encarnação et al., 2016), suggesting that RAB3A may play an 
important role in maintaining the fidelity of SV membranes after various cycles of 
exocytosis and endocytosis. A summary of key synaptic proteins and their features is 
given in a table below (Table 1.2.3). 
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Table 1.2.3: Summary of key SV proteins and their functions. The table above summarises a 
selection of key SV proteins, their copy numbers (per SV) and their key features at the presynaptic 
terminal. 
 
SV Protein Copy Number (per SV) Key Function 
SNAP-25 2 t-SNARE protein 
Syntaxin-1 6 t-SNARE protein 
Synaptophysin 30 SYB2 iTRAP 
Synaptobrevin 2 70 v-SNARE protein 
SV2A 2-12 SYT1 iTRAP 
Synaptotagmin 1 20 Ca2+ sensor for 
synchronous release 
V-GLUT1 10 Transporter for glutamate 
loading into SVs 
V-ATPase 2 Vesicular proton pump to 
maintain intravesicular pH 
RAB(s) 10 Targeting of SVs to active 
zone 




Figure 1.2.3: Molecular Model of a Typical Synaptic Vesicle(Takamori et al., 2006). The figure shows 
the morphology of a typical synaptic vesicle (SV) and its various key SV proteins. The most abundant 
protein is synaptobrevin II (SYB2), with approximately 70 copies per SV. SYB2 plays an integral role in 
SV exocytosis as one of the SNARE proteins alongside syntaxin and SNAP-25. The next most 
abundant protein is synaptophysin (SYP), with approximately 30 copies per SV. SYP plays a key role in 
the localisation of SYB2 to nerve terminals as well as the retrieval of SYB2 during SV endocytosis. 
Synaptotagmin I (SYT1) is the Ca2+ sensor for activity-induced SV exocytosis and is present on the SV 
with approximately 15 copies per SV. Vesicle glutamate transporter protein 1 (VGLUT1) and RAB3A 
are present with approximately 10 copies per SV, and have roles in loading of neurotransmitter and 
targeting of SVs to the active zone respectively. 
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1.3 – Synaptic Vesicle Exocytosis: Fusion of Vesicles and Release of 
Neurotransmitter 
On average, around 20-50% of SVs are stored in the TRP of the nerve terminal under 
resting conditions. When there is intense synaptic activity occurring in the neurone, 
SVs in the TRP are translocated to the active zone (see chapter 1.1). At the active 
zone, the recruitment and assembly of SNARE proteins into a complex is crucial for 
the docking and priming of SVs (Figure 1.3). Docked SVs at the plasma membrane 
collectively form the RRP. These SVs subsequently fuse and release neurotransmitter 
(a process termed exocytosis) upon activity-dependent calcium influx.  
Neurotransmitter release mediated by Ca2+ -induced action potentials occurs at a fast 
speed and vesicle fusion is synchronised to the activity at the synapse. This type of 
release is also known as synchronous release. 
The synaptic proteins synaptobrevin 2 (SYB2), syntaxin-1 and SNAP-25 make up 
the SNARE family proteins (Südhof and Rothman, 2009). SYB2 is localised on the 
SV, whilst syntaxin-1 and SNAP-25 are located at the presynaptic plasma membrane 
(Sudhof, 2004). Syntaxin-1 is first kept in a ‘closed conformation’ by the protein 
Munc18 prior to SV arrival at the active zone (Dulubova et al., 1999). Syntaxin-1 
cannot form SNARE complexes in this conformation, presumably as a preventative 
mechanism to inhibit premature SNARE complex assembly. Arrival of a SV at the 
active zone triggers a conformational change in Munc18 that alters its interaction 
with syntaxin-1 at two spatially separated sites (Burkhardt et al., 2008). Another 
protein, Munc13, is then presumed to adopt a role in unlocking syntaxin-1 from 
Munc18 and allows syntaxin-1 to adopt an ‘open conformation’ and promote 
SNARE complex assembly (Ma et al., 2011). Munc13 is also shown to play a role in 
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priming the attachment site of the vesicle at the active zone (Augustin et al., 1999), 
as it has been shown to form a tripartite complex with the proteins RAB3A and RIM 
(RAB3 interacting molecule, an organiser of the active zone) (Lu et al., 2006). Upon 
contact of the SV and membrane SNAREs, the proteins associate with each other in a 
trans-conformation at the N-terminal ends. A tight bundle consisting of four parallel 
α-helical domains (one each from SYB2 and syntaxin-1, two from SNAP-25) is 
progressively formed and proceeds in an amino to carboxy-terminal direction 
(Hanson et al., 1997). This pulls the membrane tightly together in a zippering action 
to initiate priming.  The zippering process is proposed to be controlled by a small 
cytoplasmic protein, complexin, which occurs via two possible mechanisms: 1) 
binding to the surface of the SNARE complex to start the zippering process (Xue et 
al., 2010); 2) acting as a clamp to prevent full progression of the SNARE zippering 
(Yang et al., 2010). Once primed, the SV readily fuses when the SNARE machinery 
is triggered into action by influx of calcium into the nerve terminal. 
The role as molecular sensors for calcium influx at the presynaptic nerve terminal is 
generally mediated by the synaptotagmins, which are a family of membrane 
trafficking proteins. There has been many studies performed which investigate the 
role of the various isoforms of synaptotagmin at the presynapse. However, 
synaptotagmin I (SYT1) is the dominant isoform for evoked synchronous 
neurotransmitter release. SYT1 is a SV protein consisting of a single transmembrane 
region connected to two C2 domains (termed C2A and C2B) via flexible linker 
regions (see chapter 3 for a more detailed review on SYT1). Ablation of SYT1 in 
mice resulted in a selective loss of fast Ca2+-triggered exocytosis both in 
hippocampal synapses without impairment of other parameters of synaptic function 
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(Geppert et al., 1994). In the presence of Ca2+, the C2 domains of SYT1 can chelate 
the Ca2+ ions and bind them with acidic phospholipid residues at the presynaptic 
membrane (Chapman, 2008). The chelation process moves the SV into close 
proximity with the membrane and potentially destabilises the membrane bilayers in 
order to facilitate the fusion process. The merger of the vesicle bilayer and the 
membrane bilayer at the contact site develops into the opening of an aqueous channel 
(termed as the fusion pore) whereby neurotransmitter is released from the luminal 
domain of the vesicle into the synaptic cleft (Qian and Huang, 2012).  
  





Figure 1.3: Docking and priming of a SV at the active zone (Südhof and Rizo, 2011). The modular 
protein Munc13 forms a priming complex with the active zone organiser RIM and Rab3. Calcium 
influx triggers two reactions which facilitate exocytosis: 1) The liberation of Munc13 from the 
priming complex which unlocks syntaxin-1 from Munc18 and allows SNARE assembly to complete 
zippering; 2) The coordination of the C2 domains of synaptotagmin I and the acidic phospholipid 
residues in the plasma membrane to Ca2+ ions, bringing the vesicle into close proximity whilst 
destabilising the membrane bilayer, allowing for fusion with the plasma membrane. 
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1.3.1 – Asynchronous and Spontaneous Release 
Fast synaptic transmission (or synchronous release) in the brain requires coordinated 
vesicle fusion that is evoked by action potentials induced by Ca2+ influx. However, 
nerve terminals are also able to release neurotransmitters in the absence of an action 
potential. There are two main types of neurotransmitter release in the absence of an 
action potential: 1) Asynchronous release, which is a persistent release of 
neurotransmitter immediately after action potential-dependent synchronous release 
and 2) Spontaneous release, which occurs in the absence of presynaptic membrane 
depolarisation and occurs stochastically throughout the lifetime of a neurone. 
Although synchronous release accounts for almost all (greater than 90%) 
neurotransmitter release at synapses under low-frequency stimulation, asynchronous 
release is also prominent in certain networks in the brain, in particular the synapses 
from the deep cerebellar nuclei to the inferior olive (Best and Regehr, 2009). 
Asynchronous release is usually evoked by sustained moderate to high-frequency 
stimulation, and the magnitude of asynchronous release is usually linked to a steep 
frequency dependence that are aligned to the range of firing frequencies experienced 
by the synapse (Kaeser and Regehr, 2014). Numerous roles have been suggested for 
asynchronous release in mammalian physiology. One of the key roles is the 
prolonged release of GABA in inhibitory synapses to provide a smooth and gradual 
inhibition that is unreliant on the precise timing of individual action potentials (Lu 
and Trussell, 2000). High-frequency activation of fast-spiking cortical interneurones 
results in the asynchronous release of GABA which lasts several seconds (Manseau 
et al., 2010), suggesting that asynchronous release may play a role in the suppression 
of epileptiform activity caused by widespread synchronous activity.  
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Asynchronous release is triggered by Ca2+ influx in a manner similar to synchronous 
release. The introduction of the slow Ca2+ chelator, ethyleneglycol tetraacetic acid 
(EGTA), into the presynaptic terminal eliminated the presence of asynchronous 
release whilst having very little effect on synchronous release (Atluri and Regehr, 
1998), suggesting that a different Ca2+ sensor is responsible for asynchronous release 
that responds to general bulk cytosolic Ca2+ levels rather than high local Ca2+ caused 
by influx. Several Ca2+-sensing proteins, such as SYT7 (Maximov et al., 2008) and 
DOC2 (Yao et al., 2011), have been proposed to be mediators for asynchronous 
release. Other SV proteins such as VAMP4 have been proposed to play a mediating 
role in SV movement in asynchronous release by binding to t-SNAREs in order to 
drive asynchronous SV fusion. Overexpression of VAMP4 in SYB2-knockout mice 
showed limited rescue of synchronous release and a prolonged postsynaptic current 
late in a train of stimuli that could be eliminated in the presence of EGTA (Raingo et 
al., 2012). There have been many research studies on the diverse mechanisms that 
mediate asynchronous release in a variety of neuronal sub-types. These mechanisms 
will not be covered in the scope of this review. 
Spontaneous release is the release of neurotransmitter that is independent of action 
potential-induced presynaptic membrane depolarisation. Spontaneous release was 
first described in experiments by Bernard Katz and colleagues in the 1950s, where 
they observed neurotransmitter release occurring in discrete ‘quantal’ events in 
cholinergic neuromuscular junction preparations (FATT and KATZ, 1950, FATT 
and KATZ, 1952). Spontaneous release occurs at a rate of around 10-3 SVs per 
second, which is far reduced from the rate of synchronous release (103 SVs per 
second) (Kaeser and Regehr, 2014). Unlike evoked release, which is mediated by the 
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total recycling pool of SVs, spontaneous release in central synapses is mediated by 
the resting pool of SVs (Sara et al., 2005, Fredj and Burrone, 2009). Effectively, this 
limits action potential-independent activity at the synapse. Spontaneous release has 
been implicated in synaptic stabilisation as well as long-term synaptic plasticity. Cell 
spine density and length in hippocampal slice cultures decreased after application of 
AMPA receptor antagonists to block spontaneous glutamate release (McKinney et 
al., 1999), suggesting that spontaneous release exerts a trophic effect on dendritic 
spines to maintain their fidelity. In cultured hippocampal pyramidal cells, 
spontaneous glutamate release activates NMDA receptors and suppresses local 
protein synthesis in dendrites (Sutton et al., 2006). Pharmacological blockade of 
NMDA receptors resulted in a regulatory increase of AMPA receptors after a few 
hours, an effect which required a much longer timeframe if only evoked activity was 
eliminated. This suggests that spontaneous release plays a key role in regulating 
homeostatic plasticity at the synaptic terminal through regulation of local dendritic 
protein synthesis.  
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1.4 – Synaptic Vesicle Endocytosis: Retrieval of Vesicular Cargo and Membrane 
SV endocytosis involves both: 1) retrieval of SV proto-vesicle components from the 
plasma membrane and 2) the regeneration of functional SVs with the proper 
molecular composition. Neuronal synapses differ greatly with respect to typical 
firing pattern, thus different neuronal subtypes may require specific adaptations to 
meet the needs of membrane retrieval and reformation of functional synaptic vesicles 
to replenish the reserve pool. For example, high firing synapses such as the Calyx of 
Held (firing at many hundreds of Hz) require a more efficient and faster mode of SV 
cargo retrieval in order to release vesicle docking sites compared to synapses in the 
hippocampus (firing at tens to low hundreds of Hz) (Neher, 2010). As different 
neurones are exposed to different range of stimulus frequencies, several endocytic 
pathways exist in neurones that differ in their capabilities to retrieve SV cargo with 
respect to speed of retrieval, maintenance of SV identity and molecular composition. 
There are currently three distinct endocytosis pathways shown to occur in neurones: 
1) Clathrin-mediated endocytosis; 2) Bulk endocytosis and 3) Ultrafast endocytosis.  
The study of SV recycling is complex, and many tools and assay techniques have 
been generated by various academic groups to study different presynaptic 
phenomena. A selection of these tools and techniques are discussed in the sub-
sections below and a summary table is provided (Table 1.4.1). 
 
1.4.1 – Methods to Visualise and Monitor SV Cargo Retrieval in Neurones 
There are several methods and tools available for conducting investigations of SV 
exocytosis and endocytosis at the presynaptic nerve terminal. The most common 
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protocols are based on fluorescence imaging techniques such as styryl FM dye 
assays, pHluorin retrieval assays as well as internalisation of bulk fluorescent 
molecules such as dextran. Electron microscopy may also be utilised for resolution of 
fine structural morphology at the synaptic terminal. 
 
1.4.1.1 – Styryl (FM) Dyes 
Styryl (FM) dyes are chemical molecules that have a hydrophilic head group and a 
hydrophobic tail, which gives the dye molecules similar chemical properties to 
phospholipid molecules in the plasma membrane. The dye molecules can partition 
themselves reversibly into the plasma membrane without fully permeating the 
membrane. Fluorescence only occurs when the molecules are partitioned in the 
membrane and not in solution. These properties makes styryl dyes a useful tool for 
tracking the kinetics of SV recycling in living cells. The length of the lipophilic tail 
in the dye determines the intensity of fluorescence output as well as how 
permanently the dye is partitioned into the membrane. Dyes with short tails are less 
lipophilic, so bind less tightly to the membrane and fluoresce less brightly (e.g. FM2-
10, which contains two carbon atoms in its tail). Dyes with longer tails are more 
lipophilic so bind strongly to the membrane and fluoresce more brightly (e.g. FM1-
43, which has four carbon atoms in its tail) (Betz et al., 1996). Neuronal cultures 
incubated in the presence of FM dyes will have selected vesicle pools labelled when 
stimulated by either an elevated K+ solution or a train of action potentials. The FM 
dye molecules partition themselves into the neuronal plasma membrane and the 
membrane is retrieved by various mechanisms of SV endocytosis. This labels all SVs 
that are turned over because of the stimulus. The remaining unpartitioned dye 
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molecules can be washed away with extracellular media, leaving the FM-labelled 
synapse. Since these FM dyes can be departitioned from the plasma membrane, a 
subsequent stimulus can release the SV-partitioned dyes during exocytosis. The 
decrease in the level of fluorescence due to this stimulus can be quantified to provide 
information about the turnover of SVs at the synapse (Cousin and Robinson, 1999). 
FM dyes may also be photo-converted into an electron dense marker for SVs at a 
presynapse so that it may be imaged using electron microscopy (Harata et al., 2001). 
This allows FM-labelling investigations of SV turnover at the individual synapse 
level, allowing clarification of the endocytosis pathway that is in use by the specific 
synapse in question.  
 
1.4.1.2 – PH Sensitive GFP-Fused Protein Reporters (pHluorins) 
The advent of pHluorins have enabled the study of the kinetics of vesicle re-
acidification and other aspects of SV trafficking. pHluorins are green fluorescent 
proteins (GFP) which have been genetically engineered to be highly sensitive to pH 
changes and can be fused to a target SV-related protein of choice to be investigated. 
The pH-sensitive GFP in pHluorins is located in the intraluminal domain of the 
vesicle (as it is specifically fused to the luminal domain of an exogeneous SV 
protein) and fluorescence is quenched under the pH conditions in this domain (pH ~ 
5.6). During SV exocytosis, the vesicle fuses to the plasma membrane and the pH-
sensitive GFP fluoresces when exposed to the high pH of the extracellular 
environment (pH ~ 7.4). Fluorescence is quenched again following SV endocytosis 
and re-acidification and the GFP molecule is returned to the environment of the 
intraluminal domain (Miesenböck et al., 1998, Sankaranarayanan and Ryan, 2000). 
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In cultures of hippocampal neuronal synapses, SV re-acidification was thought to 
occur on a timescale of around 4-5 s after internalisation (Granseth and Lagnado, 
2008, Atluri and Ryan, 2006), however more recent experiments using the probe 
mOrange have indicated it to be around 15 s (Egashira et al., 2015). The rate-limiting 
step is therefore the rate of pHluorin internalisation during SV endocytosis, thus the 
rate of pHluorin quenching can be directly linked as a measure of SV endocytosis at 
the synaptic terminal. As SV endocytosis and re-acidification takes place at the same 
time as SV exocytosis during evoked stimulation, delinearisation of the two 
processes is required to provide accurate information of rates of SV exocytosis. 
Prevention of SV re-acidification can be achieved by pharmacological inhibition of 
the vesicle proton pump V-ATPase using the drug bafilomycin, allowing rates of SV 
exocytosis to be directly related to rates of pHluorin fluorescence (Ryan, 2001). 
Different SV protein-pHluorin constructs have been reported in the literature. These 
include, but are not limited to: 1) SynaptopHluorin, which is a conjugate of 
synaptobrevin II and pHluorin (SYB2-pHluorin) (Sankaranarayanan and Ryan, 
2000); 2) SypHy, which is a conjugate of synaptophysin and pHluorin (SYP-
pHluorin) (Granseth et al., 2006); 3) SYT1-pHluorin (Wienisch and Klingauf, 2006); 
4) VGLUT1-pHluorin (Voglmaier et al., 2006); SV2A-pHlourin (Kwon and 
Chapman, 2012) and 5) VAMP4-pHluorin (Raingo et al., 2012). 
Elegant use of pHluorins in various experiments may provide specific information on 
SV protein expression and retrieval mechanisms at the synaptic terminal. The surface 
fraction of SV protein expression and the variations in fluorescence along the neurite 
can be revealed using acidic (pH ~ 5.5) and basic (pH 7.4) imaging media to reveal 
the total expressed pHluorin in the neurone(Gordon et al., 2011). Recent work has 
   
32 
 
shown that most SV pHluorins report protein retrieval via the CME mechanism, with 
the exception of VAMP4-pHluorin, which reports retrieval of VAMP4 via ADBE 
(Nicholson-Fish et al., 2015). Therefore, future investigations to determine pathways 
of endocytic retrieval in novel cell types may use SYP-pHluorin and VAMP4-
pHluorin as reporters for CME and ADBE respectively. 
 
1.4.1.3 – Dextran Conjugates 
Dextrans are large, inert polysaccharide molecules that are conjugated to fluorescent 
dyes such as rhodamine. Fluorescent conjugates of dextran are impermeable to the 
plasma membrane and are generally excluded from uptake by single recycling SVs 
due to their large molecular size. As a result, dextran conjugates can be used as 
selective markers for fluid phase ADBE events at the synapse without being affected 
by CME. Large fluorescent dextrans have been used in snake motor neurone 
terminals (Teng et al., 2007), retinal bipolar cells in goldfish (Holt et al., 2003) and 
rat cerebellar granule neurones (Clayton et al., 2008). 
 
1.4.1.4 – Horseradish Peroxidase (HRP)/Electron Microscopy (EM) 
The uptake of horseradish peroxidase (HRP) has been frequently used as a method to 
visualise the fine structural morphology of neurones as well as to distinguish 
between the various mechanisms of endocytosis in neurones. As a fluid phase 
marker, neurones are able to uptake HRP during SV endocytosis, which provides 
non-selective labelling of different endocytosis pathways. During preparation, the 
membrane is stained using osmium or uranium and HRP is converted into an electron 
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dense product by oxidation with 3-diaminobenzidine and hydrogen peroxide. This 
increases scattering of electrons to give high contrast 'dark spots' in the electron 
micrograph. This method can be used to visualise synaptic vesicle pools, bulk 
endosome vacuoles, plasma membrane deformities and other morphological changes 
at individual synapses (Marxen et al., 1999, Leenders et al., 2002, de Lange et al., 
2003, Evans and Cousin, 2007). 
 
1.4.1.5 – Membrane Capacitance Measurements 
The fusion and retrieval of SV cargo and membrane leads to change in the total 
volume of membrane at the cell surface. As biological membranes have an electrical 
potential across them, accurate measurements of the change in the electrical 
capacitance of the membrane can be directly related to the insertion and removal of 
membrane volume at a nerve terminal (Neher and Marty, 1982). This method is best 
used to observe bulk trafficking of membrane and cargo in large synapses such as 
retinal bipolar cells or the Calyx of Held. Although membrane capacitance 
measurements are a useful tool, they lack specificity in the identities of the cargo 
being trafficked and their use is limited to large synapses as central nerve terminals 




Method of Visualisation Measured Parameter Advantages Disadvantages 
 
Styryl (FM) Dyes 
• Changes in fluorescent 
dye binding to 
membranes 
• Live monitoring of fluorescent 
probe recycling 
• No need for genetic 
manipulation or transfection 
• Poor temporal resolution 
• Low signal to noise ratio 
 
pHluorins 
• pH dependence of 
intravesicular 
fluorescence 
• Recycling can be monitored in 
live cell preparations 
• Good temporal resolution 
• Requires genetic 
manipulation/transfection 
• Dependency on SV re-
acidification kinetics to give 
indirect measure of SV recycling 
 
Fluid phase markers (e.g. 
dextran or HRP) 
• Morphology of plasma 
membrane or  
membrane-derived 
intermediates 
• Very high spatial resolution • Poor temporal resolution 
• Requires careful tissue 
preservation 
• Time consuming 
 
Membrane Capacitance 
• Membrane surface area • Very high temporal resolution • Limited to large presynaptic terminals (e.g. calyx of Held) 
• Limited detail in the nature of 
internalisation and its contents 
Table 1.4.1: A summary table comparing the advantages/disadvantages of the different methods of visualising SV cargo retrieval.  
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1.4.2 – Clathrin-mediated Endocytosis 
The internalisation of SV membrane into the cell from the membrane surface by SVs 
coated with the structural protein clathrin is known as clathrin-mediated endocytosis 
(CME). CME is remains to this date as the best-characterised and understood model 
of endocytosis. Clathrin was initially discovered to form a lattice-like coat structure 
around SVs in 1976 (Pearse, 1976). Clathrin-coated SVs isolated later from nerve 
terminals exhibited strong association with SV proteins, giving the first indication 
that clathrin plays a key role in the recycling of SV proteins at the synapse (Maycox 
et al., 1992). The formation of clathrin-coated SVs develops through six stages: 
nucleation, cargo sorting, coat assembly, membrane deformation, scission and 
uncoating. 
 
1.4.2.1 – Initiation of Endocytosis and Cargo Sorting 
The budding of a vesicle from the plasma membrane starts from the formation of a 
membrane invagination called a ‘pit’. Initiation of a clathrin-coated pit is triggered 
by the recruitment of the assembly protein complex 2 (AP-2), mediated by the 
binding of endocytic motifs in the cytoplasmic tail of AP-2 (α and μ subunits) to the 
plasma-membrane specific lipid phosphatidylinositol-4,5‑bisphosphate [PI(4,5)P2] 
(Höning et al., 2005). Recent work has suggested that formation of a putative 
nucleation module on the plasma membranes defines the sites of clathrin recruitment. 
FCH domain only protein (FCHO), intersectins (Henne et al., 2010) and epidermal 
growth factor pathway substrate 15 (EPS15) (Suzuki et al., 2012) have been 
suggested to be essential for the function of the nucleation module, as mutation or 
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depletion of these proteins result in the inhibition of clathrin coat recruitment. 
Clathrin coats are formed from the cytosolic recruitment and assembly of three 
clathrin heavy chain units and three clathrin light chain units into a polyhedral lattice 
(Brodsky et al., 2001). The nucleation module is responsible for the recruitment the 
AP-2 which in turn binds clathrin and other cargo specific adaptor proteins (e.g. 
stonin-2, AP-180, CALM) to mediate cargo selection (Koo et al., 2011, Kononenko 
et al., 2013). AP-2 also targets transmembrane proteins with tyrosine (Yxx𝜙𝜙, where 
ϕ is a bulky hydrophobic residue) and di-leucine ([DE]XXXL[LI]-based motifs for 
internalisation. The specific mechanisms behind endocytic sorting signals and 
adaptors will be described in more detail in chapter 3.  
 
1.4.2.2 – Membrane Deformation and Scission 
After the sorting of SV cargo and clathrin around the membrane, it is necessary to 
deform the membrane in order to initiate budding of the SV from the cell surface. It 
is currently accepted that mechanisms that initiate invaginations of early clathrin 
coated pits involves membrane-deforming proteins. The most important class of 
these membrane-deforming proteins is the Bin-Amphyphysin-RVS (BAR) domain-
containing superfamily of proteins. BAR-domain-containing proteins include 
examples such as amphiphysin, endophilin, syndapin and sorting nexin 9 (SNX9) 
(Qualmann et al., 2011). BAR-domain proteins were initially discovered as 
conserved domains in BIN1, amphiphysin and the yeast proteins RVS161p and 
RVS167p (David et al., 1994). Crystallographic studies later revealed that the BAR-
domain proteins are dimers consisting of three long helices of each monomer. BAR-
domain proteins are known effectors of membrane curvature, and the scaffolding 
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mechanism is generally mediated by the binding of positively charged membrane-
interacting residues with negatively charged lipids such as phosphoinositide and 
phosphatidylserine (Peter et al., 2004). BAR-domain proteins are intrinsically 
curved, thus forces the membrane surface to adopt a similar shape. Within the 
superfamily of BAR-domain proteins, different proteins effect different levels of 
curvature on the membrane. N-BAR proteins such as amphiphysin and endophilin 
have strong curvatures where the angle of the dimer interception point is 
approximately 30º (Casal et al., 2006), whereas in F-BAR proteins such as syndapin 
the angle of interception is much less at approximately 10º (Wang et al., 2009).  This 
suggests that F-BAR proteins may act at the early stages of membrane deformation, 
whilst the N-BAR proteins act as late-stage co-ordinators of SV scission and 
uncoating (Frost et al., 2009).  
Another class of membrane-deforming proteins include epsin and its auxiliary 
interacting partner EPS15.  Epsin contains the epsin N-terminal homology (ENTH) 
which binds directly to the membrane lipid PI(4,5)P2, in conjunction with clathrin, 
and induces membrane curvature. Binding of epsin to PI(4,5)P2 results in the 
formation of an amphipathic α-helix in epsin, which is inserted into one leaflet of the 
lipid bilayer and induces membrane curvature (Ford et al., 2002). Disruption of epsin 
interactions by use of presynaptic microinjections of antibodies to either the ENTH 
domain or the clathrin/AP-2 binding region resulted in accumulation of distorted 
coated structures and the presence of a bias towards early endocytic intermediates 
such as shallow coated pits (Jakobsson et al., 2008). This suggests that epsin not only 
has a role in curvature generation, but also in the generation of uniform SVs. 
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BAR domain proteins also harbour Src Homology 3 (SH3) domains that bind to the 
proline-rich domain of the GTP-ase protein dynamin I (DYN1) (Anggono et al., 
2006, Sundborger et al., 2011). DYN1 plays a key role in the membrane scission of 
the fully formed clathrin coated pits, suggesting an extremely close physical and 
functional link that exists between membrane deformation and SV scission. 
Oligomeric polymerisation of dynamin around the neck of the clathrin-coated pit 
facilitates GTP-mediated hydrolysis of the protein and subsequent membrane 
scission (Sweitzer and Hinshaw, 1998). The exact mechanism of dynamin action at 
the SV neck remains debated to this day, but several proposals have been made: 1) 
DYN1 acts like a spring which ‘pops’ the coated pit from the plasma membrane 
upon hyperextension of the protein helix (Stowell et al., 1999); 2) DYN1 constricts 
around the neck of the coated pit, thereby ‘pinching’ it free from the plasma 
membrane (McNiven et al., 2000); 3) DYN1 induces a ‘twisting’ action on the neck 
of the coated pit upon GTP hydrolysis, inducing a high tension which is only 
released when the tubule breaks and the SV is free (Roux et al., 2006) and 4) DYN1 
constriction acts like a ‘corkscrew’, based on X-ray crystallography and cryo-
electron microscopy studies (Mears et al., 2007). The functional role of DYN1 in 
scission cannot be disputed, since various electron microscopy studies on central 
synapses from several mammalian DYN1 knockout systems have demonstrated 
defective fission of clathrin-coated pits from the plasma membrane (Ferguson et al., 
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1.4.2.3 – Uncoating of Clathrin from the SV 
Shortly after vesicle scission, the released nascent vesicles shed their coat as the 
clathrin lattice assemblies disassemble back to their triskelia forms. SV uncoating is 
mediated by the ATPase heat shock protein – 70 kDa (HSC70) and its cofactor, 
auxilin (Rothnie et al., 2011). Since HSC70 is an ATPase, the uncoating process is 
ATP-dependent. This is evidenced by the observation that presence of ATP 
significantly increases the rate of HSC70/auxilin complex formation, whilst presence 
of ADP inhibits this complex formation (Prasad et al., 1994). The cofactor, auxilin, 
was identified early on as a member of the DnaJ protein family due to the presence 
of the J-domain at its C-terminus. DnaJ proteins have roles in protein folding, 
transmembrane protein transport as well as selective disruption of protein-protein 
interactions. Deletion of the J-domain in auxilin resulted in the loss of cofactor 
activity (Ungewickell et al., 1995). The interactions between clathrin, auxilin and 
HSC70 are highly specific. Biochemical studies have revealed that auxilin first binds 
to clathrin triskelion baskets on the SV, followed by binding of HSC70-ATP to the 
auxilin-clathrin complex. After initiation of the uncoating process, auxilin can then 
migrate to another clathrin triskelion (Barouch et al., 1997). Cryo-electron 
microscopy studies on the HSC70/auxilin/clathrin interaction showed that binding of 
auxilin induced a local change in the contacts of clathrin heavy chains, creating a 
distortion of the clathrin coat. This destabilisation of the clathrin lattice facilitates 
general SV uncoating (Fotin et al., 2004). Electron microscopy studies have further 
demonstrated that knockout of auxilin in mice central synapses results in the 
inhibition of SV uncoating at the synapse (Yim et al., 2010). 
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Another key protein associated with the SV uncoating process is synaptojanin I 
(SYJ1). SYJ1 is a phosphatidylinositol-5-phosphate (PI(5)P) phosphatase, which is 
directly responsible for the dephosphorylation of PI(4,5)P2. The BAR proteins 
endophilin and amphiphysin bind SYJ1 via their SH3 domains (Cestra et al., 1999). 
Total internal reflection fluorescence microscopy studies have shown that endophilin 
and SYJ1 are recruited together at a late stage of clathrin-coated pit formation, 
suggesting that endophilin may play a role as a recruiter of SYJ1 to the plasma 
membrane (Perera et al., 2006). However, recent electron microscopy studies have 
shown that endophilin may play a more active role in the timing of SV uncoating. 
Genetic ablation of all three isoforms of endophilin in mice resulted in the 
accumulation of clathrin-coated SVs, but not clathrin-coated pits, at the synapse 
(Milosevic et al., 2011). This suggests that presence of SYJ1 at the SV is required for 
uncoating, but a precise trigger mediated by endophilin is required for activation of 
the uncoating process. SYJ1 knockout neurones have shown that dual action of both 
phosphatase domains in SYJ1 is necessary for SV cycling. Rescue with SYJ1 
containing point mutations in either phosphatase domain resulted in a failure to 
restore the normal phenotype as observed when rescued using wild type SYJ1 (Mani 
et al., 2007). If we consider all evidence, it is highly likely that SV uncoating 
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1.4.2.4 – Kinetics of CME 
The kinetics of CME has been a widely debated topic in presynaptic neuronal cell 
biology over the last decade. Several optical imaging and membrane capacitance 
studies in different model systems have shown that it occurs on a timecourse of 
around 10-20 s at room temperature using lower intensity stimulation paradigms 
(Granseth et al., 2006, Jockusch et al., 2005, Balaji and Ryan, 2007). Increasing the 
intensity of stimulation in central synapses appears to increase the timecourse of 
which CME operates to about 30-60 s (Sankaranarayanan and Ryan, 2000, Wu et al., 
2014). There is evidence which indicates that CME generally accelerates to a 
timecourse of around 5-6 s under physiological temperatures (37ºC) (Nicholson-Fish 
et al., 2015), however the role of CME as the dominant mode of SV endocytosis at 
physiological temperatures has been debated (Watanabe et al., 2014). 
  




Figure 1.4.2: The clathrin-mediated endocytosis (CME) pathway (McMahon and Boucrot, 2011). 
Formation of a putative nucleation module is mediated by the proteins FCHO, EPS15 and intersectin. 
The nucleation module is responsible for the recruitment of AP-2 and other cargo specific adaptors 
(e.g. stonin-2, AP-180, CALM) to ensure the correct SV molecular composition. AP-2 is also 
responsible for the recruitment of clathrin triskelia, which assembles into a polyhedral lattice. 
Association of clathrin with BAR proteins, which effect membrane curvature, allows the formation of 
an early stage clathrin coated pit. BAR proteins are also responsible for the recruitment of the 
GTPase dynamin to the neck of the pit. GTP-hydrolysis mediated conformational changes in dynamin 
initiate membrane scission and fission of the nascent vesicle. The clathrin coat then disassembles 
back into triskelia by through the co-ordinated action of HSC70, auxilin, and the PI(4,5)P2 
phosphatase synaptojanin I. 
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1.4.3 – Activity Dependent Bulk Endocytosis 
Although CME alone is capable of regenerating SVs from the plasma membrane, the 
timescale of which it occurs (15-20 s) is too slow for maintaining neurotransmission 
under periods of intense neuronal activity. The recruitment of clathrin triskelia itself 
requires seconds (Cocucci et al., 2012), therefore CME cannot be solely responsible 
for the retrieval of SVs during intense activity. Previously discussed pHluorin-
imaging experiments in hippocampal neurones have also showed that CME has a 
maximal rate that does not scale with increasing stimulation intensity (Granseth et 
al., 2006, Balaji and Ryan, 2007). Therefore, under prolonged periods of high-
frequency stimulation (up to hundreds of Hz), CME becomes saturated with activity 
and an additional mechanism for fast membrane retrieval is required to maintain 
neurotransmission. Electron microscopy studies have shown that under periods of 
high-frequency stimulation (40-80 Hz), large endosomal vacuoles of plasma 
membrane are internalised via a clathrin-independent retrieval pathway in rat 
cerebellar granule neurones (Clayton et al., 2008). This specific clathrin-independent 
pathway of membrane retrieval is known as activity-dependent bulk endocytosis 
(ADBE). Since ADBE is triggered only by high-frequency stimulation and has the 
capacity to rapidly reverse the increase in plasma membrane surface area of a nerve 
terminal due to excess SV exocytosis, it is the dominant mode of membrane retrieval 
during intense neuronal activity. 
The mechanism by which ADBE operates is driven by the dephosphorylation of the 
GTPase protein dynamin I (DYN1) by the calcium-dependent phosphatase 
calcineurin triggered by calcium influx during intense stimulation (Clayton et al., 
2009). Mutagenesis studies have identified two key phosphorylation sites on DYN1 
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which are crucial to mediating the interaction between DYN1 and the BAR protein 
syndapin I (PACSIN1) (Anggono et al., 2006). The recruitment of PACSIN1 is 
essential for the maintenance of ADBE, as methods that inhibit or ablate expression 
of the protein resulted in arrest of the retrieval process (Koch et al., 2011). PACSIN1 
is a BAR protein containing an F-BAR domain, which is responsible for in the 
initiation of membrane curvature to produce a bulk invagination in ADBE. F-BAR 
domain proteins such as PACSIN1 have been demonstrated to have low-curvature 
(around 10º), and thus they are suggested to fit the profile of large diameter 
organelles (such as bulk endosomes) better in comparison to high-curvature N-BAR 
domain proteins such as endophilin and amphiphysin (Henne et al., 2007, Shimada et 
al., 2007). Deeper probing of the mechanisms behind ADBE has revealed a role for 
the enzymes glycogen synthase kinase 3 (GSK3) and cyclin-dependent kinase 5 
(CDK5) in the phosphorylation-dependent activation of DYN1 in ADBE.  Protein 
mutagenesis studies in rat cerebellar granule neurones have shown that CDK5 primes 
DYN1 by phosphorylating at residue S778, allowing GSK3 to phosphorylate DYN1 
at residue S774 to prime DYN1 for ADBE (Clayton et al., 2010). The specific 
requirement for DYN1 for ADBE has been contested. ADBE was still observed in 
DYN1/DYN3 knockout mice, possibly due to very low but functional levels of 
DYN2 present (Raimondi et al., 2011). Photo-inactivation of dynamin in drosophila 
mutants has shown that bulk membrane cisternae are still present at the nerve 
terminal despite the apparent lack of dynamin (Kasprowicz et al., 2014). More 
recently, pHluorin imaging and biochemical studies have indicated that vesicle 
associated membrane protein 4 (VAMP4) is another essential protein for the 
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maintenance of ADBE, though its exact role is yet to be elucidated (Nicholson-Fish 
et al., 2015). 
After the DYN1/PACSIN1-mediated formation and internalisation of the bulk 
endosome vacuole is complete, SVs begin to bud from the endosome to replenish the 
depleted SV pools. The exact mechanisms underlying the SV budding process are 
currently still unclear. The process is clathrin-dependent, as photo-inactivation of 
clathrin heavy chain in drosophila neurones resulted in the arrest of the SV cycle 
even though bulk endosomes were still observed to be present by electron 
microscopy (Heerssen et al., 2008, Kasprowicz et al., 2008). Calcium and calcineurin 
activity has also been demonstrated to a key process in SV budding. Chelation of 
both calcium and calcineurin by pharmacological methods resulted in the arrestment 
of SV generation from bulk endosomes (Cheung and Cousin, 2013). Interestingly, 
the inhibition of SV re-acidification using bafilomycin also arrested SV generation, 
suggesting that calcium release upon endosome re-acidification plays a major role in 
SV budding.  
 
1.4.3.1 – Cargo Sorting at the Bulk Endosome 
In order to ensure that viable SVs are formed from the bulk endosome, an efficient 
SV cargo sorting process must take place on the endosome itself, in a similar manner 
to SV cargo sorting at the plasma membrane. There are lines of evidence that 
implicates the requirement of adaptor proteins in generating viable SVs from the 
bulk endosome. Early studies show that brefeldin A-mediated inhibition of the 
GTPase ADP-ribosylation factor 1 (ARF1) resulted in the arrests SV generation from 
synthetic endosomes (Drake et al., 2000). ARF1 was previously shown to be 
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essential for the recruitment of the adaptor proteins AP-1 and AP-3 to the plasma 
membrane (Faúndez et al., 1998). Taken together, the data suggests that AP-1 and 
AP-3 plays a crucial role in facilitating SV generation at bulk endosomes. In 
agreement with this, later FM-dye labelling studies showed that genetic ablation of 
AP-1 and AP-3 in rat cerebellar granule neurones resulted in inhibition of reserve 
pool replenishment from bulk endosomes (Cheung and Cousin, 2012). There is also 
evidence for a key role for AP-2 in SV generation from endosomes. Electron 
microscopy studies in hippocampal neurones from conditional AP-2(µ) knockout 
mice revealed an accumulation of endosome-like vacuoles in the structure as well as 
reduced SV density (Kononenko et al., 2014). 
  




Figure 1.4.3: Molecular mechanisms for activity-dependent bulk endocytosis (ADBE) (Cousin, 
2015). ADBE is the dominant mode for membrane retrieval during high-frequency stimulation. 
Phophorylation of S778 of Dynamin I (DYN1) by cyclin-dependent kinase 5 (CDK5) primes another 
residue, S774, for phosphorylation by glycogen synthase kinase 3 (GSK3). Subsequent 
dephosphorylation of both residues in DYN1 by the calcineurin results in the triggering of a 
DYN1/syndapin 1 (PACSIN1) interaction, which is key to formation and internalisation of the bulk 
endosome. On the bulk endosome, the generation of viable SVs is mediated by the proteins AP-1, 
AP-2, AP-3 and calcineurin. Calcineurin is thought to play in role in calcium release during endosome 
re-acidification, whilst the adaptor proteins AP-1/2/3 play a role in SV cargo sorting to reform viable 
SVs. 
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1.4.4 – Ultrafast Endocytosis 
Recent experiments using high pressured, flash freezing of neuronal cells in worms 
and mouse hippocampal neurones (Watanabe et al., 2013a, Watanabe et al., 
2013b)have detailed a novel mode of ultrafast endocytosis (UFE) observed at 
physiological temperatures which is fundamentally different from CME and ADBE. 
In UFE, bulk membrane invaginations of ~80 nm in diameter appear within 50-100 
ms of a single action potential between the active and the peri-active zone of the 
plasma membrane(Watanabe et al., 2013b). 
UFE is clathrin-independent at the membrane retrieval stage, but subsequently 
requires clathrin to form fully functional SVs from the internalised endosomes 
(Watanabe et al., 2014). This has led to the theory that ultrafast endocytosis may be 
required as a specialised mechanism to rapidly restore the surface area on the plasma 
membrane. More recently, direct patch clamp recordings of membrane capacitance 
from small central synapses in real time have corroborated earlier results using flash-
freezing (Delvendahl et al., 2016). The mechanism behind this novel mode of 
endocytosis remains to be elucidated in full. UFE appears to share the same 
molecular mechanisms as ADBE but have two key differences: 1) the timeframe of 
completion of UFE is within 100 ms, whereas ADBE operates on a timeframe of 
seconds to minutes and 2) the amount of membrane internalised by UFE is much 
more consistent than ADBE (~60-80 nm in diameter). Nevertheless, these 
experiments have demonstrated that UFE is dependent upon the activity of dynamin 
I/III and actin polymerisation. GTPase-dependent activity and actin polymerisation 
are both known to be temperature sensitive and therefore may explain the 
diminishing influence of UFE at lower temperatures. There is an argument against 
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the importance of CME at physiological temperatures and that UFE is the dominant 
mode of endocytosis in these conditions. In support of this theory, SV endocytosis in 
hippocampal neurones has been shown to occur on multiple timescales from less 
than a second to several seconds at physiological temperature and is largely 
independent of clathrin and AP-2 (Soykan et al., 2017). However, there is recent 
evidence that suggest that CME does still occur at physiological temperatures (with a 
tau of around 5-6 s) (Nicholson-Fish et al., 2015).  
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1.5 – Overall Hypothesis and Aims of Research 
This thesis will focus on the core interaction between two key SV proteins SV2A and 
SYT1. SV2A is retrieved by the adaptor protein AP-2, whilst SYT1 is retrieved by 
its monomeric adaptor protein, stonin-2. Recent evidence has indicated that the 
trafficking of SYT1 is intrinsically linked to SV2A function (Kaempf et al., 2015, 
Zhang et al., 2015)during SV recycling. The overall hypothesis of this work is that 
disruption of SV2A retrieval by AP-2 will lead to downstream defects in the 
recycling of SYT1, a key SV protein involved in SV docking and fusion at the 
plasma membrane. Malfunctions in the intrinsic trafficking partnership between 
SV2A and SYT1 may represent a novel underlying mechanism by which 
epileptogenesis may occur, as well as a novel presynaptic target by which certain 
anti-epileptic drugs (such as levetiracetam) may have a mode of action in the 
treatment of epilepsy. 
The aims of the research are: 
1) To establish and characterise the phenotype of SYT1 and general SV 
recycling when SV2A recycling is perturbed in mouse hippocampal 
neurones. 
 
2) To establish and characterise the phenotype of SYT1 and general SV 
recycling when known human mutation of SV2A implicated in epilepsy 
(R383Q) replaces normal SV2A in mouse hippocampal neurones. 
 
3) To determine if the anti-epileptic drug, levetiracetam, has a mode of action on 
SYT1 or general SV recycling at the presynaptic terminal. 








2.0 – Materials and Methods  
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2.1 – Materials 
Synaptophysin (SYP) -pHluorin was obtained from Dr. Leon Lagnado (Sussex, UK). 
Vesicular glutamate transporter 1 (VGLUT1) -pHluorin was a gift from Dr. Rob 
Edwards, MD (San Francisco, USA). Synaptotagmin (SYT1) -pHluorin was a gift 
from Prof. Volker Haucke (Berlin, Germany). SV2A knockdown was achieved using 
the published oligonucleotide sequence 
(GAATTGGCTCAGCAGTATGTTCAAGAGACATACTGCTGAGCCAATTC) 
which forms a short hairpin against the rat sequence of SV2A that is identical to the 
mouse sequence (shRNA) (Zhang et al., 2015). SV2AshRNA, SV2AshRNA-SYT1-
pHluorin, wild type (WT) SV2A-mCer and T84A SV2A-mCer plasmids were 
obtained courtesy of Prof. Dario Alessi (Dundee, UK).  All other SV2A-mCer 
plasmids were synthesised in-house. Full details are provided in the tables below 
(Tables 2.2.11, 2.2.14). 
FastDigest and Rapid Ligation enzymes and buffers were obtained from 
ThermoFisher Scientific™ (Paisley, UK). p-GEM T-Easy Vector system was 
obtained from Promega™ (Southampton, UK). P-GEX 4T-1 GST Gene Fusion 
System was obtained from GE Healthcare™ (Amersham, UK). Primary antibodies 
against SV2A, V-ATPase, Tubulin and eGFP were obtained from Abcam 
(Cambridge, UK). Primary antibody against Actin was obtained from Sigma-
Aldrich™ (Poole, UK). Fluorescent secondary antibodies were obtained from Life 
Technologies™ (Paisley, UK). Minimal Essential Media (MEM) and Lipofectamine 
2000 used in cultures and transfections were obtained from Invitrogen™ (Paisley, 
UK). XL10 E.Coli DNA Expression and BL21 E.Coli Protein Expression systems 
were obtained from Invitrogen™ (Paisley, UK) and bacteria were continually 
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replicated in-house from commercial stocks. All other chemicals and reagents used 
were obtained from Sigma-Aldrich™ (Poole, UK). Materials and media used in cell 
culture of mouse primary hippocampal neurones are listed in the table below (Table 
2.2). 
 
Reagent Supplier Catalogue 
Foetal bovine serum Biosera (Sussex, 
UK) 
S1810-500 
B27 supplement Life Technologies 
(Paisley, UK) 
17504-044 
DMEM/F-12 medium Life Technologies 21331-020 
Dulbecco's phosphate 
buffered saline 
Life Technologies 14190-094 
L-Glutamine solution Life Technologies 25030-024 
Neurobasal medium Life Technologies 21103-049 
Penicillin-Streptomycin 
solution 
Life Technologies 15140-122 




















Table 2.1: Materials and media required for cell culture of mouse hippocampal neurones. 
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2.2 – Methods 
2.2.1 – Preparation of Hippocampal Neuronal Cultures 
Wild type mice were maintained from a C56BL/6J background line. Primary 
hippocampal dissociated cultures were prepared from embryonic day 17.5 mice. 
Pregnant mice were culled by neck dislocation by a technician, in accordance with 
Schedule 1 Section F2 of the Animals (Scientific Procedures) Act 1986. Embryonic 
mice were extracted from the parent and culled by decapitation, in accordance with 
Schedule 1 Section F6B of the Animals (Scientific Procedures) Act 1986. 
Prior to animal collection, pre-autoclaved microscope coverslips were soaked in a 
solution of poly-D-lysine [PDL, 50 µg/mL final concentration] in sterile boric acid 
(100 mM, pH 8.5) and placed on a tube roller overnight. The boric acid was removed 
and the coverslips washed with water (x 4), separated and left to air-dry on a piece of 
sterilised lab paper for 30 min. Coverslips were placed into each well of the required 
number of 6-well plates. Laminin was thawed on ice and added to Neurobasal media 
(supplemented with B-27 supplement (2% v/v), L-glutamine (0.5 mM) and 
penicillin/streptomycin solution (1% v/v)] to a final concentration of 0.1 µg/mL and 
mixed by gentle inversion. The laminin-enriched Neurobasal was pipetted as 50 µL 
spots onto the centre of each coverslip in 6-well plates and placed in a 37°C / 5% 
CO2 incubator. 
Hippocampi were dissected from the brains and digested in papain (10 units/mL) for 
20 min at 37ºC. Excess papain was removed using a pipette, the cells were 
resuspended in DMEM/F12 [2 mL, supplemented with penicillin/streptomycin 
solution (1% v/v) and foetal bovine serum (FBS, 10% w/v), and carefully titurated 
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until a homogeneous suspension was obtained. Excess DMEM/F12 (3 mL) was 
added, the cells were pelleted (340 g, 5 min, RT) and the supernatant was removed. 
Supplemented Neurobasal media (100 µL per head dissected) was added to the cell 
pellet and the cells were titurated carefully until a homogeneous suspension was 
obtained. The cells were counted using a haemocytometer and the final cell count 
was multiplied by 104 to give a concentration (in cells/mL) then further diluted to a 
final concentration of 0.5 x 107 cells per mL. The diluted cell suspension (10 µL, 
50000 cells) was injected into the 50 µL Laminin-enriched Neurobasal spots in the 
pre-prepared 6-well plates and incubated for 45 min in a 37°C / 5% CO2 incubator. 
Supplemented Neurobasal media (2 mL) was added to each well and the cells 
maintained in a 37°C / 5% CO2 incubator for 2-3 days in culture. Cytosine β-D-
arabinofuranoside (Ara-C) was added to a final concentration of 1 µM per well to 
prevent glia proliferation. 
 
2.2.2 – Transfections 
Transfections using two or less DNA constructs were performed after 7 days in 
culture. Conditioned Neurobasal media was removed from each well (containing cell 
cultures to be transfected), replaced with Minimum Essential Media (MEM, 
ThermoFisher Scientific) (2 mL) and incubated at 5 % CO2 at 37°C. The required 
DNA constructs (1 µg/well) and Lipofectamine 2000 (2 µL/well) were mixed and 
preincubated in MEM (0.5 mL/well) for 20 min. The DNA/Lipofectamine mixture 
was then added to the cells (0.5 mL/well) and incubated for 2 h. After transfection, 
the cells were washed with MEM (1 mL per well) prior to replacement of 
conditioned Neurobasal media. 
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Transfections using three DNA constructs were performed after 7 days in culture. 
Conditioned Neurobasal media was removed from each well (containing cell cultures 
to be transfected), replaced with Opti-MEM (2 mL, ThermoFisher Scientific) and 
incubated at 5% CO2 at 37°C. The required DNA constructs (0.7 µg/well) and 
Lipofectamine 2000 (2 µL/well) were mixed and preincubated in Opti-MEM (0.5 
mL/well) for 20 mins. The DNA/Lipofectamine mixture was then added to the cells 
(0.5 mL/well) and incubated for 2 h. After transfection, the cells were washed with 
Opti-MEM (1 mL per well) prior to replacement of conditioned Neurobasal media. 
 
2.2.3 – Imaging of pHluorin-mediated Fluorescence Responses 
PHluorins were used to report the trafficking of a target SV protein as well as general 
SV recycling. The pH-sensitive GFP in pHluorins is located in the intraluminal 
domain of the vesicle (as it is specifically fused to the luminal domain of an 
exogeneous SV protein) and fluorescence is quenched under the pH conditions in 
this domain (pH ~ 5.6). During SV exocytosis, the vesicle fuses to the plasma 
membrane and the pH-sensitive GFP fluoresces when exposed to the high pH of the 
extracellular environment (pH ~ 7.4). Fluorescence is quenched again following SV 
endocytosis and re-acidification and the GFP molecule is returned to the environment 
of the intraluminal domain (Miesenböck et al., 1998). 
Hippocampal cell cultures were mounted in a Warner RC-21BRFS imaging chamber 
with embedded parallel platinum wires and placed on the stage of a Zeiss Axio 
Observer A1 epifluorescence microscope. Neurones were visualized with a Zeiss 
Plan Apochromat x40, 1.3 numerical aperture (NA 1.3) oil-immersion objective lens. 
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The transfected neurones were visualised at either 430 nm (mCerulean – a cyan 
fluorescent protein used as a marker for transfected cells) or 500 nm (pHluorin 
reporters) excitation using a dichroic > 525 nm and a long-pass emission filter > 535 
nm. Fluorescent images were captured at 4 s intervals. For imaging certain pHluorins 
with low photon emission, individual pixels were ‘binned’ together as a group in 
order to increase the signal to noise ratio (no binning for SYP-pHluorin and 
VGLUT1-pHluorin imaging; 2:2 binning for SYT1-pHluorin imaging). Images were 
captured using a Zeiss AxioCam MRm Rev.3 digital camera and a workstation 
installed with Zeiss Zen2012 Blue software. Cultures were subjected to continuous 
perfusion with cell imaging buffer [NaCl (119 mM), KCl (2.5 mM), CaCl2 (2.0 mM), 
MgCl2 (2.0 mM), glucose (30 mM), HEPES (2.5 mM), pH 7.4] for 60 s (15 image 
frames) to capture baseline fluorescence then stimulated with a train of 300 action 
potentials delivered at 10 Hz (100 mA, 1 ms pulse width). In these experiments, there 
were no independent measures of action potentials taken and the term ‘action 
potential’ is used to describe the number of electrical pulses given. All results given 
in this thesis are described and explained based on the assumption that the full 
number of pulses given is successfully converted into action potentials by the 
observed neurone. A caveat of this assumption is that any observed phenotype (or 
lack thereof) may be a result of a failure of the neurone to convert all electrical 
pulses into action potentials. The subsequent neuronal response and fluorescence 
recovery was recorded for 220 s (55 image frames) after which perfusion was 
changed to an alkaline cell imaging buffer [NaCl (69 mM), NH4Cl (50 mM), KCl 
(2.5 mM), CaCl2 (2.0 mM), MgCl2 (2.0 mM), glucose (30 mM), HEPES (2.5 mM), 
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pH 7.4] for a period of 120 s (30 image frames) to reveal the total SV pool in the 
synapses. 
2.2.4 – Imaging Surface Fraction Expression of pHluorin Reporters 
Quantification of the surface fraction expression of various pHluorin reporters was 
achieved by perfusion of acidic imaging buffer to quench the surface expressed 
pHluorin after imaging of its resting fluorescence. The average fluorescence 
difference between both conditions the reveals the surface expressed fraction of the 
cell (Gordon et al., 2011). 
Hippocampal cell cultures were perfused with standard cell imaging buffer for 90 s 
and switched to an acidic cell imaging buffer [NaCl (119 mM), KCl (2.5 mM), CaCl2 
(2.0 mM), MgCl2 (2.0 mM), glucose (30 mM), MES hydrate (2.5 mM), pH 5.5] for 
90 s and 5 image frames (4 s interval) were captured. The cells were perfused with 
standard cell imaging buffer for another 90 s to allow pHluorin fluorescence 
recovery, after which alkaline cell imaging buffer was perfused for further 90 s to 
reveal the total SV pool. Fluorescent images were captured for 20 s (4 s intervals) 
after the end of each perfusion period. Neurones were visualized on a Zeiss Axio 
Observer A1 epifluorescence microscope using a Zeiss Plan Apochromat x40 (NA 
1.3) oil-immersion objective and fluorescence was visualised at either 430 nm 
(mCerulean) or 500 nm (pHluorin reporters) excitation using a dichroic > 525 nm 
and a long-pass emission filter > 535 nm. Images were captured using a Zeiss 
AxioCam MRm Rev.3 digital camera and Zeiss Zen2012 Blue software. 
 
2.2.5 – Analysis of Surface Fraction Expression of pHluorin Reporters 
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Regions of Interest (ROIs) were selected as described previously. The surface 
fraction of pHluorin (as a percentage of total pHluorin) expressed within each ROI 
was estimated using the following equation: [(average resting baseline fluorescence – 
minimum acidic fluorescence) / (maximum alkaline fluorescence – minimum acidic 
fluorescence) x 100]. The values obtained from each ROI were then averaged to give 
a representative value of surface expression for each coverslip (Gordon et al., 2011). 
Experimental results were averaged over several replicates and analysed for 
statistical significance. All statistical analyses were performed using Microsoft Excel 
2013 and GraphPad Prism 6.0 software. 
 
2.2.6 – Analysis of Coefficient of Variation for Surface Fraction 
The coefficient of variation (CV) is a calculation for the diffuseness of the 
fluorescence for the total pHluorin pool along a fixed length of neurite (Lyles et al., 
2006). Captured images of hippocampal cell cultures subjected to alkaline imaging 
buffer (see chapter 2.2) were used for these analyses. Lines of interest (LOI) of at 
least 50-µm long were drawn over selected neurones using FIJI’s freehand line 
drawing tool and the fluorescence was quantified along the profile. CV of pHluorin 
fluorescence along axons was determined by the following equation:  
[(standard deviation of the fluorescence signal / the mean value of the fluorescence 
signal) x 100].  
Five LOIs were taken for each coverslip and examined to obtain an average CV 
value for the coverslip. Experimental results were averaged over several replicates 
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and analysed for statistical significance. All statistical analyses were performed using 
Microsoft Excel 2013 and GraphPad Prism 6.0 software. 
 
2.2.7 – Imaging of Intracellular Free Calcium Responses using Fluo-3 AM 
Fluo-3 was used to monitor evoked changes in intracellular free calcium in response 
to action potential stimulation. It reports this by exhibiting a large fluorescence 
increased upon co-ordination of the molecule to free Ca2+ ions (Minta et al., 1989). 
Hippocampal cell cultures were incubated with the fluorescent Ca2+ indicator Fluo-3 
AM (10 µM in cell imaging buffer, ThermoFisher Scientific) for 30 min. Excess 
Fluo-3 AM was washed off by perfusion with normal cell imaging buffer prior to 
stimulation. In experiments using elevated KCl to clamp membrane potential at an 
excited state, a solution of elevated KCl cell imaging buffer [NaCl (71.5 mM), KCl 
(50 mM), CaCl2 (2.0 mM), MgCl2 (2.0 mM), glucose (30 mM), HEPES (2.5 mM), 
pH 7.4] was perfused over the cells for a period of 30 s and subsequently washed 
away with a second perfusion of imaging buffer. After a recovery period of 60 s, the 
cells were stimulated with a train of 300 action potentials at 10 Hz (100 mA, 1 ms 
pulse width) and visualised using a Zeiss Axio Observer A1 epifluorescence 
microscope using a Zeiss Plan Apochromat x40 (NA 1.3) oil-immersion objective 
and fluorescence was visualised at 500 nm excitation using a dichroic > 525 nm and 
a long-pass emission filter > 535 nm. Images were captured with a Zeiss AxioCam 
MRm Rev.3 digital camera and Zeiss Zen2012 Blue software.  
In order to increase the neuronal network activity of the cultures, a solution of 4-
aminopyridine (4-AP, 50 µM in cell imaging buffer) was perfused over the cells for a 
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period of 120 s and subsequently washed away with a second perfusion of imaging 
buffer. After a recovery period of 90 s, the cells were stimulated with a train of 300 
action potentials at 10 Hz (100 mA, 1 ms pulse width) and visualised using the same 
system described above.   
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2.2.8 – Analysis of pHluorin/Fluo-3 AM Imaging 
The series of raw images captured from the microscope workstation were aligned 
and analysed using Fiji is Just ImageJ (FIJI) software (National Institute of Health, 
Maryland, USA) together with the following plugins Time Series Analyser v3.0 
(Balaji J., UCLA California, USA) and MBGReg (Donal Stewart, Edinburgh, UK). 
In order to correct for slight occurences of image drift, raw images were first aligned 
using the MBGReg plugin to the frame with maximal pHluorin fluorescence (Frame 
90). Responsive nerve terminals were selected by toggling between the image frames 
and visually identifying boutons that displayed a clear increase in fluorescence when 
perfused with alkaline image buffer (Frames 90-120) when compared to baseline 
fluorescence under standard imaging buffer (Frames 1-20). Between 75 to 100 
regions of interest (ROIs) of identical size (5x5 pixels for 1:1 binning; 3x3 pixels for 
2:2 binning) were placed over the selected nerve terminal boutons (Figure 2.2.8 A) 
and the total fluorescence intensity of each ROI was monitored over time and plotted 
as a graph of fluorescence vs time. The data of each individual ROI was input into 
ROITraceSelector v11.0 software (Donal Stewart, Edinburgh) in order to remove 
unsuitable ROIs from the data pool. Selection of usable ROIs were based on three 
criteria: 1) an increase in fluorescence upon stimulation; 2) a mono-exponential 
decay of fluorescence back down to baseline or close to baseline; 3) A sharp, visible 
increase of fluorescence after perfusion with alkaline imaging buffer to reveal to total 
SV pool (Figure 2.2.8 B). After ROI selection, the data was transferred to Microsoft 
Excel 2013 where the pHlourin fluorescence change was expressed as a ratio of the 
raw fluorescence of each ROI (∆F) over the average baseline fluorescence prior to 
stimulation (F0) as represented by the following formula: 
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PHlourin fluorescence change (∆F/F0) = [ROI fluorescence during selected frame / 
ROI average fluorescence during last 5 frames of acquisition prior to stimulation 
(frames 11-15)]  
The time constant of the fluorescence decay (tau) of each ROI after stimulation is 
indicative of the time it takes for pHluorin fluorescence to fall to 37% of its initial 
maximum fluorescence (which can be associated with the time taken to retrieve 63% 
of pHluorin molecules from the plasma membrane). In order to obtain this value, 
data was taken from the time point immediately after stimulation to a cut-off point at 
180 s after the start of the experiment (image frames 16 - 45). A mono-exponential 
decay curve function was fitted to the data using GraphPad Prism 6.0 software, as 
described below: 
[F = (F0 - Fmin)exp(-Kt) + Fmin] 
where F = normalised fluorescence, F0 = maximum fluorescence after stimulation, 
Fmin = minimum fluorescence after decay, K = rate constant and t = time after 
stimulation.  
Tau values were then obtained from calculating 1/K. It is noted that pHlourin 
experiments produce, on occasion, a mono-exponential decay with a non-zero 
asymptote. This phenomenon has been previously observed in similar experiments 
from other research groups (Fernández-Alfonso et al., 2006, Kaempf et al., 2015) and 
its underlying cause remains unexplained to date. As a result, no constraints have 
been placed on the value of the asymptote during fitting of the mono-exponential 
decay function in this thesis. The fitting of a mono-exponential decay function to 
non-equal, non-zero asymptotes may produce small systematic errors due to 
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comparison differences; however, these differences are considered very small and are 
assumed not to affect the overall statistical significance of any observed phenotype in 
the experiments. Traces that did not produce tau values or produced tau values of 
infinity were discarded and removed from analysis. Individual ROI traces were then 
averaged to produce a single representative trace for all responding boutons with the 
coverslip field of view.  
Any traces that displayed mono-exponential decay prior to stimulation (due to 
photobleaching) were corrected using GraphPad Prism 6.0 software by fitting the 
above described mono-exponential decay function to the first 15 frames of image 
acquisition. The decay function was then mathematically subtracted from the raw 
trace in order to produce the decay corrected trace. 
The resulting values were normalised in two different manners for further analysis: 
1) Normalisation to the peak of stimulation (maximum fluorescence value obtained 
during the 300 AP, 10 Hz stimulation period) to reveal differences in the rates of 
pHluorin retrieval during SV endocytosis; 2) Normalisation to the peak of the 
alkaline buffer pulse (maximum fluorescent value obtained during the alkaline NH4 
buffer pulse period = 1) to reveal differences in the amount of externalised pHluorin 
at the plasma membrane during stimulation during SV exocytosis. All ‘n’ values 
expressed in this thesis refer to the number of coverslips examined. Experimental 
results were averaged over several replicates and analysed for statistical significance.  
All statistical analyses were performed using Microsoft Excel 2013 and GraphPad 
Prism 6.0 software. 
 




Figure 2.2.8: Analysis of pHluorin imaging. A) Regions of interest (ROIS, blue circles) were selected 
on the neuronal field of view using the FIJI plugin Times Series Analyser v3.0. The change in 
fluorescence after baseline correction (∆F/F0) vs. time was calculated for each individual ROI and 
averaged to give the average trace for the experiment. Scale bar = 10 µM. B) Screening of ROIs using 
ROI Trace Selector v0.11. Selection of usable ROIs were based on three criteria: 1) an increase in 
fluorescence upon stimulation; 2) a mono-exponential decay of fluorescence back down to baseline 
or close to baseline; 3) A sharp, visible increase of fluorescence after perfusion with alkaline imaging 
buffer to reveal to total SV pool. ROIS deemed unsuitable were unchecked from the list to the right.  
A
B
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2.2.9 – Immunocytochemistry of SV2A Expression 
Culture media was aspirated from each coverslip and the transfected cells washed 
with phosphate buffered saline [PBS, NaCl (140 mM), Na2PO4 (10 mM), KCl (2.7 
mM), KH2PO4 (1.8 mM)]. Paraformaldehyde (PFA, 4 % in PBS) was added to each 
coverslip and incubated at room temperature for 20 min to fix the cells. The PFA was 
aspirated, a solution of NH4Cl (50 mM in PBS) was added to quench the excess PFA 
and the cells incubated at room temperature for 10 min. The NH4Cl solution was 
aspirated, cells were washed with PBS (x 3), a solution of Triton-X 100 (0.1% in 1 % 
BSA/PBS) was added to permeabilise the cell membrane and the cells incubated for 
5 min. The Triton-X solution was aspirated, cells washed with PBS (x 1), and a 
solution of BSA (1 % in PBS) was added as a blocking reagent and the cells 
incubated for a further 30 min. Coverslips were then removed and incubated in rabbit 
anti-SV2A (1:200, 1 % BSA in PBS, Abcam) and chicken anti-GFP (1:5000, 1% 
BSA in PBS, ThermoFisher Scientific) primary antibodies at room temperature for 1 
hr. The coverslips were washed with PBS (x 3) and incubated in the corresponding 
secondary antibodies [goat anti-rabbit AlexaFluor 568 (A21069, ThermoFisher 
Scientific), goat anti-chicken AlexaFluor 488 (A11039, ThermoFisher Scientific), 
1% BSA in PBS] in the dark at room temperature for 1 hr. The coverslips were then 
rinsed with ddH2O, dried in the dark and mounted onto glass microscope slides with 
FluorSafe™ mounting medium. Immunostained neurones were visualised using a 
Zeiss Axio Observer A1 epifluorescence microscope using a Zeiss Plan Apochromat 
x40 (NA 1.3) oil-immersion objective and fluorescence was visualised at either 500 
nm excitation / 525 nm emission (GFP, AlexaFluor 488) or 550 nm excitation / 603 
nm emission (SV2A, AlexaFluor 568) using a dichroic > 525 nm and a long-pass 
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emission filter > 535 nm. Images were captured with a Zeiss AxioCam MRm Rev.3 
digital camera and Zeiss Zen2012 Blue software. 
 
2.2.10 – Analysis of SV2A Immunocytochemistry 
Images obtained from fluorescence imaging were analysed and aligned using the 
Align RGB planes plugin (G.Landini, Birmingham, UK) in FIJI software (National 
Institute of Health, Maryland, USA). Still images of GFP and SV2A expression were 
exactly aligned and between 75-100 counts of regions of interest (ROIs) of identical 
size (5x5 pixels) were placed over nerve terminal boutons where both proteins were 
co-expressed to represent transfected boutons. ROIs (75-100 count) of untransfected 
boutons in the same field of view (not overlaying with GFP) were visually selected 
separately from the whole field. Excessively bright or dim boutons were not included 
in the data. ROIs (75-100 count) were also randomly chosen from dark regions of the 
field of view where there was absence of neurites to quantify the background auto-
fluorescence. Immunofluorescence was quantified and normalised to the average 
fluorescence of non-transfected nerve terminal boutons using the following equation:  
[(Raw transfected ROI average fluorescence – raw background ROI average 
fluorescence) / (Raw non-transfected ROI average fluorescence – raw background 
ROI average fluorescence)].  
Experimental results were averaged over several replicates and analysed for 
statistical significance. All ‘n’ values refer to the number of neurones examined for 
immunocytochemistry experiments only. All statistical analyses were performed 
using Microsoft Excel 2013 and GraphPad Prism 6.0 software. 
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2.2.11 – Site Directed Mutagenesis of SV2A-mCer Mutants 
Template DNA (1 ug/mL) and the appropriate sense primer and anti-sense primers 
(0.5 nM, see Table 2.2.11 below) were dissolved in PCR master mix buffer (50 µL) 
[dNTP mixture (20 µM), Tris-HCl (20 mM), KCl (10 mM), (NH4)2SO4 (10 mM), 
MgSO4 (2 mM), Triton® X-100 (0.1% v/v) and nuclease-free BSA (0.1 mg/mL), pH 
8.8]. Pfu DNA polymerase enzyme (0.5 µL, 1 unit, Promega) was added and the 
reaction subjected to PCR mediated site directed mutagenesis (1 Cycle – 96ºC for 2 
min; 20 Cycles – 96 ºC for 30 s, 52 ºC for 10 s, 72 ºC for 8 minutes (1 minute/kb 
plasmid); 1 Cycle – 72 ºC for 10 min; Hold at 4 ºC). DPN1 enzyme (1 μL, 5 units, 
Promega) was added to the PCR product to digest template DNA and the reaction 
mixture incubated at 37°C for 1 hr and immediately transformed (see 2.2.12) into 
competent XL10 E. Coli bacterial cells for expression. Transformed bacteria were 
plated onto agar plates containing either ampicillin (100 µg/mL) or kanamycin (50 
µg/mL) overnight and single colonies were selected. Bacterial cultures were grown 
overnight at 37°C from the colonies in LB media (10 g/L tryptone, 5 g/L yeast 
extract, 0.086 M NaCl) (5 mL) and DNA was extracted by use of a GENEJet 
Plasmid Miniprep Kit (ThermoScientific™) as per manufacturer’s instructions. 
Primer Sequence 
Y46A SV2A Sense TATTCCCGAAGGTCCGCCTCCCGCTTTGAGGAG 
Y46A SV2A Anti-Sense CTCCTCAAAGCGGGAGGCGGACCTTCGGGAATA 




Table 2.2.11: List of SV2A primers used for site-directed mutagenesis studies. All primers were 
commercially purchased from Eurogentec Ltd. 
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2.2.12 – Preparation of Chemically Competent E.Coli Cells 
A sample of commercially available Top 10/XL10/BL21 E.coli bacteria (Sigma 
Aldrich) were obtained from commercially available sources and inoculated in a 5 
mL culture overnight at 37ºC with shaking. A sample of the overnight culture (1 mL) 
was added to LB media (100 mL) and sterile MgSO4 (20 mM) was added to the 
mixture.  The new culture was incubated at 37ºC until an optical density of 0.4-0.6 
was reached to allow bacteria to reach maximum growth rate. Cells were centrifuged 
(5000 g, 5 min, 4°C), the supernatant was discarded and the remaining pellet re-
suspended in a solution of TFB1 (40 mL) [Potassium acetate (30 mM), CaCl2 (10 
mM), MnCl2 (50 mM), RbCl (100 mM), Glycerol (15% final conc)] for 5 min. After 
incubation, the cells were centrifuged again (5000 g, 5 min, 4°C), the supernatant 
was discarded and the cells re-suspended in a solution of TFB2 (5 mL) [MOPS (10 
mM), CaCl2 (75 mM), RbCl (10 mM), Glycerol (15% final conc.)] for 30 min. After 
incubation, the cells were aliquoted, snap frozen and stored at -80ºC for future use. 
 
2.2.13 – Transformation of DNA into Competent E.Coli Cells 
An aliquot of competent E.Coli cells was defrosted on ice and the desired DNA (5 
ng) was added. The mixture was then incubated on ice for 30 min to allow DNA 
attachment to the cells. The E.Coli cells were then heat shocked at 42ºC for 45 s and 
allowed to incubate on ice for a further 2 min. LB medium (200 µL) was added to the 
cells and allowed to recover for 30 min at 37ºC. A sample of the mixture (100 µL) 
was plated of agar plates containing either ampicillin (100 µg/mL) or kanamycin (50 
µg/mL).  
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2.2.14 – Fusion Protein Expression of Glutathione S-Transferase (GST) – SV2A 
Mutants 
Template DNA (1 ug/mL), dNTPs (20 μM) and the appropriate sense primer and 
anti-sense primers (0.5 nM, see table 2.2.14) were dissolved in 1 x Expand High 
Fidelity PCR buffer (Sigma-Aldrich™, w/ 1.5 mM MgCl2). GoTaq Expand DNA 
polymerase enzyme (1 µL, 5 units, Promega) was added and the reaction subjected to 
PCR mediated DNA amplification (1 Cycle – 95ºC for 2 min; 30 Cycles – 95 ºC for 
30 s, 55 ºC for 1 min, 72 ºC for 1 minute (0.5 minute/kb plasmid); 1 Cycle – 72 ºC 
for 10 min; Hold at 4 ºC). The PCR product was ligated into a p-GEM T-Easy Vector 
System for easy formation of a circular vector to aid accuracy of digestion. The 
ligation was performed by adding T4 DNA Ligase (1 µL, 5 units) to a mixture of 
PCR product (1 µL), vector (3 µL) and 1 x Rapid Ligation Buffer (up to 10 uL). The 
p-GEM PCR product was digested using BamHI and XhoI FastDigest™ restriction 
enzymes (1 µL each, 1 unit) and ligated into a p-GEX 4-T1 GST Gene Fusion 
System for expression of the GST-fused DNA, using the same protocol as described 
above. The pGEX-ligated DNA was then transformed (as previously described in 
2.2.13) into competent XL10 E. Coli bacteria for complete plasmid expression. 
Transformed bacteria were plated onto agar plates w/ ampicillin (100 µg/mL) 
overnight and single colonies were selected. Bacterial cultures were grown overnight 
at 37°C from the colonies in LB media (5 mL) [10 g/L tryptone, 5 g/L yeast extract, 
0.086 M NaCl] and DNA was extracted by use of a GENEJet Plasmid Miniprep Kit 
(ThermoScientific™) and test-digested using BamHI and XhoI FastDigest™ 
enzymes (1 µL each, 1 unit, ThermoFisher Scientific) for the presence of the vector 
insert. Samples containing the correct plasmid DNA were then re-transformed in 
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BL21 E.Coli bacteria for high level IPTG-induced protein expression of target genes 
in T7 expression vectors and 40% glycerol stocks were made and stored at -80ºC. 
Mutations in the SV2A cytosolic loop (R383Q + R383E) were created using the 
same primers and methods as previously described in 2.2.11.  
 
Primer Sequence 
GST SV2A loop Sense 
(BamHI) 
GGATCCGAGAGTCCCCGCTTCTTCCTAGAGA 
GST SV2A loop Sense 
(XhoI) 
CAGTCCAGAGTATCGGCGCATCACGTGACTCGAG 












Table 2.2.14: List of primers used for engineered GST-SV2A loop constructs and its mutants. All 
primers were commercially purchased from Eurogentec Ltd. 
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2.2.15 – Preparation of GST-SV2A Tagged Glutathione Beads for Pulldown Assay 
GST pulldown assays were used to identify any interactions between the SV2A 
cytosolic loop and proteins in the brain lysate. The strong interaction between 
glutathione and glutathione transferase acts as the anchor for the fusion protein, 
allowing all interacting proteins to be isolated (Smith and Johnson, 1988). 
The Glutathione Sepharose 4B (GS4B) resin (1 mL, 50% slurry, GE Healthcare) was 
prepared by washing with PBS (x 1), then with PBS-Triton X [0.1 % v/v] (x 1) to 
remove hydrophobic impurities and again with PBS (x 1). The beads were then 
pelleted (23 g, 5 min, 4°C) and kept at 4°C until later use.  A sample of GST-SV2A 
DNA variants in BL21 E.Coli bacteria, taken from previously made glycerol stocks, 
were cultured overnight at 37°C in ampicillin (100mg/mL) enriched LB media (5 
mL) [10 g/L tryptone, 5 g/L yeast extract, 0.086 M NaCl]. The overnight culture (3 
mL) was further diluted in LB media (250 mL) to allow the bacteria to reach their 
maximum growth phase and the new culture was incubated at 37°C until the culture 
reached an optical density of 0.6 as the bacteria enters this phase. Isopropyl β-D-1-
thiogalactopyranoside (IPTG, 1 mM) was added to induce protein expression and the 
culture was allowed to incubate for a further 4 hrs. The culture was then pelleted in a 
centrifuge (1137 g, 15 min, 4°C), supernatant discarded, and the pellet resuspended 
in STE buffer (40 mL) [Tris buffer (10 mM), NaCl (150 mM), EDTA (1 mM),  
phenylmethylsulfonyl fluoride (1 mM), protease inhibitor cocktail (150 µL of a 
DMSO solution, P8849, Sigma Aldrich), pH 8]. Lysosyme (13.3 μg/mL final 
concentration) was added to lyse the bacterial cells and the suspension was incubated 
on ice for 30 min. Dithiothreitol (DTT, 5 mM) and Triton-X 100 (1% v/v) was added 
as further measure to prevent protease action and the lysate was sonicated on ice (30 
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s x 6) and pelleted (12000 rpm, 5 min, 4°C). The lysate supernatant was incubated 
with previously prepared GS4B beads for 1 hr at 4°C. Protein bound beads were 
pelleted (23 g, 5 min, 4°C), washed with PBS (x 5), washed with NaCl (1.2 M, x 1) 
to remove any non-specific bound proteins, and then washed again with PBS (x 2). 
The resulting beads were then made up to a 50% slurry in PBS ready for use in GST 
pulldown assays. 
 
2.2.16 – Preparation of Crude P2 Synaptosomes 
One adult rat was killed by cervical dislocation and the brain removed. The 
cerebellum and visible white matter was then removed and the remaining cortex 
rinsed in an ice-cold sucrose/EDTA solution (20-50 mL) [Sucrose (0.32 M), 
ethylenediamine tetraacetic acid (EDTA, 1 mM), Tris buffer (5 mM), pH 7.4]. The 
cortices were transferred to a tube containing ice-cold sucrose/EDTA (10 mL/rat, 
~10% suspension), minced with a pair of scissors and homogenised immediately 
using a Thomas "AA" 5 mL teflon/glass homogeniser. The homogenised mixture 
was then pelleted (403 g, 10 min, 4°C), re-suspended in ice-cold sucrose/EDTA 
solution (15 mL) and pelleted again (403 g, 10 min, 4°C). The supernatants from 
both spins were combined and re-pelleted (8691 g, 10 min, 4°C). The crude 
synaptosome P2 pellet was re-suspended in ice cold HEPES-Buffered-Krebs (20 mL) 
[NaCl (118.5 mM), KCl (4.7 mM), Na2HPO4 (1 mM), MgSO4 (1.2 mM), glucose (10 
mM), HEPES (20 mM), pH 7.4], pelleted (8691 g, 10 min, 4°C) and the supernatant 
removed. Ice-cold lysis buffer (8 mL) [Tris-HCl (25 mM), NaCl (150 mM), 
ethyleneglycol tetraacetic acid (EGTA, 1 mM), EDTA (1 mM), PMSF (1 mM), 
Protease Inhibitors (150 µL of DMSO solution, P8849, Sigma Aldrich)] was added 
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and the mixture pelleted once more (8691 g, 10 min, 4°C). The supernatant lysate 
was then aliquoted (200 μL each) and stored at -80°C.   
 
2.2.17 – Pulldown Assay for GST-SV2A Mutants 
A suspension of GST coupled beads in PBS (150 μL) was added to a MobiSpin mini 
spin filter column (Boca Scientific), washed with lysis buffer (0.5 mL) and the buffer 
extracted by centrifugation (728 g, 10 s , 4°C). Crude P2 synaptosome lysate (200 
μL) was then added to the beads in the column and incubated at 4°C for 2 hrs with 
rotation using a sample tube rotator. The synaptosome lysate was then extracted by 
centrifugation (728 g, 10 s, 4°C) and the beads washed sequentially with ice cold 
lysis buffer (x 3), high salt lysis buffer (x 1) [Tris-HCl (25 mM), NaCl (150 mM), 
ethyleneglycol tetraacetic acid (EGTA, 1 mM), EDTA (1 mM), PMSF (1 mM), 
Protease Inhibitors (75 µL of DMSO solution, P8849, Sigma Aldrich)],  lysis buffer ( 
x 3) and Tris buffer (20 mM, pH 7.4). The bound proteins were extracted with 1 x 
SDS sample buffer [Tris buffer (67 mM) EDTA (2 mM), sodium dodecyl sulfate 
(SDS) (67 mM), Glycerol (3%), Bromophenol blue (0.0002%), β-mercaptoethanol 
(0.04%)], boiled at 90°C and separated by SDS gel electrophoresis (SDS-PAGE) 
using a mini-PROTEAN Tetracell electrophoresis chamber (Bio-Rad) at 120 V with 
a 10% acrylamide gel [ddH2O (3.2 mL), acrylamide/bis (2.67 mL, 30%, 37.5:1), 
Tris-HCl (2 mL, 1.5 M, pH 8.8), N,N,N′,N′-tetramethylethylene-diamine (TEMED, 8 
µL), SDS (80 µL, 10%), ammonium persulfate (APS, 80 µL, 10%)] in gel running 
buffer [Tris (25mM), Glycine (190 mM), SDS (0.1% w/v), pH 8.3]. The gel was 
stained with Coomassie Blue for mass spectrometry and scanned with an Epson 
scanner. Identified bands of interest were excised using a scalpel, with appropriate 
   
75 
 
care to avoid contamination, and placed in autoclave tubes. Samples were sent to the 
Wishart Group (Roslin Institute, Edinburgh) for analysis by ESI-QUAD TOF mass 
spectrometry. 
 
2.2.18 – Western Blotting of GST Isolated Proteins 
Western blotting was used to characterise all interacting proteins identified from the 
GST pull down and mass spectrometry experiments (Burnette, 1981). 
Eluted proteins from the pulldown assays (in 1 x SDS sample buffer) were separated 
by SDS-PAGE using a mini-PROTEAN Tetracell electrophoresis chamber (Bio-
Rad) at 120 V with a 10% acrylamide gel [ddH2O (3.2 mL), acrylamide/bis (2.67 
mL, 30%, 37.5:1), Tris-HCl (2 mL, 1.5 M, pH 8.8), N,N,N′,N′-tetramethylethylene-
diamine (TEMED, 8 µL), SDS (80 µL, 10%), ammonium persulfate (APS, 80 µL, 
10%)] in running buffer. The separated proteins were transferred to a nitrocellulose 
membrane using a mini Trans-Blot electrophoretic transfer cell for 15 hours (20 V, 
Bio-Rad) [Transfer buffer recipe: Tris buffer (25 mM), glycine (190 mM), methanol 
(20% v/v)]. The nitrocellulose membrane was stained with Ponceau S after transfer 
to check the viability of the transfer. The membrane was destained with water and 
blocked with LICOR™ blocking buffer (LBB) /PBS (1:1) for 1 hr. The membrane 
was incubated with the desired primary antibodies [see table 2.2.18; dissolved in 1:1 
LBB/PBS-Tween (0.1% v/v)] for 1 hr. The membrane was then washed with PBS-
Tween (0.1% v/v) for 5 min (x 4). The membrane was incubated with the desired 
LICOR™ secondary antibodies [see table 2.2.18, dissolved in 1:1 LBB/PBS-Tween 
(0.1% v/v)] for 1 hr and washed with PBS-Tween (0.1%) (x 4). The membrane was 
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Species Dilution Dye 
Anti-GST Abcam (ab19256) Rabbit 1:10000  
Anti-actin Sigma Aldrich 
(A2228) 
Mouse 1:100000 - 
Anti-β3-tubulin Sigma Aldrich 
(SAB4300623) 










Rabbit 1:5000 - 
Anti-SV2A Abcam (ab32942) Rabbit 1:1000 - 
Anti-SYT1 Abcam (ab13259) Mouse 1:1500 - 
Anti-SYP Synaptic Systems 
(SS101002) 
Rabbit 1:8000 - 
Secondary 
Antibody 
Company Species Dilution Dye 
Anti-Rabbit Li-Cor (P/N 925-
32210) 
Goat 1:10000 IRDye 680 
Anti-Mouse Li-Cor (P/N 925-
68071) 
Goat 1:10000 IRDye 800 
Table 2.2.18: List of antibodies used for western blotting analysis. The antibodies are listed along 
with the company which they are obtained from, the animal species in which they were raised in, the 
dilution used in the experiments and the dye wavelength in which they emit. 
  
   
77 
 
2.2.19 – Analysis of Western Blots 
Western blot images taken with the LICOR Odyssey scanner was analysed using 
ImageStudio Lite software (LICOR Biotechnology, UK). Rectangular ROIs were 
placed over the blots using the in-built analysis toolbar in the software, providing 
raw quantification of the fluorescence as an integer. Background correction was 
automatically accounted for by the software and the background region was defined 
as the area surrounding the perimeter of the blot. In order to account for slight 
differences in protein loading, the GST fusion protein loading for each experiment 
was analysed and normalised to the lowest amount to obtain a ratio. Raw data from 
each experiment was then normalised to this ratio to obtain the final data used for 
analysis. 
Normalised blot data = [Raw blot fluorescence/ Normalised GST fluorescence] 
In order to provide an improved analysis of the pulldown assay results of each 
condition (GST, WT SV2A, R383Q SV2A and R383E SV2A), the collated 
normalised blot data was expressed as a ratio of amount of WT SV2A present (WT 
SV2A set to a value of 1.0).  All normalisations were performed on Microsoft Excel 
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2.2.20 –  Statistical Analysis 
All datasets with n = or > 7 used in this thesis were tested for a normal distribution 
using the Shapiro-Wilk normality test. All of these datasets were found to be 
normally distributed (p > 0.05). Datasets with n < 7 were assumed to fit a normal 
distribution, as the small sample size did not allow for good curve fitting. 
For normally distributed datasets with three or more independent groups (surface 
fraction, CV, pHluorin taus, fraction of externalisation), a one-way analysis of 
variance (ANOVA) with Bonferroni’s post-hoc test (to account for multiple tests) 
was used to determine statistically significant differences (P and F values). For 
experiments where there are two or more independent variables interacting with a 
dependent variable (pHluorin ∆F/F0 vs time), a two-way ANOVA with Bonferroni’s 
post-hoc test was used to determine any statistically significant differences. Where 
there is a comparison of only two independent variables, a student’s t-test was used 
to determine any statistically significant differences. Values of p < 0.05 were deemed 
statistically significant. One star represents statistical significance of p ≤ 0.05; two 
stars p ≤ 0.01; three stars p ≤ 0.001; and four stars p ≤ 0.0001. All experiments were 
expressed as mean +/- standard error measurement (SEM). All statistical analyses 
were performed using Microsoft Excel 2013 and GraphPad Prism 6.0. Unless 
otherwise specified, all ‘n’ values refer to the number of independent experiments 
(coverslips) analysed.  
  







3.0 – The Effects of Ablating the 
SV2A/AP-2 Interaction on SYT1 
Trafficking at the Presynapse 
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3.1 – Introduction to SV Cargo Retrieval 
The maintenance of neurotransmission is dependent upon the reformation of synaptic 
vesicles (SVs) with the correct molecular composition during the endocytic process. 
The selection, sorting and incorporation of SV cargo into nascent SVs needs to be a 
tightly regulated process in order to ensure that the cargo is present in the correct 
stoichiometries for SV function. Under normal physiological conditions, cargo is 
incorporated into SVs during clathrin-mediated endocytosis (CME, see chapter 1.3). 
Under CME conditions, clathrin adaptor proteins (AP) act as the primary medium 
that facilitates cargo selection as well as the recruitment of necessary accessory 
molecules associated with endocytosis (Kelly and Owen, 2011). Despite this clear 
importance of APs in CME, it was demonstrated that both expression silencing and 
genomic ablation of the classical adaptor protein AP-2 resulted in only minor 
observable effects on SV endocytosis (Kim and Ryan, 2009, Kononenko et al., 
2014). This suggests that AP-2 is not the only molecule responsible for the sorting 
and clustering of SV cargo and that other molecules are required for this process.  
Many monomeric, cargo-specific adaptor proteins (e.g. stonin-2, AP-180/CALM) 
have been identified which have been shown to be essential for ensuring efficient SV 
cargo retrieval during endocytosis (Rao et al., 2012). Most interestingly, several lines 
of evidence have recently been documented which suggests that SV cargos have the 
ability to interact between themselves to ensure accurate sorting and 
retrieval(Gordon et al., 2011, Kononenko et al., 2013, Zhang et al., 2015). This 
introduction will explore the roles and interactions of two crucial SV cargoes in 
particular, synaptic vesicle protein 2A (SV2A) and synaptotagmin I (SYT1), and the 
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mechanisms by which these interactions assist the accurate sorting and retrieval of 
both proteins during SV endocytosis. 
 
3.1.1 – Role of Synaptic Vesicle Protein 2 (SV2) at the Presynapse 
Synaptic vesicle protein 2 (SV2) is a synaptic vesicle glycoprotein which is present 
in the secretory vesicles of neural and endocrine cells. SV2 consists of 12 
transmembrane domains and cytoplasmic N- and C- terminus regions (Figure 3.1.1). 
Three isoforms of SV2 are currently known to exist: SV2A, SV2B and SV2C. SV2A 
is the most widely expressed throughout the body and is most widely abundant in 
subcortical areas such as the thalamus and basal ganglia (Bajjalieh et al., 1993). 
SV2B (which has a 57% identity match with SV2A) is enriched and has an 
overlapping expression with SV2A in the cortex and hippocampus but is absent in 
other areas such as the pallidum, hippocampal dentate gyrus, reticular substantia 
nigra and reticular thalamic nucleus (Bajjalieh et al., 1994). The third isoform, SV2C 
(62% identity match with SV2A), is expressed in high levels in phylogenetically old 
regions of the brain such as the pallium, substantia nigra, midbrain, brain stem and 
olfactory bulb. No SV2C expression was detected in the cerebral cortex or 
hippocampus (Janz and Südhof, 1999). SV2A has a large, 169 amino acid-long N-
terminus which consists of a phosphorylation-dependent binding region for the 
calcium sensor protein synaptotagmin I (SYT1) (Pyle et al., 2000, Schivell et al., 
2005). The role of SYT1 will be further described in the next section. SV2A also 
contains a conserved, 91 amino acid-long cytoplasmic loop between the sixth and 
seventh transmembrane domains, as well as a highly glycosylated, 130 amino acid-
long extracellular loop between the seventh and eighth transmembrane domains.  
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The exact role of SV2A in SV recycling and neurotransmission remains unclear. 
SV2A was initially proposed to be a transporter, due to its high degree of sequence 
homology with the major facilitator superfamily (MFS) transporters and its 
localisation on SVs. Visualisations of SV2A conformations in situ by use of protein 
tomography revealed a compact, funnel shaped structure that is indicative of a pore 
opening (Lynch et al., 2008). This conformation is highly similar in configuration to 
another MFS transporter, the E.Coli lactose permease sugar transporter (Holyoake 
and Sansom, 2007), giving evidence of a role in transport. In agreement with this 
hypothesis, human SV2A has recently been demonstrated to function as a galactose 
transporter in yeast cells (Madeo et al., 2014). 
SV2A has been found in nerve terminals that utilise different neurotransmitters, 
therefore a role as a specific neurotransmitter carrier has been ruled out. In 
agreement with this, the absence of SV2A does not affect mEPSC amplitudes at 
synapses. This suggests that the amount of glutamate molecules being packaged into 
SVs remains unaffected by the loss of SV2A (Custer et al., 2006).  The role of SV2A 
as a Cl- transporter has also been discussed. The widespread expression of SV2A 
throughout the brain is consistent with the fact that Cl- transport is required by all 
SVs (Bajjalieh et al., 1994). Interactions of SV2A with presynaptic Cl- channels may 
also affect the ability of GABAergic neurones to produce or sustain action potentials 
(Crowder et al., 1999). In disagreement with these lines of evidence, it has been 
shown that vesicular glutamate transporter 1 (VGLUT1), rather than SV2A, 
represents the major Cl- permeation pathway in SV recycling (Schenck et al., 2009). 
SV2A is also hypothesised to be a Ca2+ transporter, as there is existing evidence to 
suggest that the conserved presence of negatively charged residues in the first 
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transmembrane region of SV2A plays a role in facilitating Ca2+-dependent regulation 
of neurotransmitter release during repetitive stimulation (Janz et al., 1999). In 
contrast to this evidence, it was later demonstrated that neither overexpression nor 
the isoform-specific silencing of SV2A affected depolarisation-triggered Ca2+ influx, 
arguing against a Ca2+ transport role for SV2A (Iezzi et al., 2005). 
Though SV2A may not be directly responsible for Ca2+ transport, there have been 
several lines of evidence presented to suggest that they could play in a role in the 
maintenance of neurotransmission. SV2A knockout mice demonstrate limited growth 
and are excessively prone to seizures that lead to death approximately 3 weeks after 
birth (Crowder et al., 1999). Loss of SV2 results in a reduction of both excitatory and 
inhibitory action potential-dependent neurotransmission, whereas action potential-
independent neurotransmission remained unaffected. The altered neurotransmission 
in SV2A KO mice did not arise from changes in the number of synapses or the 
morphology of the synapses, and was not required for SV biogenesis (Crowder et al., 
1999, Custer et al., 2006). Analyses of soluble NSF attachment protein receptor 
(SNARE) complexes in brain tissue have shown that a loss of SV2A results in the 
association of fewer complexes, indicating that SV2A may play a role in the 
modulating the formation of key protein complexes integral for fusion and therefore 
the progression of SVs to a fusion competent state (Xu and Bajjalieh, 2001). Several 
studies have suggested that SV2 may play a role in modulating Ca2+ mediated 
exocytosis. Firstly, deletion of SV2 resulted in diminished synaptic transmission 
which could be reversed by application of the Ca2+ -chelating agent EGTA, 
indicating that SV2 has an effect downstream of SV priming but upstream of the 
Ca2+ triggering of release (Chang and Suedhof, 2009). A plausible explanation for 
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this phenomenon is that SV2 enhances the responsiveness of primed SVs to Ca2+ 
influx. Secondly, SV2 (primarily SV2B) regulates the concentration of resting and 
evoked presynaptic Ca2+ levels indicating a role in the regulation of exocytosis (Wan 
et al., 2010). 
Another function that SV2A may play is in the immobilisation and subsequent 
liberation of neurotransmitter. The glycosylated region of SV2A in the intraluminal 
region of the SV forms a proteoglycan matrix that controls the adsorption of 
acetylcholine and ATP in Torpedo SVs. SV2A is suggested to modulate 
neurotransmitter release by regulating the availability of freely diffusible 
acetylcholine and ATP (Reigada et al., 2003). 
  




Figure 3.1.1: Schematic Representation of Synaptic Vesicle Protein 2A (SV2A) (Mendoza-
Torreblanca et al., 2013). SV2A is 12-transmembrane domain protein with a large, 169 amino acid-
long N-terminus which consists of a phosphorylation-dependent binding region for the calcium 
sensor protein synaptotagmin I (SYT1). SV2A also contains a conserved, 91 amino acid-long 
cytoplasmic loop between the sixth and seventh transmembrane domains, as well as a highly 
glycosylated, 130 amino acid-long extracellular loop between the seventh and eighth 
transmembrane domains. Y46 (green) is required for trafficking of SV2A to SVs via AP-2 binding. Ten 
putative protein phosphorylation sites in the N-terminus are shown in pink. Fourteen amino acids 
implicated in racetam binding (red) are also highlighted. R231 is a canonical MFS transporter motif, 
and W300 and W666 are essential for SV2 action in synaptic transmission. 
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3.1.2 – Roles of Synaptotagmin I (SYT1) at the Presynapse 
Synaptotagmin I (SYT1) is a member of a family of proteins that are defined by a 
single transmembrane domain that is joined to two Ca2+ binding domains (C2A and 
C2B) through a linker region. Initial efforts to characterise the function of SYT1 
revealed that loss of the protein resulted in defects in neurotransmission in several 
animal models (Littleton et al., 1994, Nonet et al., 1993, Borden et al., 2005). The 
presence of these calcium binding C2 domains on SYT1 strongly indicates a primary 
role for SYT1 in facilitating Ca2+-dependent interactions. At the presynapse, 
neurotransmitter release can be classified into two forms: 1) a fast, synchronous form 
which is Ca2+-dependent and takes place on a timescale of around 5-10 ms; and 2) a 
slower, asynchronous form which is predominantly Ca2+-independent and takes place 
on a time scale of 100-200 ms (Goda and Stevens, 1994). This dual phase nature of 
neurotransmitter release supports the hypothesis that two separate Ca2+ sensors are 
involved in each form. In order for a protein to function as a viable Ca2+ sensor to 
facilitate neurotransmission, it needs to have two major properties: 1) an ability to 
bind quickly and reversibly to Ca2+ and 2) an ability to form an integral relationship 
with other SNARE proteins to facilitate their interactions with membrane 
phospholipids. The ablation of the C2B domain of SYT1 in mice resulted in a 
reduction of the fast synchronous release without affecting the slower asynchronous 
release in electrophysiological studies (Geppert et al., 1994). In support of this, 
similar results were obtained in Drosophila SYT1 null mutants where the fast 
component of release was absent and synaptic communication was limited to the 
slower release component (Yoshihara and Littleton, 2002). These lines of evidence 
strongly indicates that SYT1 acts as a Ca2+ sensor for fast synchronous release, but 
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does not do so for the slower asynchronous release. Apart from sensing Ca2+, a 
second postulated function for SYT1 at the presynapse is a role in the regulation of 
SNARE complex machinery. SNARE complex machinery is involved in SV docking 
and fusion to the plasma membrane during exocytosis (see chapter 1).  Binding of 
SYT1 to SNARE machinery to trigger membrane fusion takes place in a Ca2+-
dependent manner on a millisecond timescale (Chapman et al., 1995, Bai et al., 
2004). The way in which SYT1 drives membrane fusion under Ca2+ influx remains 
controversial, however recent studies have shed further light on three possible 
mechanisms: 1) Formation of specific interfaces that promote interactions between 
SYT1 and the plasma membrane to re-model areas of the membrane in order to drive 
fusion (Zhou et al., 2015); 2) Regulating the binding of SYT1 to PI(4,5)P2 in 
membrane patches (Park et al., 2015); 3) Facilitation of dynamic interactions 
between SYT1 and SNARE complexes in driving membrane fusion (Brewer et al., 
2015). A third major protein interaction mediated by SYT1 C2 domains is the Ca2+- 
induced oligomerisation of SYT1 on SVs. Overexpression of SYT1 in PC12 cells 
extends the transition between fusion pore opening and dilation, indicating that 
SYT1 oligomerisation may play a stabilising role in maintaining the fusion pore prior 
to full fusion(Wang et al., 2001). 
Although it is clear for both mammals and flies that the function of SYT1 is required 
for the fast component of release, the biochemical properties that provide the 
molecular basis for Ca2+ sensing remain in debate. The C2 domains of SYT1 are 
homologous to the C2 domains of protein kinase C (PKC), and therefore SYT1 was 
believed to facilitate the localisation of PKC onto the plasma membrane by binding 
to membrane phospholipids in a Ca2+-dependent manner (Nishizuka, 1988). Initial 
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biochemical studies on SYT1 revealed that it binds to both Ca2+ and phospholipids 
on a millisecond timescale (Brose et al., 1992, Davis et al., 1999), which satisfies the 
requirements for it to function as a Ca2+ sensor. Early work on the Ca2+ cooperativity 
of neurotransmitter release has shown a minimum of four Ca2+ ions are required to 
bind onto a single neurotransmitter molecule in order to trigger transmission (Dodge 
and Rahamimoff, 1967). After the discovery of SYT1 as the primary Ca2+ sensor, 
functional analysis using genetic deletions or mutations in alleles coding for specific 
regions of SYT1 revealed the identity of the domains which were integral for Ca2+ 
binding and modulation (Littleton et al., 1994). The different mutant versions of 
SYT1 investigated were: AD1, which contained a deletion of the entire C2B domain 
and resulted in the loss of oligomerisation and SNARE-binding activity of the 
protein; AD3, which contained a point mutation (Y364N) and ablated 
oligomerisation activity only; AD4, which consisted of an early stop codon that 
deleted the entire cytoplasmic region of SYT1 and represented a complete loss-of-
function model. The AD4 mutant (both C2 domains deleted) exhibited a complete 
loss of synchronous release but interestingly, also showed an increase in the amount 
of asynchronous release. Compared to AD4, the AD1 mutant (C2B domain deleted) 
only partially restored synchronous release and resulted in the slight increase of 
asynchronous release. Furthermore, the C2B domain deletion reduced the Ca2+ 
cooperativity of neurotransmission from 4 to 0.77. The AD3 mutant (both C2 
domains present), which restored the ability of SYT1 to bind to the SNARE complex 
via the C2B domain, allowed near-full synchronised release to take place (Ca2+ 
cooperativity ~ 3.5) but had no significant effect on asynchronous release (Yoshihara 
and Littleton, 2002). Because the AD1 mutant protein lacks the C2B domain, this 
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indicates that the C2B domain is required for Ca2+ cooperativity. Therefore, the 
reductions in Ca2+ cooperativity values associated with certain mutations of SYT1 
indicate the Ca2+ sensing domain of SYT1 can be primarily attributed to the C2B 
domain. These results also support the idea that both the C2A and the C2B domains 
of SYT1 are involved in the suppression of asynchronous release. However, the 
primary Ca2+ sensing function for SV fusion is provided mainly by the C2B domain 
(Gaffaney et al., 2008), thereby distinguishing the molecular determinants of 
synchronicity of release. Recent work on the linker region between the C2A and C2B 
domain indicated that the region plays a role in mediating the ability of SYT1 to 
insert into the plasma membrane as well facilitate interactions between the C2A and 
C2B domain that allows control of both synchronous and asynchronous release (Lu 
et al., 2014).  
In addition to roles as a Ca2+ sensor and a SNARE fusion complex effector, SYT1 
has also been proposed to play other key roles at the presynaptic terminal. Discrete 
Ca2+ co-ordinating residues in both the C2A and C2B domain of SYT1 have an 
effect on the SV endocytosis kinetics as well as SV size (Poskanzer et al., 2006). 
More recently, the juxtamembrane region of SYT1 has been shown to interact with 
the pleckstrin homology (PH) domain of dynamin I, leading to a prolonging of the 
fission pore lifetime that affects the overall dynamics of vesicle retrieval (McAdam 
et al., 2015). 
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3.1.3 – Classical Mechanisms of SV2A and SYT1 Retrieval during Endocytosis 
Newly formed SVs need to be consistently generated with consistent high fidelity for 
functional viability to participate in subsequent exocytic events. A large proportion 
of transmembrane proteins use a number of unrelated sorting signals to allow 
regulation of protein numbers during membrane uptake. The sorting of SV proteins 
at the plasma membrane is usually facilitated by adaptor proteins (e.g. AP-2) which 
recognise binding motifs present on key SV proteins and facilitate their 
internalisation during endocytosis. Two major classes of frequently used endocytic 
sorting signals have been identified for AP-2 binding: 1) tyrosine-based [YxxØ] 
motifs, and 2) acidic cluster di-leucine ([DE]xxLL) motifs (where x = any amino 
acid and Ø = a bulky hydrophobic amino acid). Both of these signals directly bind to 
distinct sites on the AP-2 complex (Royle et al., 2005). SV2A contains two such 
distinct tyrosine motifs: 1) YSRF at amino acids 46-49 in the cytoplasmic N-
terminus, and 2) YRRI at amino acids 443-446 in the cytoplasmic loop preceding 
transmembrane domain 7. This suggests the existence of two possible sites where 
SV2A may bind to AP-2 in order to facilitate its sorting into SVs. In studies on SYT1 
endocytic binding motifs, an AP-2-binding site has been located in the C2B domain 
of SYT1 although the site appears to lack the classical tyrosine or di-leucine based 
endocytic motifs. This was supported by evidence showing that a basic C2B domain- 
derived peptide was able to disrupt interactions between native SYT1 and the µ2 
subunit of AP-2 (Grass et al., 2004). In addition to AP-2, SYT1 retrieval is further 
facilitated during endocytosis by a second adaptor protein, stonin-2. Systematic 
deletion and site-directed mutagenesis approaches paired with modelling studies 
have been identified the interaction sites involved in complex formation between 
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SYT1 and stonin-2 (Jung et al., 2007). These studies have revealed that the µ-
homology domain of stonin-2 recognises basic motifs present within both C2 
domains of SYT1, with C2A forming the major interaction surface. Expression of 
stonin-2 also is sufficient to drive clathrin/AP-2-dependent internalisation of SYT1 
in non-neuronal cells, while leaving transferrin or EGF endocytosis unaffected (Diril 
et al., 2006). Knockout of stonin-2 in neurones result in the accumulation of SYT1 at 
the plasma membrane and an acceleration of SYT1 retrieval during SV endocytosis, 
similar to the phenotype seen in the total absence of SV2A (Kononenko et al., 2013). 
These data establish stonin-2 as a SYT1-specific endocytic sorting adaptor for SV 
recycling. 
 
3.1.4. – Trafficking Partnerships of SV Cargo during Endocytosis 
Although the classical adaptor proteins are central to the process for SV cargo 
selection and recruitment to nascent SVs, they do not seem to be essential to the 
maintenance and regulation of SV endocytosis. When the expression of AP-2 is 
reduced using siRNA or ablated using genomic knockout strategies, relatively minor 
effects on SV endocytosis at the plasma membrane are observed (Willox and Royle, 
2012, Jung et al., 2015), suggesting that other key molecules are required to ensure 
efficient cargo retrieval and SV endocytosis in general. Intriguingly, certain SV 
cargos interact with each other during recruitment and thus facilitate each other’s 
retrieval during SV endocytosis as part of a transport complex. These co-interacting 
SV cargos have been termed ‘intrinsic trafficking partners’(Gordon and Cousin, 
2016). This unusual relationship has been documented in two sets of integral 
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membrane proteins: 1) synaptobrevin II (SYB2; also called vesicle associated 
membrane protein 2, VAMP2) and synaptophysin (SYP), and 2) SV2A and SYT1. 
 
3.1.4.1. – Intrinsic Trafficking Partners: SYB2 and SYP 
Synaptobrevin II (SYB2) is a vesicular SNARE protein that associates with the 
membrane SNARE proteins syntaxin and SNAP-25 for priming and driving SV 
fusion during exocytosis (see chapter 1). SYB2 is an essential component of the 
molecular machinery of the SV, and thus its correct targeting and localisation is 
essential for maintaining neurotransmission. SYB2 has no canonical motifs for AP-2, 
therefore the recruitment of SYB2 to SVs must be a result of the function of other 
trafficking partner molecules. Early work identified the monomeric clathrin adaptor 
protein AP-180 and the related protein clathrin assembly lymphoid myeloid 
leukaemia (CALM) as regulators of SYB2 targeting in C.elegans (Nonet et al., 
1999). Subsequently, AP-180 and CALM were demonstrated to regulate SYB2 
targeting in other model systems such as lap (drosophila analogue for AP-180) 
mutant flies (Bao et al., 2005) and mice (Koo et al., 2011). In the latter studies, 
immunoprecipitation experiments revealed a direct interaction between the ANTH 
domains of AP-180 and CALM and the SNARE motif of SYB2. Knockout of AP-
180 results in the stranding of SYB2 to the surface of the plasma membrane and its 
inefficient retrieval during endocytosis. This effect is exacerbated in AP-180 
knockout mammalian neuronal systems (Koo et al., 2015).  
It has been shown recently that synaptophysin (SYP), a four-transmembrane domain 
protein that contains cytoplasmic N- and C-termini, also plays a role as an intrinsic 
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trafficking partner for SYB2 to facilitate targeting of SYB2 to SVs in parallel with 
AP-180 and CALM.  Recent studies of SYB2 trafficking in SYP-knockout mice have 
shed some light on the intricacies of the SYB2-SYP relationship. In the absence of 
SYP, SYB2 was mislocalised from synaptic terminals and accumulated at the plasma 
membrane. This mistargeting of protein was shown to be a result of a specific deficit 
in the activity-dependent retrieval of SYB2 from the plasma membrane during 
compensatory endocytosis. SYB2 retrieval was severely slowed in SYP-knockout 
neurones. The re-addition of exogenous SYP to the SYP-knockout neurones resulted 
in the full rescue of SYB2 retrieval to wild type levels (Gordon et al., 2011). Further 
evidence for a key role for SYP in SYB2 retrieval came from the analysis of various 
SYP mutants identified in X-linked intellectual disability. SYP mutants identified to 
be implicated in intellectual disability all failed to rescue wild type SYB2 retrieval in 
the knockout model system (Gordon and Cousin, 2013). Interestingly, all except one 
of the mutations were predicted to interfere with the transmembrane SYB2-SYP 
interaction (Calakos and Scheller, 1994, Adams et al., 2015). This data establishes 
that SYP is essential for the accurate retrieval of SYB2 during compensatory 
endocytosis. 
 
3.1.4.2. – Intrinsic Trafficking Partners: SV2A and SYT1 
The interaction between SV2A and SYT1 has been mapped, showing that the 
cytoplasmic N-terminus of SV2A binds to the C2B domain of SYT1 (Schivell et al., 
1996). This binding interaction is enhanced by casein kinase 1 family (CK1) 
dependent phosphorylation of SV2A in vitro(Pyle et al., 2000). It was recently 
established that the CK1 kinases are responsible for promoting and modulating the 
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phosphorylation of SV2A, and this occurs at a highly conserved cluster of amino 
acids in SV2A (S80, S81 and T84) (Zhang et al., 2015). Within the C2B domain of 
SYT1, the SV2A binding site resides within a specific, surface-exposed pocket of 
three lysine residues (K314, K326, K328). This lysine pocket resides in close 
proximity to various other molecules such as phosphoinositides (Schiavo et al., 
1996), calcium channels (Leveque et al., 1992), t-SNARE dimers (Bhalla et al., 
2006) as well as other isoforms of synaptotagmin (Chapman et al., 1996), indicating 
that modulation of SYT1 at this specific pocket may affect its function in other 
presynaptic processes.  
SV2A functions to direct SYT1 targeting to SVs alongside stonin-2. In neurones that 
have SV2A depleted or removed, SYT1 fails to target correctly to synaptic terminals 
and accumulates at the plasma membrane. This effect was shown to be SV2A-
dependent, since restoration of wild type SV2A in the neurones restored normal 
plasma membrane levels of SYT1 (Yao et al., 2010, Kaempf et al., 2015). SV2A-
deficient neurones which were rescued with mutant forms of SV2A which did not 
bind AP-2 (Yao et al., 2010) or SYT1 (Kaempf et al., 2015) also resulted in the same 
stranding of SYT1 at the plasma membrane, providing strong evidence that the 
SV2A-SYT1 interaction is required for efficient targeting of SYT1 to synaptic 
terminals. In addition to the synaptic targeting, deficiencies in SV2A expression also 
resulted in accelerated SYT1-specific retrieval during SV endocytosis (Kaempf et al., 
2015, Zhang et al., 2015). This was an unexpected observation, as the stranding of 
SV cargo at the plasma membrane has been historically linked to a perturbation of 
SV endocytosis (Willox and Royle, 2012, Kononenko et al., 2014). Interestingly, 
silencing of SV2A expression in stonin-2 knockout neurones revealed an 
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exacerbation of SYT1 accumulation and a further re-acceleration of its retrieval 
(Kaempf et al., 2015). This work provided strong evidence that both stonin-2 and 
SV2A are required for efficient SYT1 trafficking. These additive effects on SYT1 
suggest that SV2A and stonin-2 function via discrete parallel mechanisms, or 
perform synergistic roles in SYT retrieval. 
 
3.1.4.3 – Further Evidence for Intrinsic Trafficking Partnerships 
In addition to specific SYB2-SYP and SV2A-SYT1 interactions as documented 
above, vesicular glutamate transporter 1 (VGLUT1) has recently been shown to have 
a central role in co-ordinating SV cargo retrieval during compensatory endocytosis. 
The siRNA-mediated silencing of VGLUT1 in rat hippocampal cultures resulted in 
defective retrieval of the key SV cargos SV2A, SYB2 and SYP. SYT1, however, was 
shown to be unaffected by VGLUT1 perturbations (Pan et al., 2015). The 
demonstration that different cargos may be retrieved with different kinetics at the 
same synaptic terminals provides evidence that SV cargos are not equally sorted at 
the plasma membrane and that SV cargo sorting is likely to be function of multiple 
parallel mechanisms. It was proposed that SYT1 and VGLUT1 could be acting in 
parallel upstream in the endocytic sorting mechanisms; however, this proposal is in 
disagreement the previously described works that directly link the trafficking of 
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3.1.5 – Aims and Objectives 
Mutation of the Y46 residue from tyrosine to alanine (Y46A) was previously shown 
to ablate SV2A binding to AP-2, resulting in the stranding of SYT1 at the plasma 
membrane (Yao et al., 2010). However, there is currently no published literature that 
investigates the effect of the Y46A SV2A mutation on the internalisation of SYT1 
during compensatory endocytosis. I hypothesise that as SV2A and SYT1 are intrinsic 
trafficking partners, the disruption of SV2A trafficking by ablation of AP-2 binding 
will also result in downstream disruption of SYT1 trafficking and thus its 
internalisation from the plasma membrane during endocytosis. Previously published 
literature has demonstrated that mutation of residue 84 in SV2A from threonine to 
alanine (T84A) results in the disruption of the phosphorylation dependent binding of 
SV2A to SYT1, leading to defects in SYT1 trafficking during SV recycling(Zhang et 
al., 2015). In this investigation, I also aim to compare and contrast the mechanisms 
by which mutation of the SV2A/AP-2 binding motif and SV2A/SYT1 binding motif 
operates. 
 
The primary objectives of the research in this chapter are: 
1) To validate the knockdown of wild type SV2A by use of a small hairpin RNA 
(shRNA) sequence and subsequent rescue of SV2A expression with wild type 
(WT) or Y46A SV2A 
 
2) To characterise the effect of Y46A SV2A on the surface expression of SYT1 
at the plasma membrane and its localisation to presynaptic terminals 




3)  To characterise the effect of Y46A SV2A on the rate of SYT1 retrieval from 
the plasma membrane during compensatory endocytosis 
 
4) To establish the SYT1 specificity of defects in SV recycling which are caused 
by Y46A SV2A 
 
5) To distinguish the different mechanistic pathways which alter the SV2A-
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3.2. – Results of Studies Using Y46A SV2A 
Prior studies have evidenced a role for the Y46 residue in SV2A in binding to the 
adaptor protein, AP-2 during SV recycling. Disruption of this tyrosine-based binding 
motif by mutation of the tyrosine residue to alanine (Y46A) ablates the binding of 
SV2A to AP-2 at the N-terminus, resulting in the stranding of SYT1 at the plasma 
membrane surface and a failure of SYT1 to localise to synaptic terminals (Yao et al., 
2010). This phenotype may cause defects in the efficiency of SYT1 internalisation 
during SV compensatory endocytosis. In support of this hypothesis, it has been 
reported that ablation of the phosphorylation-dependent interaction of SV2A with 
SYT1 by mutation of residue 84 from threonine to alanine (T84A) results in the 
increased SYT1 plasma membrane expression and accelerated SYT1 retrieval during 
compensatory endocytosis (Zhang et al., 2015). Although the partnership between 
SV2A and SYT1 during endocytosis has been widely documented, there is currently 
no published literature on the effects of disruption of SV2A retrieval on the activity-
dependent retrieval of SYT1. In this chapter, I aimed to characterise the effect of 
SV2A Y46A mutation on: 1) surface fraction and localisation of SYT1 and 2) rate of 
retrieval of SYT1 during SV endocytosis. I then proceeded to distinguish the 
mechanism of Y46A SV2A action of SYT1 and other known mechanisms by which 
SYT1 trafficking dysfunction may be caused (T84A SV2A). 
Key research findings of this chapter: 
• Y46A SV2A leads to the acceleration of SYT1 retrieval kinetics, increased 
surface expression and mislocalisation of SYT1 on the plasma membrane. 
• The Y46A and T84A SV2A mutations perturb the same mechanistic pathway 
at the presynapse, suggesting SV2A modulates retrieval of SYT1 by AP-2. 
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3.2.1 – Expression of Y46A SV2A-mCer Successfully Rescues Defects in SV2A 
Expression Levels Caused By shRNA-mediated Knockdown 
The first experiments aimed to validate and quantify the effectiveness of the 
efficiency of the exogeneously expressed wild-type SV2A-mCer (WT SV2A) and 
Y46A SV2A-mCer (Y46A SV2A) plasmids in rescuing the depletion of SV2A 
expression levels caused by shRNA-mediated knockdown. Primary cultures of mice 
hippocampal cells were co-transfected with: 1) a SYT1-pHluorin plasmid also 
containing a shRNA sequence for SV2A (SV2A shRNA/SYT1-pHluorin) to 
simultaneously deplete SV2A levels and express SYT1-pHluorin in neurones; 2) 
plasmids containing either WT SV2A-mCer or Y46A SV2A-mCer to rescue SV2A 
expression after shRNA-mediated knockdown. Final SV2A expression levels in the 
cultures after transfection were detected by immunofluorescence experiments (Figure 
3.2 A). 
The co-transfection of the SV2A shRNA/SYT1-pHluorin with an mCerulean N1 
(mCer) empty plasmid into neurones resulted in up to 48% knockdown of SV2A 
expression. The levels of SV2A observed in non-transfected neurones in the same 
field of view was used as an internal control for each experiment [Ratio of SV2A 
expression in transfected neurones/untransfected neurones = 0.521 ± 0.039 (mCer); p 
< 0.0001 (mCer vs WT), one-way ANOVA, Bonferroni’s post-hoc]. The co-
transfection of the SV2A shRNA/SYT1 pHluorin with either wild-type (WT) SV2A 
or Y46A SV2A plasmids into neurones resulted in a complete rescue of SV2A 
expression [Ratio of SV2A expression in transfected neurones/untransfected 
neurones = 1.062 ± 0.077 (WT SV2A), 1.138 ± 0.050 (Y46A SV2A); p < 0.0001 
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(WT vs mCer, Y46A vs mCer); one-way ANOVA, P < 0.0001, F = 33.9, 
Bonferroni’s post-hoc] (Figure 3.2 B). 
These experiments therefore show that neuronal SV2A levels were successfully 
depleted by transfection of a previously described combined SV2A shRNA/SYT1-
pHluorin plasmid. Normal SV2A expression was successfully rescued when 
neurones were co-transfected with plasmids expressing either exogeneous WT SV2A 
or Y46A SV2A, indicating that the neuronal culture system was able to withstand 
acute genetic depletion of SV2A and expression of exogeneously mutant SV2A.  
 
  




Figure 3.2: Expression of Y46A SV2A-mCer rescues deficits in SV2A expression caused by shRNA-
mediated knockdown: A) Images of cultures co-transfected with SV2A shRNA/SYT1–pHluorin vector 
and either empty rescue (mCer), wild-type (WT) SV2A-mCer or Y46A SV2A-mCer. Grayscale panels 
highlight transfected neurones (GFP), whereas false colour panels display exogenous SV2A revealed 
by immunofluorescence staining. Arrows highlight nerve terminals. Scale bar = 10 μM.  B) Bar graph 
shows levels of rescue of SV2A expression. The background-corrected SV2A immunofluorescence 
obtained from transfected neurones was normalised to the SV2A immunofluorescence obtained 
from non-transfected neurones within the same field of view [n=10 mCer empty, purple; n=10 WT 
SV2A-mCer, blue; n=10 Y46A SV2A-mCer, red; ****p<0.0001 (mCer vs WT, mCer vs Y46A); one-way 
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3.2.2 – Y46A SV2A Results in Increased but Delocalised Surface Expression of SYT1 
Previous studies have shown that the Y46A mutation in SV2A results in the 
stranding of SYT1 at the plasma membrane surface and a failure for SYT1 to localise 
to synaptic terminals (Yao et al., 2010). In order to corroborate this previous 
observation in my model system, I proceeded to investigate the effect of mutating the 
AP-2 binding motif in SV2A on the surface expression and localisation of SYT1 to 
presynaptic terminals. As in the above experiments, SV2A shRNA/SYT1-pHluorin 
was transfected into primary cultures to knockdown SV2A expression and co-
express the SYT1-pHluorin reporter. Neuronal SV2A expression was rescued by co-
transfection of either WT or Y46A SV2A-mCer plasmid (Figure 3.3 A). 
In order to investigate surface expression of SYT1 after perturbation of SV2A levels, 
the fraction of surface-expressed SYT1-pHluorin in transfected neurones was 
compared to the total SYT1-pHluorin pool in the neurone (see chapter 2.2). Surface 
fraction experiments revealed that knockdown of SV2A in neurones and rescue using 
an empty plasmid resulted in a significant increase of surface-expressed SYT1-
pHluorin compared to control rescue experiments using WT SV2A. Knockdown of 
SV2A in neurones and rescue with Y46A SV2A plasmid also resulted in a significant 
increase in the percentage of surface-expressed SYT1-pHluorin when compared to 
control rescue experiments using WT SV2A [Surface expression of SYT1-pHluorin 
(% of total SYT1-pHluorin pool) = 18.5 ± 2.3 (WT SV2A), 38.8 ± 1.9 (mCer), 49.8 
± 4.0 (Y46A SV2A); p < 0.0001 (Y46A vs WT), p < 0.001 (mCer vs WT); one-way 
ANOVA, Bonferroni’s post-hoc, P < 0.0001, F = 27.6] (Figure 3.3 B). These results 
demonstrate that depletion of SV2A in neurones leads to increased expression of 
SYT1 at the plasma membrane surface. Rescue of SV2A expression with the Y46A 
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SV2A fails to rescue this defect in the proportion of surface-expressed SYT1. These 
observations suggest that the Y46A mutation in SV2A plays a crucial role in 
disrupting the internalisation of SYT1. 
In order to investigate the effect of Y46A SV2A on the localisation of SYT1 to 
synaptic terminals, an analysis of the coefficient of variation (CV) for SYT1-
pHluorin fluorescence was performed. The CV is a calculation for the diffuseness of 
the fluorescence for the total pHluorin pool along a fixed length of neurite (see 
chapter 2.2). CV analysis of the expression of the total SYT1-pHluorin pool in a 50-
µm length of neurite in SV2A knockdown cultures co-expressing a mCer empty 
plasmid revealed a significantly decreased coefficient of variation compared to 
control rescue experiments using WT SV2A. In SV2A knockdown cultures co-
expressing the Y46A SV2A plasmid, CV analysis of SYT1-expression in a 50-µm 
length of neurite revealed similarly decreased CVs compared to control rescue 
experiments using WT SV2A [Mean CV = 33.6 ± 6.2 (WT SV2A), 13.2 ± 2.7 
(mCer), 14.8 ± 0.9 (Y46A SV2A); p < 0.01 (mCer vs WT), p < 0.05 (Y46A vs WT); 
one-way ANOVA, Bonferroni’s post-hoc, P = 0.0053, F = 8.37] (Figure 3.3 C). 
These experiments demonstrate that depletion of SV2A leads to increased 
diffuseness of SYT1 expression across the neurite, suggesting a defect in the 
targeting SYT1 to presynaptic terminals during SV recycling. A similar phenotype is 
observed when the AP-2 binding motif in SV2A is mutated, suggesting that the 
binding site in SV2A plays a significant role in regulating the mechanism for SYT1 
targeting to presynaptic terminals. 
  




Figure 3.3: Y46A SV2A results in increased but delocalised surface expression of SYT1. A) 
Hippocampal neurones were co-transfected with an SV2A shRNA/SYT1-pHluorin plasmid and either 
wild-type (WT) or Y46A SV2A-mCer. Representative greyscale images show that rescue with Y46A 
SV2A-mCer resulted in less localisation to nerve terminals compared to WT SV2A-mCer rescue. Scale 
bar = 10 μM. B) Surface expression of SYT1–pHluorin after rescue with SV2A-mCer variants displayed 
as a percentage of total SYT1-pHluorin pool ± SEM [n=5 mCerN1 empty, purple; n=5 WT SV2A-mCer, 
blue; n=5 Y46A SV2A-mCer, red; ****p<0.0001 (Y46A vs WT); ***p<0.001 (mCer vs WT); one-way 
ANOVA, Bonferroni’s post-hoc, P<0.0001, F=27.6]. C) Bar graph displays the mean coefficient of 
variation of SYT1-pHluorin fluorescence along axons of neurones in alkaline buffer. Data are 
presented as ± SEM (n=5 mCerN1 empty, purple; n=5 WT SV2A-mCer, blue; n=5 Y46A SV2A-mCer, 
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3.2.3 – Y46A SV2A Fails to Rescue the Acceleration of SYT1 Retrieval caused by 
Knockdown of SV2A 
In order to determine the effect of mutating the AP-2 binding motif in SV2A on 
SYT1 trafficking, I proceeded to investigate SYT1 trafficking during SV recycling in 
the presence of Y46A SV2A. As in previous experiments, SV2A shRNA/SYT1-
pHlourin was used as a reporter for SYT1 recycling at the synaptic terminal and for 
knockdown of SV2A expression after transfection into neurones. Neuronal SV2A 
expression was rescued by the co-transfection either WT or Y46A SV2A-mCer.  
ShRNA-mediated knockdown of SV2A in neurones and rescue with an empty 
plasmid resulted in a slowing of SYT1 retrieval compared with control rescue 
experiments using WT SV2A [p < 0.05 (mCer vs WT), two-way ANOVA of traces 
normalised to peak at evoked transmission]. Knockdown of SV2A and rescue with 
mutant Y46A SV2A in neurones resulted in a failure to rescue SYT1 retrieval to WT 
levels, mimicking the SYT1-pHlourin recycling phenotype seen in SV2A-deficient 
neurones [p < 0.05 (Y46A vs WT), two-way ANOVA of traces normalised to the 
peak at evoked stimulation] (Figure 3.4 A). Knockdown of SV2A and rescue with 
the Y46A mutant resulted in a non-significant, slightly increased proportion of SYT1 
externalisation during stimulation [Max ΔF/F0 (as a fraction of the total pHluorin 
pool) = 0.463 ± 0.086 (WT SV2A), 0.565 ± 0.068 (mCer), 0.630 ± 0.035 (Y46A 
SV2A); ns, one-way ANOVA, P = 0.197, F = 1.74] (Figure 3.4 B), suggesting that 
presence of Y46A SV2A exerts no significant effect on SYT1 trafficking during 
exocytosis. The quantification of the average time constant for retrieval (tau) of the 
evoked SYT1-pHluorin response allows for a direct comparison of retrieval time 
constants between the different experimental conditions. This provides an extra line 
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of evidence to demonstrate that the rate of SYT1 retrieval during compensatory 
endocytosis accelerated when SV2A levels are depleted in neurones. In agreement 
with the analysis of the average time traces, the knockdown of SV2A in neurones 
and rescue using either mCer or Y46A SV2A significantly decreased the tau of 
SYT1-pHluorin retrieval compared to control rescue experiments using WT SV2A. 
[Tau (s) = 75.0 ± 9.2 (WT SV2A), 47.3 ± 5.2 (mCer), 38.8 ± 3.8 (Y46A SV2A); p < 
0.01 (Y46A vs WT), p < 0.05 (mCer vs WT); one-way ANOVA, Bonferroni’s post-
hoc, P = 0.0018, F = 8.33] (Figure 3.4 C). Therefore, the phenotype observed with 
the Y46A SV2A rescue experiments was similar to that seen with the mCerN1 empty 
vector rescue in all cases.  
These experiments indicate that depletion of SV2A/mutation of the SV2A AP-2 
binding region in neurones results in faster retrieval of SYT1 during endocytosis 
without affecting its trafficking during exocytosis. The possible reasons for these 








Figure 3.4: Y46A SV2A fails to rescue the acceleration of SYT1 retrieval caused by knockdown of 
SV2A. A) Hippocampal neurones were co-transfected with an SV2A shRNA/SYT1-pHluorin vector and 
either mCerulean (mCer) empty vector or SV2A-mCer variants. Cultures were stimulated using a train 
of 300 action potentials (APs, 10 Hz, indicated by bar). After 200 seconds of recovery, the total 
recycling synaptic vesicle (SV) pool was revealed with a NH4Cl pulse. Graph displays the mean ΔF/F0 
time course for SYT1–pHluorin ± SEM normalized to the peak of stimulation [n=7 mCer empty, 
purple; n=10 wild-type (WT) SV2A-mCer, blue; n=10 Y46A SV2A-mCer, red; *p<0.05 (Y46A vs WT); 
two-way ANOVA, Bonferroni’s post-hoc (over times indicated by solid lines)]. B) Mean maximum 
evoked SYT1-pHluorin response (ΔF/F0) expressed as a fraction of the total SV pool (ns, one-way 
ANOVA, P=0.197, F=1.74). C) Graph shows quantification of the average time constant (Tau) ± SEM 
of the evoked SYT1-pH response [**p<0.01 (Y46A vs WT), *p<0.05 (mCerN1 vs WT); one-way 
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3.2.4 – Y46A SV2A Does Not Affect Synaptophysin Retrieval or Surface Expression 
Previous results have shown that mutation of the AP-2 binding motif in SV2A leads 
to a defect in the localisation and the retrieval of SYT1 at the presynaptic terminal. 
However, it is unknown of this defect was specific to SYT1 or a general dysfunction 
of SV cargo sorting which may affect several key SV proteins. In order to discount 
the possibility of Y46A SV2A having a global effect on SV recycling, I investigated 
the effect of Y46A SV2A on the localisation of synaptophysin (SYP) and the rate of 
SYP retrieval from the plasma membrane. In these experiments, neuronal cultures 
were transfected with three constructs: 1) SV2A shRNA to knockdown SV2A 
expression in neurones; 2) synaptophysin-pHluorin (SYP-pHluorin) as a reporter for 
SYP expression and retrieval in neurones during compensatory endocytosis; 3) either 
WT or Y46A SV2A-mCer for the purposes of rescuing SV2A expression after 
knockdown. 
ShRNA-mediated knockdown of SV2A in neurones and rescue using an empty 
vector resulted in no observable effect on SYP-pHluorin retrieval during endocytosis 
compared to control rescue experiments using WT SV2A. Similarly, shRNA-
mediated knockdown of SV2A and rescue using Y46A SV2A did not affect the rate 
of SYP-pHluorin retrieval compared to control rescue experiments using WT SV2A 
(ns, two-way ANOVA of traces normalised to peak at evoked transmission) (Figure 
3.5 A). Knockdown of SV2A and rescue using either an empty vector or Y46A 
SV2A also did not have an effect on the amount of SYP-pHluorin externalisation 
during stimulation when compared to control rescue experiments with WT SV2A 
[Max ΔF/F0 (as a fraction of the total pHluorin pool) = 0.372 ± 0.027 (WT SV2A), 
0.378 ± 0.019 (mCer), 0.375 ± 0.025 (Y46A SV2A); ns, one-way ANOVA, P = 
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0.988, F = 0.0121] (Figure 3.5 B). In agreement with the analysis of the average time 
traces, the quantification of the retrieval time constants for SYP-pHluorin in SV2A 
knockdown neurones rescued with Y46A SV2A revealed no significant effect 
compared to control rescue experiments using WT SV2A [Tau (s) = 38.1 ± 4.6 (WT 
SV2A), 40.9 ± 8.9 (mCer), 32.5 ± 2.7 (Y46A SV2A); ns, one-way ANOVA, P = 
0.486, F = 0.752] (Figure 3.5 C). Surface fraction experiments revealed that 
knockdown of SV2A in neurones and rescue using an empty plasmid did not affect 
the expression of SYP-pHluorin compared to control rescue experiments using WT 
SV2A. Likewise, the rescue of SV2A expression using Y46A SV2A did not affect 
the surface expression of SYP-pHluorin [Surface expression of SYP-pHluorin (% of 
total SYP-pHluorin pool) = 20.0 ± 2.4 (WT SV2A), 23.8 ± 4.8 (mCer), 23.4 ± 3.0 
(Y46A SV2A); ns, one-way ANOVA, P = 0.718, F = 0.344] (Figure 3.5 D). 
This set of results provides evidence to support the hypothesis suggesting that 
mutation of the AP-2 binding motif in SV2A does not have an effect on the rate of 
SV retrieval, amount of externalisation during compensatory endocytosis and the 
surface expression of synaptophysin. Therefore, the findings from previous 
observations made using SYT1-pHluorin as a reporter can be attributed to a specific 
effect on the trafficking of SYT1 at the synaptic terminal and not a global effect on 
SV recycling.  




Figure 3.5: Y46A SV2A does not affect SYP retrieval or surface expression. A) Hippocampal 
neurones were co-transfected with SV2AshRNA, SYP-pHluorin and mCer or SV2A-mCer variants. 
Cultures were stimulated using a train of 300 APs (10 Hz, indicated by bar) and the total recycling 
synaptic vesicle (SV) pool was revealed with a NH4Cl pulse at the end of the experiment. Graph 
displays the mean ΔF/F0 time course for SYP–pHluorin ± SEM normalized to the peak of stimulation 
(n=4 mCerN1 empty, purple; n=8 wild type (WT) SV2A-mCer, blue; n=8 Y46A SV2A-mCer, red; ns, 
two-way ANOVA). B) Mean maximum evoked response (ΔF/F0) of SYP-pHluorin during stimulation 
expressed as a fraction of the total SV pool (ns, one-way ANOVA, P=0.988, F=0.0121). C) Graph 
shows quantification of the average time constant (Tau) ± SEM of the evoked SYP-pHluorin response 
(ns, one-way ANOVA, P=0.486, F=0.752). D) Surface expression of SYP–pHluorin after rescue with 
SV2AmCer variants displayed as a percentage of total releasable pHluorin pool ± SEM (n=4 mCerN1 
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3.2.5 – T84A/Y46A SV2A Does Not Exacerbate Defects in SYT1 Retrieval 
The findings from previous experiments have given evidence to support a role for the 
tyrosine-based AP-2 binding motif in SV2A in the surface expression, localisation 
and retrieval kinetics of SYT1 in cultured neurones. These effects are dependent on 
the phosphorylation-mediated binding of SV2A to SYT1 at T84A. As a result, the 
combination of both T84A and Y46A SV2A mutations should not exacerbate the 
observed defects to SYT1 trafficking and any exacerbation observed may be a direct 
indication of a separate SYT1 retrieval mechanism in action during endocytosis.  
In order to shed further light on the SYT1-binding dependency of Y46A SV2A-
induced defects in SYT1 trafficking, the T84A/Y46A SV2A double mutant was 
genetically engineered and used to rescue SV2A expression in SV2A knockdown 
neurones and the rate of SYT1 retrieval during endocytosis was compared with the 
individual single mutants to reveal any additive defects in SYT1 trafficking that may 
be present. The shRNA-mediated knockdown of SV2A and rescue using the 
T84A/Y46A SV2A double mutant resulted in a failure to rescue normal SYT1 
recycling behaviour compared to control rescue experiments using WT SV2A. The 
observed phenotype was consistent with the findings obtained from rescue 
experiments using the single mutants only. Comparison of the average SYT1-
pHluorin traces obtained from experiments using the T84A/Y46A SV2A double 
mutant to experiments using the corresponding single mutants did not reveal any 
additive defects in SYT1 recycling (p < 0.05 (T84A/Y46A vs WT), ns (T84/Y46A vs 
T84A or Y46A), two-way ANOVA of traces normalised to the peak at evoked 
stimulation) (Figure 3.6 A). Knockdown of SV2A in neurones and rescue using the 
T84A/Y46A SV2A double mutant did not affect the proportion of SYT1 
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externalisation during evoked transmission when compared to control rescue 
experiments using WT SV2A. Comparison of the proportion of SYT1 externalisation 
in experiments using the T84A/Y46A SV2A double mutant and the T84A SV2A 
single mutant revealed no significant defects. This observation is in contrast with 
experiments using the Y46A single mutant, which indicated an increased level of 
SYT1 externalisation during evoked transmission [Max ΔF/F0 (as a fraction of the 
total pHluorin pool) = 0.339 ± 0.029 (WT SV2A), 0.377 ± 0.022 (T84 SV2A), 0.473 
± 0.040 (Y46A SV2A), 0.340 ± 0.008 (T84A/Y46A SV2A); p < 0.05 (Y46A vs 
WT), one-way ANOVA, Bonferroni’s post-hoc, P = 0.0101, F = 5.17] (Figure 3.6 
B). The quantification of retrieval time constants for SYT1-pHluorin in SV2A 
knockdown neurones rescued with T84A/Y46A SV2A revealed a significant 
decrease in retrieval time compared to control rescue experiments using WT SV2A. 
No additive disruption to SYT1 retrieval was observed when analysis of the 
T84A/Y46A double mutant time constants was compared to T84A and Y46A SV2A 
single mutants [Tau (s) = 70.8 ± 5.1 (WT SV2A), 45.0 ± 3.4 (T84A SV2A), 47.2 ± 
4.9 (Y46A SV2A), 44.8 ± 7.1 (T84A/Y46A SV2A); p < 0.05 (T84A/Y46A vs WT), 
ns (T84A/Y46A vs T84A or Y46A), one-way ANOVA, Bonferroni’s post-hoc, P = 
0.0082, F = 5.46] (Figure 3.6 C). 
These experiments indicate that mutation of both the AP-2 binding motif and the 
SYT1 binding motif in SV2A result in a failure to rescue normal SV2A function. The 
presence of T84A/Y46A SV2A resulted in faster retrieval of SYT1 during 
endocytosis and no significant effect on its trafficking during exocytosis. The results 
suggest that Y46A-induced defects in SYT1 trafficking are dependent upon binding 
of SV2A to SYT1.  




Figure 3.6: T84A/Y46A SV2A does not exacerbate defects in SYT1 recycling. A) Hippocampal 
neurones were co-transfected with SV2AshRNA-SYT1-pHluorin and mCer or SV2A-mCer variants. 
Cultures were stimulated using a train of 300 APs (10 Hz, indicated by bar) and the total releasable 
vesicle pool was revealed with a NH4Cl pulse at the end of the experiment. Graph displays the mean 
ΔF/F0 time course for SYT1–pHluorin ± SEM normalized to the peak of stimulation [n=5 wild type 
(WT) SV2A-mCer, blue; n=5 T84A SV2A-mCer, cyan; n=6 Y46A SV2A-mCer, red; n=5 T84A/Y46A SV2A-
mCer, pink; *p<0.05 (T84A/Y46A vs WT), two-way ANOVA, Bonferroni’s post-hoc (over times 
indicated by solid lines)]. B) Mean maximum evoked response (ΔF/F0) of SYT1-pHluorin during 
stimulation expressed as a fraction of the total releasable vesicle pool [*p<0.05 (Y46A vs WT); one-
way ANOVA, Bonferroni’s post-hoc, P=0.0101, F=5.17]. C) Graph shows quantification of the average 
time constant (Tau) ± SEM of the evoked SYT1-pH response [*p<0.05 (T84A/Y46A vs WT, T84A vs 
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3.2.6 – T84A/Y46A SV2A Does not Exacerbate Defects in SYT1 Surface Expression 
and Localisation 
After ascertaining that the double mutation of the SV2A/AP-2 and SV2A/SYT1 
binding motifs had no significant additive effect on the time constant of SYT1 
retrieval and its externalised proportion during stimulation, I proceeded to investigate 
if the same SV2A double mutation could potentially affect the surface expression of 
SYT1 and its localisation to presynaptic terminals in neurones. As in previous 
experiments, SV2A shRNA/SYT1-pHluorin was transfected into primary cultures to 
knockdown SV2A expression and co-express the SYT1-pHluorin reporter. Neuronal 
SV2A expression was rescued by co-transfection of WT, T84A, Y46A and 
T84A/Y46A SV2A-mCer plasmids (Figure 3.7 A). 
An investigation of the fraction of surface-expressed SYT1-pHluorin in SV2A 
knockdown neurones rescued with T84A/Y46A SV2A double mutant revealed a 
significant increase of surface fraction when compared to control rescue experiments 
using WT SV2A, consistent with previous results obtained from the single SV2A 
mutants. Comparison of results obtained from experiments rescued with the 
T84A/Y46A double mutant to experiments rescued with the corresponding single 
mutants revealed no additive effects to the surface expression of SYT1 [Surface 
expression of SYT1-pHluorin (% of total SYT1-pHluorin pool) = 16.0 ± 0.9 (WT 
SV2A), 36.0 ± 3.5 (mCer), 32.1 ± 3.0 (T84A SV2A), 44.5 ± 3.3 (Y46A SV2A), 34.6 
± 4.4 (T84A/Y46A SV2A); p < 0.01 (T84A/Y46A SV2A vs WT), ns (T84A/Y46A 
SV2A vs T84A or Y46A SV2A), one-way ANOVA, Bonferroni’s post-hoc, P = 
0.0001, F = 10.3] (Figure 3.7 B). CV analysis of the expression of the total SYT1-
pHluorin pool in a 50-µm length of neurite in SV2A knockdown cultures co-
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expressing the T84A/Y46A SV2A double mutant revealed a significantly decreased 
coefficient compared to control rescue experiments using WT SV2A. Comparison of 
rescue experiments using the T84A/Y46A double mutant to rescue experiments 
using the corresponding single mutants revealed no additive effects to the CV [Mean 
CV = 29.3 ± 3.0 (WT SV2A), 11.7 ± 0.9 (mCer), 16.2 ± 1.9 (T84A SV2A), 14.8 ± 
0.9 (Y46A SV2A), 18.9 ± 1.4 (T84A/Y46A SV2A); p < 0.01 (T84A/Y46A SV2A vs 
WT), ns (T84A/Y46A SV2A vs T84A or Y46A SV2A), one-way ANOVA, 
Bonferroni’s post-hoc, P < 0.0001, F = 14.1] (Figure 3.7 C).  
These experiments demonstrate that mutation of both the SV2A/AP-2 and 
SV2A/SYT1 binding motifs in SV2A leads to increased surfaced expression and 
increased diffuseness of SYT1 expression across the neurite, but with no additive 
effects compared to those observed in experiments with just a single SV2A mutation. 
This suggests that mutation of both binding sites in SV2A serve to disrupt targeting 
of SYT1 to presynaptic terminals via a similar mechanistic pathway to be discussed 
in later chapters. 
  




Figure 3.7: T84A/Y46A SV2A does not exacerbate defects to SYT1 surface expression and 
localisation. A) Hippocampal neurones were co-transfected with an SV2A shRNA-SYT1-pHluorin 
plasmid and either wild-type (WT) or SV2A-mCer variants. Representative greyscale images show 
that rescue with T84A/Y46A SV2A-mCer resulted in less localisation to nerve terminals compared to 
WT SV2A-mCer rescue. Scale bar = 10 μM. B) Surface expression of SYT1–pHluorin after rescue with 
SV2AmCer variants displayed as a percentage of total SYT1-pHluorin pool ± SEM [n=5 mCerN1 
empty, purple; n=5 WT SV2A-mCer, blue; n=5 T84A SV2A-mCer, cyan; n=5 Y46A SV2A-mCer, red; n=5 
T84A/Y46A SV2A-mCer, pink; ****p<0.0001 (Y46A vs WT); **p<0.01 (mCer vs WT, T84A/Y46A vs 
WT); *p<0.05 (T84A vs WT); one-way ANOVA, Bonferroni’s post-hoc, P=0.0001, F=10.3]. C) Bar graph 
displays the mean coefficient of variation of SYT1-pHluorin fluorescence along axons of neurones in 
alkaline buffer. Data are presented as ± SEM (n=5 mCerN1 empty, purple; n=5 WT SV2A-mCer, blue; 
n=5 T84A SV2A-mCer, cyan; n=5 Y46A SV2A-mCer, red; n=5 T84A/Y46A SV2A-mCer, pink; 
****p<0.0001 (mCer vs WT); ***p<0.001 (T84A vs WT, Y46A vs WT); **p<0.01 (T84A/Y46A vs WT); 
one-way ANOVA, Bonferroni’s post-hoc, P<0.0001, F=14.1). 
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3.3. –Discussion on the Presynaptic Effects of Y46A SV2A 
SV2A and SYT1 are hypothesised to be intrinsic trafficking partners, therefore the 
disruption of SV2A trafficking by ablation of AP-2 binding should also result in 
downstream disruption of SYT1 trafficking and thus its internalisation from the 
plasma membrane during endocytosis. Mutation of the Y46 residue from tyrosine to 
alanine (Y46A) was previously shown to ablate SV2A binding to AP-2, resulting in 
the stranding of SYT1 at the plasma membrane (Yao et al., 2010). Recent studies 
have confirmed that Y46A SV2A displays retarded retrieval during endocytosis (Dr. 
C. Harper, Cousin Lab, data not shown), confirming a role for the AP-2 binding 
motif in clustering SV2A during SV compensatory endocytosis. However, the effect 
of Y46A SV2A on SYT1 trafficking, and by extension SV recycling has never been 
documented in previously published literature. 
 
3.3.1 – ShRNA-mediated Knockdown of SV2A Expression in Neurones Can Be 
Successfully Rescued by Use of Exogeneously Transfected Y46A SV2A 
Knockdown of endogeneous SV2A was achieved using a small hairpin DNA 
sequence and successfully reduced expression of SV2A to about 50% of its original 
level. This observation was noted to be slightly lower than in previously reported 
data (>75%) (Zhang et al., 2015) and discrepancies may have arisen from the method 
of immuno-quantification used. In this approach, averaged fluorescence from SV2A-
depleted nerve terminals was expressed as a percentage of averaged fluorescence 
from normal, non-SV2A-depleted nerve terminals within the same field of view. 
Selection of nerve terminals for analysis is highly subjective between persons and 
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may inevitably lead to differences when reporting data. In comparison with internal 
controls, there was still significant reduction in average SV2A levels. SV2A is 
known to have a relatively low copy number on SVs at the nerve terminal (around 2-
12 per SV) compared to other intergral SV proteins such as SYT1 (20 per SV), SYP 
(30 per SV) and SYB (70 per SV) (Takamori et al., 2006, Wilhelm et al., 2014), 
therefore a 50% reduction in expression levels would still be expected to greatly 
affect the sorting of SV2A and its related cargo. 
SV2A expression in these knockdown cells was then rescued by the transfection of 
exogenous DNA that codes for either full length WT SV2A or full length Y46A 
SV2A. The Y46A SV2A mutant was shown to rescue SV2A expression to similar 
levels to that seen when WT SV2A is used. Therefore, any observable phenotype due 
to the use of these constructs is attributed to an effect resulting from the presence of 
the Y46A mutation and not due to an experimental failure to rescue SV2A 
expression in the cell. 
 
3.3.2 – Y46A SV2A Leads to Acceleration of SYT1 Retrieval Kinetics and Increased 
Surface Expression and Mislocalisation of SYT1 
The presence of Y46A SV2A in hippocampal neurones resulted in an acceleration of 
SYT1 retrieval during compensatory endocytosis, mimicking the phenotype observed 
when there is a deficiency of SV2A at the synaptic terminal. This was not a general 
acceleration of endocytosis, as other SV cargos such as synaptophysin were not 
affected in a similar manner by the presence of the Y46A mutation. The Y46A SV2A 
mutation also leads to an increased fraction of SYT1 surface expression and 
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defective localisation of SYT1 to synaptic terminals. These observations are in 
agreement with previously published work describing specific defects in SYT1 
trafficking upon perturbation of SV2A (Yao et al., 2010, Zhang et al., 2015). 
The acceleration of SYT1 retrieval caused by Y46A SV2A is unusual, since the 
disruption of endocytic sorting mechanisms either by depletion of monomeric 
adaptors or adaptor protein complexes (Willox and Royle, 2012, Kononenko et al., 
2014) or by mutagenesis of key endocytosis motifs (Foss et al., 2013) usually result 
in the retardation of SV cargo retrieval during compensatory endocytosis. When 
considering other SV cargo complexes at the presynapse such as the synaptophysin-
synaptobrevin 2 (SYP-SYB2) complex, evidence has shown that the trafficking of 
SYB2 is retarded in neurones derived from mice lacking in either SYP (Gordon et 
al., 2011) or the classical SYB2-specific adaptor, AP-180 (Koo et al., 2015). In 
contrast, increased SYT1 surface expression and an acceleration of SYT1 retrieval 
during endocytosis has also been previously observed in neurones derived from 
stonin-2 knockout mice (Kononenko et al., 2013). Stonin-2 is a specific endocytic 
adaptor for SYT1, providing further evidence that perturbation of the trafficking 
partners of SYT1 leads to very specific defects in SYT1 trafficking which do not fall 
in line with the trafficking behaviour of other SV cargo complexes.  
There are several potential explanations for this interesting phenotype. The most 
likely explanation is that SYT1 is retrieved by a parallel endocytic mode with faster 
retrieval kinetics than classical clathrin-mediated endocytosis (CME). Examples of 
fast modes of retrieval are ADBE (Clayton et al., 2008) and ultrafast endocytosis 
(Watanabe et al., 2013b). It is possible that the accumulation of SYT1 at the plasma 
membrane acts as a trigger for these modes. Thus, although the Y46A SV2A 
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mutation may lead to underlying defects in post-exocytic SYT1 retrieval via CME 
(which is evidenced from the increased stranding of SYT1 at the surface plasma 
membrane), the retrieval of newly deposited SYT1 could be mediated by an alternate 
endocytosis mode. In order to test this hypothesis, labelling of SYT1 during 
immunoelectron microscopy of cultured neurones after stimulation may shed light on 
the possible increased accumulation of SYT1 on bulk endosomal structures in Y46A 
SV2A or defective SYT1-binding stonin-2 neurones compared to WT neurones, thus 
providing evidence of ADBE as an alternative retrieval mechanism for SYT1 when 
CME is perturbed by ablation of AP-2 binding. In addition, immunolabelling of 
SYT1 during ‘flash-and-freeze’ cryo-electron microscopy studies (Watanabe et al., 
2013b) on hippocampal tissue from Y46A SV2A or stonin-2 knockout mice models 
may provide evidence of a role for ultrafast endocytosis in the retrieval of SYT1 
when CME is perturbed. 
Another possible explanation for this phenotype is that there is a reduction in SYT1 
retrieval during spontaneous SV endocytosis, but an increase in the retrieval of SYT1 
during activity dependent SV endocytosis. However, in argument against this theory, 
it was previously observed that plasma membrane SYT1 levels remained normal and 
that there was no gradual accumulation of SYT1 at the plasma membrane when 
neuronal activity was silenced in neurones depleted in SV2A (Kaempf et al., 2015). 
Spontaneous/Active SV recycling assays using single-label marking of SVs with 
biotinylated antibodies recognising the luminal domain of SYT1 (Wilhelm et al., 
2010) applied to cultured tissue from Y46A or stonin-2 knockout mice may shed 
further light on this theory. 
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3.3.3 – How Might SV2A Control SYT1 Retrieval? 
In conjunction with the classical monomeric adaptors AP-2 and stonin-2, SV2A is 
reported here to be a chaperone for the efficient post-exocytosis trafficking of SYT1. 
Specific interactions between SV2A, SYT1, stonin-2 and AP-2 at the synaptic 
terminal may aid the presentation of these SV cargos in the correct conformation 
needed for binding and clustering. It is possible that these conformations are not 
wholly achieved or maintained in the absence of one or more members of the 
complex. SV2A interacts with SYT1 at the C2B domain in a phosphorylation 
dependent manner (Zhang et al., 2015), whereas stonin-2 primarily interacts with the 
C2A domain of SYT1 (Jung et al., 2007). This means that it is possible that SV2A 
and stonin-2 could interact simultaneously with SYT1 via different C2 domains. In 
addition, both SV2A and stonin-2 interact with AP-2 via canonical internalisation 
motifs (Diril et al., 2006, Yao et al., 2010), however SV2A and stonin-2 do not 
appear to interact directly with each other. This provides further evidence that SV2A 
may have the ability to control SYT1 endocytosis through regulation of the binding 
affinity between stonin-2 and SYT1. In support of this concept, the region within the 
µ2 subunit of AP-2 where SV2A interacts is distinct from the region that interacts 
with the SYT1 C2B domain, explaining its ability to increase affinity (Haucke et al., 
2000). Co-immunoprecipitation studies have also shown the presence of a tripartite 
complex of SV2A, AP-2 and SYT1, suggesting they come together to form an 
internalisation complex in mammalian brain systems (Haucke and De Camilli, 1999). 
Specific interactions between SV2A, SYT1, stonin-2 and AP-2 at the synaptic 
terminal may aid the presentation of these SV cargos in the correct conformation 
needed for binding and clustering. This ensures maximum retrieval efficiency when 
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all members are present and potential functional redundancy when one member is 
absent or mutated. The phosphorylation of SV2A may play a key regulatory role in 
this process, as it may mediate SYT1’s access to AP-2. Phosphorylated SV2A may 
bind to both the C2B domain of SYT1 as well as AP-2. This brings SYT1 and AP-2 
to close proximity with each other and potentiates binding between AP-2 and the 
C2B domain of SYT1, facilitating the retrieval of SYT1 during SV endocytosis. 
Stonin-2 continues to interact with the C2A and C2B domains of SYT1 as well as 
AP-2 in a separate mechanistic pathway to assist further in SYT1 retrieval and 
endocytosis. Future SYT1-pHluorin fluorescence imaging experiments involving the 
knockdown of SV2A in stonin-2 deficient mice models and rescue with exogeneous 
Y46A SV2A, in comparison with WT SV2A rescue, may shed further light on 
whether the two mechanistic pathways are acting dependently or independently of 
each other. X-ray crystallographic experiments on the AP-2-SV2A-SYT1 complex 
may also shed further light on the proximity of SYT1 and AP-2 in space when both 
are bound to SV2A. 
 
3.3.4 – The Y46A and T84A SV2A Mutations Affect the Same Mechanistic Pathway 
As previously stated, the region within the µ2 subunit of AP-2 where SV2A interacts 
is distinct from the region that interacts with the SYT1 C2B domain (Haucke and De 
Camilli, 1999). SV2A may facilitate the retrieval of SYT1 by playing a role in 
mediating its access to AP-2. What happens to the retrieval of SYT1 if its 
interactions with both AP-2 and SV2A are ablated? It is reported here that genetic 
ablation of both the AP-2 and SYT1 binding motif within SV2A do not appear to 
show any additive SYT1 retrieval defects, compared to experiments when only one 
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binding motif is ablated. If SV2A merely mediated access of SYT1 to AP-2 in order 
to facilitate SYT1 retrieval during SV endocytosis, then it is not surprising that the 
ablation of both binding sites in SV2A do not present any additional mechanistic 
defects since both are an intrinsic part of the same retrieval pathway. The absence of 
additive defects also mean that the retrieval of SYT1 by stonin-2, which proceeds via 
a different retrieval pathway, is unaffected by the AP-2-SV2A-SYT1 interaction. It is 
entirely probable that SYT1 will randomly interact with AP-2 in the absence of 
SV2A. However, the results demonstrated here suggest that this probability remains 
unaffected by the binding of SV2A and AP-2 at the presynapse. It should be noted 
that the results observed in these experiments were compared to the baseline SYT1-
pHluorin retrieval time course set by genetic depletion of SV2A by use of shRNA 
silencing. Since immunofluorescence studies have demonstrated that neuronal SV2A 
depletion was only around 50%, the T84A/Y46A double mutant could only 
exacerbate the SYT1 retrieval acceleration effect if it was dominant negative over the 
remaining expressed WT SV2A. 
The presence of T84A/Y46A double mutant resulted in a reversal of the slight 
increase in SYT1 trafficking during exocytosis which was observed in the Y46A 
SV2A single mutant experiments, matching the levels of SYT1 externalisation seen 
in the T84A single mutant and WT SV2A experiments. This result was unexpected 
since both the T84A and Y46A SV2A mutations serve to disrupt SV2A interactions 
with SYT1 and AP-2 respectively, and was therefore predicted to disrupt SYT1 
trafficking at least to the same extent as the Y46A single mutant. The results suggest 
that the SV2A-AP-2 interaction may be a factor in regulating SYT1 trafficking to the 
membrane surface during exocytosis under normal circumstances, however ablation 
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of the SV2A-SYT1 interaction may trigger a separate ‘rescue mechanism’ that re-
normalises SYT1 trafficking during exocytosis. It is unlikely that this ‘rescue 
mechanism’ is the acceleration of SYT1 retrieval via a different mechanistic pathway 
(stonin-2), since the T84A/Y46A double mutant showed no exacerbation of SYT1 
retrieval defects observed with the single mutants. This defect in SYT1 trafficking 
during exocytosis may be further investigated in future experiments by perfusion of 
bafilomycin onto transfected neurones to inhibit SV re-acidification prior to 
stimulation. Bafilomycin ablates the diminishment of pHluorin fluorescence caused 
by SV re-acidification during SV endocytosis, thus enabling full quantification of 
SYT1 externalisation as a ratio of the total SV pool during stimulation and may fully 
reveal the true extent of the T84A and Y46A SV2A mutations on SYT1 
externalisation during exocytosis. 
 
3.3.5 – Is Retrieval of SV2A Affected by Defective SYT1 Retrieval During SV 
Endocytosis? 
If ablation of the AP-2 binding region in SV2A results in defective retrieval, surface 
expression and localisation of SYT1, then it is highly probable that defects in SYT1 
binding to SV2A would affect SV2A in a similar manner if they are transported as a 
cargo complex during SV endocytosis. Mutation of the K326/328A residues on 
SYT1 has previously been shown to ablate binding of SYT1 to SV2A (Zhang et al., 
2015) and results in defective SYT1 retrieval. Further experiments to probe the effect 
of K326/328A SYT1 on SV2A retrieval may provide greater insight to 
differentiating the endocytic mechanisms that drive the retrieval of SV2A and SYT1. 
It is currently unknown if: 1) ablation of SYT1 binding to SV2A leaves SV2A 
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stranded at the plasma membrane in a similar manner, thus triggering a parallel 
endocytic mode resulting in accelerated retrieval of SV2A or 2) ablation of SYT1 
binding to SV2A results in retardation of SV2A retrieval as classically observed. A 
difference in retrieval behaviour between SV2A and SYT1 in the absence of the 
other may lead to further developments in elucidating the complex interactions 
underlying the transport of SV2A and SYT1 at the presynapse. It is also currently 
unknown if AP-2 binding to SYT1 would affect kinetics of SV2A retrieval, therefore 
experiments probing the retrieval, surface expression and localisation of SV2A in the 
presence of an ablation of the SYT1-AP-2 binding region may yet reveal more key 
interactions driving the transport of the SV2A-SYT1 complex. 
Lastly, the effect of defective binding of stonin-2 to SYT1 on the retrieval of SV2A 
cannot be trivialised. Although it is likely that the pathway responsible for stonin-2-
mediated retrieval of SYT1 is separate from SV2A/AP-2-mediated retrieval of 
SYT1, this has yet to be documented in the literature. Further experiments 
investigating the retrieval of SV2A in the presence of SYT1 that is defective in 
binding to stonin-2 may provide insight to previously undiscovered roles of stonin-2 
in SV endocytosis. If retrieval of SYT1 by the stonin-2 pathway is indeed altered, 
then presence of Y46A SV2A in these experiments should result in additive defects 
in SV2A retrieval compared to WT SV2A. 
 
3.3.6 – Technical Limitations of the Study 
The use of pHluorins as a tool for determining the effects of Y46A on SYT1 
trafficking must also be considered. Firstly, analysis of the data is based on the 
assumption that vesicle re-acidification takes place on a significantly faster timescale 
   
126 
 
than SV endocytosis during neuronal activity. This may not necessarily always be 
true since recent experiments have shown that SV re-acidification takes place with a 
time constant of ~15 s, which is three to four-fold slower than previously reported 
(Egashira et al., 2015). It is also unknown if the Y46A mutation has a direct effect on 
SV re-acidification, as the phenomenon observed may be a result of defect SV re-
acidification kinetics rather than defective SYT1 retrieval during compensatory 
endocytosis. The use of an exogeneously expressed fusion protein to monitor 
presynaptic dynamics also relies on the assumption that the trafficking behaviour of 
the exogeneous cargo perfectly mimics that seen with the endogeneous cargo. It can 
be argued that fusion of a high molecular weight fluorophore such as GFP may 
significantly alter the trafficking behaviour of the cargo to an extent that it may not 
truly reflect the original behaviour. However, in these experiments all pHluorin 
investigations were compared against control experiments using GFP-fused WT 
SV2A, thus eliminating any small trafficking nuances that may have arisen from the 
presence of GFP. It is also noted that for an effect to be observed in the above 
experiments, the exogeneously-expressed mutant has to exert a dominant negative 
effect over the endogeneously-expressed WT protein. The presence of a phenotype 
with the Y46A SV2A mutant suggests that it is dominant negative over WT SV2A in 
these studies; however, the exact nature of the double mutant remains unclear. 
 
  







4.0 –The Effects of an Epilepsy-
Related SV2A Mutation on SYT1 
Trafficking at the Presynapse 
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4.1 – Introduction to Epilepsy 
Epilepsy is a group of common neurological disorders that are characterised by the 
onset of recurrent seizures in patients. The disorder affects up to 65 million people 
worldwide (1% of the world’s population) with up to 80% of cases occurring in 
developing countries. During an epileptic seizure, it is hypothesised that neurones in 
the brain begin to fire in an excessive, synchronised manner compared to the normal 
state where neuronal firing patterns are non-synchronised (Jiruska et al., 2013). 
The underlying causes of epilepsy are unknown in most cases as seizures occur 
spontaneously and they are not immediately caused by a pre-existing acute illness. In 
younger people, seizures are likely to be caused by underlying genetic disorders. 
Although some causes of juvenile epilepsies may be derived from single gene 
defects, the large majority of cases are a result of the interactions of multiple genes 
as well as environmental factors during brain development (Pandolfo, 2011). In older 
people, seizures are more likely to be caused by insults to the brain from incidents 
such as the development of brain tumours, strokes, head injuries or infections of the 
central nervous system. In accordance with the 2017 ILAE seizure classification 
guidelines, seizures are generally classified by the earliest prominent feature. 
Epileptic seizures can be classified into three main groups: i) focal onset seizures 
where the origin of the seizure is localised to a single region or hemisphere of the 
brain; ii) generalised onset seizures where the origins of the seizure are distributed 
generally throughout the whole brain and iii) unknown and unclassified onset 
seizures whereby there is inadequate information about the seizure or an inability to 
place it in other categories. After being classified into one of the three main groups, a 
seizure may be further classified into motor or non-motor onset sub-groups. Motor 
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onset seizures affect the motor activity of the body during seizure. These include 
tonic, clonic, myoclonic, atonic seizures and epileptic spasms. Non-motor onset 
seizures generally affect behaviour and include autonomic, cognitive, emotional, 
sensory seizures as well as behaviour arrest (Fisher et al., 2017). 
 
4.1.1 – Implications of General Synaptic Dysfunction in Epilepsy 
Although epileptogenesis usually initiates in the early stages of life, it has a 
neurodegenerative component that facilitates aberrant synaptic morphology and 
function and could result in cognitive failure. The underlying causes of epilepsy 
remain largely unknown to this day. Current evidence supports the hypothesis that an 
imbalance in the excitatory and inhibitory circuits facilitates the onset of the first 
seizure episodes, which in turn brings about cellular and molecular changes that may 
lower the threshold for subsequent sequential seizures. An increase in the release of 
excitatory amino acids has consistently been observed in the hippocampus during 
seizures in both humans and animals. Pilocarpine-induced status epilepticus in rat 
hippocampal cells increased the basal (spontaneous) glutamate outflow during the 
chronic period (Soukupova et al., 2015). Ultrastructural analysis of transmission 
electron micrographs of pilocarpine-treated rat hippocampal mossy fibre boutons 
revealed a significant increase in the number of release sites, active zone length, 
postsynaptic density area and number of vesicles in the readily releasable and 
recycling pools, all correlated with increased release probability in glutamatergic 
synapses (Upreti et al., 2012). These data support the theory that the excitatory 
presynaptic release machinery is persistently altered in structure and function by 
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status epilepticus, which could contribute to the development of the chronic epileptic 
state. 
Impairment of inhibitory GABA-ergic synapses is another mechanism that is likely 
to contribute to development of the chronic epileptic state. Loss of hippocampal 
gamma aminobutyric acid-ergic (GABA-ergic) interneurones during epileptogenesis 
resulted in impairment of basal GABA outflow during the early course of temporal 
lobe epilepsy and the dysfunction persisted through to the late phases of the disease 
(Soukupová et al., 2014). This data suggests that the potentiation of glutamatergic 
signalling, together with impairment of extracellular GABA levels, can favour the 
onset of spontaneous recurrent seizures and the maintenance of an epileptic state in 
the hippocampus of epileptic rats. In support of this theory, alterations in the 
distribution and composition of AMPA receptors and NMDA receptors leading to 
increased excitatory tonus (Lopes et al., 2015) and reductions in the surface 
expression of specific subunits of GABA receptors during status epilepticus leading 
to reduced GABA-mediated synaptic inhibition (Goodkin et al., 2008) may further 
exacerbate the imbalance between excitatory and inhibitory activity leading to the 
onset of status epilepticus. However, if impaired GABA-ergic neurotransmission 
were to be involved in epileptogenesis, then one would expect synaptic boutons 
obtained from epileptic animal models to be smaller in volume, have fewer and 
smaller active zones, and contain fewer vesicles (including fewer docked vesicles). 
Interestingly, electron micrographs of synapses in the hippocampal basket cell to 
granule cell layer obtained from pilocarpine-induced epileptic rats revealed the 
opposite effect. Basket cell layer synaptic boutons contained over twice the average 
volume, active zone area and number of total vesicles (including docked vesicles and 
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with more vesicles closer to active zones) (Buckmaster et al., 2016). This result 
suggests that the neurotransmission failures at synapses of epileptic rats are not 
attributable to smaller boutons or fewer docked vesicles at inhibitory synapses. 
Instead, it may be the processes that follow vesicle docking (such as priming, Ca2+ 
entry into the synapse, Ca2+ coupling with exocytosis or SV endocytosis) that are 
responsible for epilepsy-related phenotypes. 
Mutations in genes coding for ion channels have also provided evidence that are 
associated with syndromes implicated in human epilepsy. Two mutations that cause 
generalised epilepsy with febrile seizures, T875M and R1648H, have been identified 
in the SCN1A gene encoding the alpha subunit of the human voltage-gated sodium 
channel (Na(v)1.1). The T875M mutation led to enhanced slow inactivation of the 
channel, which decreased the ability of the neurone to fire action potentials at high 
frequency. Seizure activity may result from decreased firing of inhibitory neurones, 
which causes increased firing in excitatory postsynaptic neurones. The R1648H 
mutation accelerated recovery from channel inactivation, leading to neuronal 
hyperexcitability (Meisler et al., 2001). Point mutations in the human voltage-gated 
potassium channel (Kv1.1) gene have been shown to associate with episodic ataxia 
type 1 (EA1), which is a rare autosomal dominant disorder characterized by brief 
episodes of ataxia and partial epilepsy. Functional studies indicated mutant subunits 
in Kv1.1 exhibited a dominant negative effect on potassium channel function, 
possibly leading to impairment of neuronal repolarisation (Zuberi et al., 1999). 
Defects in ligand-gated neurotransmitter channels have also been implicated in 
human epilepsy. A mutation (R43Q) in the gene encoding for GABRG2, a 
GABA(A) receptor subunit, abolished in vitro sensitivity to diazepam, raising the 
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possibility that benzodiazepines may play an integral physiological role in preventing 
seizures (Wallace et al., 2001). GABA(A) receptors are ligand-gated chloride 
channels that mediate inhibitory synaptic transmission in the central nervous system. 
Reduced synaptic inhibition is a potential cause of epilepsy and many antiepileptic 
drugs, such as diazepam, are designed to target GABA. An association between a 
form of nocturnal epilepsy and a mutation (I279N) in CHRNA2, the gene encoding 
for the α2 subunit on nicotinic acetylcholine receptors (nAChR), was demonstrated 
and provided further support for the link between neuronal ion channel defects and 
epilepsy. The I279N mutation was shown to cause an increased sensitivity to 
acetylcholine, which leads to neuronal hyperexcitability (Aridon et al., 2006). The 
cause for epileptogenesis cannot be attributed to a specific defect in the 
neurotransmission pathway. Several lines of evidence (detailed in the following sub-
chapter) have suggested that the defects in the SV recycling pathway at the 
presynapse might play an important role in the onset of certain types of epilepsy.  
 
4.1.2 – Evidence of SV Recycling Defects in Epilepsy 
In searching for persistent seizure-induced alterations in brain function that might be 
causally related to epilepsy, SV recycling and presynaptic neurotransmitter release 
has been relatively understudied. Several presynaptic proteins involved in the 
homeostatic regulation of neurotransmitter release have been linked to epilepsy, 
where excessive glutamate-induced synaptic activity results in neuronal toxicity. 
Ablation or alteration of these SV proteins in animal models leads to abnormal 
neurotransmission and behavioural phenotypes that are consistent with symptoms 
derived from epileptogenesis.  
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Synapsins I and II (SYN1 and SYN2) are neuronal phosphoproteins that can 
reversibly associate with SVs and tether them to the cytomatrix to maintain a reserve 
pool of vesicles (Shupliakov et al., 2011). SYN1 KO mice showed marked alteration 
in the way SVs are organised at the presynaptic terminal, leading to an increase in 
epileptic seizures invoked by electrical stimulation (Li et al., 1995). Genetic 
epidemiology studies have identified a nonsense mutation, W356x, in the human 
SYN1 gene that leads to mRNA decay and loss of protein function and underlies X-
linked syndromic epilepsy (Giannandrea et al., 2013). Recent gene-gene interaction 
studies have also indicated that SYN2 A>G polymorphism is an important risk factor 
in the development of idiopathic generalised epilepsy in humans (Prasad et al., 
2014). There have been several theories put forward to explain the connectivity 
between the molecular function of synapsins at the neuronal level and the onset of 
epilepsy. Synapsins are thought to play a role in the formation of synaptic 
connectivity during development, thus it is likely that mutations affecting their 
expression and function will result in significant imbalances in synaptic transmission, 
plasticity and development that could be potentially related to the epileptogenesis. In 
support of this, it has been shown that knockout of SYN1 in mice reduces the readily 
releasable pool at inhibitory synapses whilst increasing the pool at excitatory 
synapses (Baldelli et al., 2007). 
Another SV protein that has been well documented to be involved in the onset of 
epilepsy is synaptosomal-associated protein 25 (SNAP-25). SNAP-25 is a member of 
the soluble NSF attachment protein receptor (SNARE) complex, along with syntaxin 
and synaptobrevin. SNARE complexes play a role in the docking, priming and fusion 
of SV vesicles at the synaptic terminal. This can occur through interactions with 
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other SV proteins such as synaptotagmin I (SYT1) and complexin, or through 
putative calcium-binding sites (see chapter 1). The first clues of SNAP-25’s possible 
involvement in neuronal hyperexcitability was documented when Raber et.al showed 
that Coloboma (Cm/+) mice, a neurological mouse model of attention deficit 
hyperactivity disorder, has a 50% reduction in SNAP-25 mRNA and protein as well 
as impaired evoked neurotransmitter release (Raber et al., 1997). Studies in SNAP-
25 heterozygous mice [SNAP-25(+/-)] mice showed that reduction of SNAP-25 
protein levels associated with moderate hyperactivity. Electroencephalographic 
(EEG) recordings of the SNAP-25(+/-) mice revealed the occurrence of frequent 
spikes, suggesting a diffuse network hyperexcitability. The mice also displayed 
degeneration of the hilar neurones, which resulted in higher susceptibility to kainate-
induced seizures. The EEG profile and defects in cognition could be improved with 
the use of anti-epileptic drugs such as carbamazepine and nimodipine (Corradini et 
al., 2014). Whole exome sequencing studies have also identified a novel SNAP-25 
c.142G>T p.Phe48Val alteration which is implicated in generalised epilepsy and 
cognitive dysfunction (Rohena et al., 2013). The role of SNAP-25 in the pathology 
of epilepsy may involve alterations in synaptic formation and transmission, similar to 
that seen with synapsins. SNAP-25 is known to play a role in neurite extension 
(Osen-Sand et al., 1996), thus a reduction in SNAP-25 expression may consequently 
lead to a defect in overall brain connectivity and an epilepsy phenotype. SNAP-25 is 
expressed at much higher levels in excitatory synapses compared to inhibitory 
synapses (99:1 ratio) (Bragina et al., 2007), therefore neuronal hyperexcitability 
could also result from perturbations of the processes that govern the balance of 
excitatory and inhibitory synapses during developmental synaptic assembly. Other 
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studies have also indicated a role for SNAP-25 in the regulation of calcium at the 
neurone. It was shown that phosphorylated SNAP-25 inhibits voltage-gated calcium 
channels, therefore negatively modulating calcium dynamics and consequently 
leading to the onset of epileptic seizures (Condliffe et al., 2010). The presynaptic 
Ca2+ sensor SYT1 has also been implicated in epilepsy, as clinical studies have 
revealed an increased expression of SYT1 in temporal lobe tissue of patients with 
refractory epilepsy (Xiao et al., 2009). 
Dynamin-associated mechanisms have been suggested as a possible target for novel 
antiepileptic drugs. Inhibition of dynamin I (DYN1) binding to syndapin with a 
peptide-based inhibitor produced an activity-dependent reduction in synaptic 
transmission. The peptide progressively inhibited synaptic transmission after a short 
delay, suggesting that this approach may lead to selective inhibition of sustained 
neuronal firing that occurs during a seizure, while allowing normal physiological 
neurotransmission (Anggono et al., 2006). Mice lacking in DYN1 displayed severe 
impairment of SV endocytosis during strong exogeneous stimulation but resumed 
efficiently when the stimulus was terminated, suggesting that DYN1 plays a key role 
in maintaining stable neurotransmission during high levels on neuronal activity 
(Ferguson et al., 2007). Synaptic dynamin-associated proteins (syndapin), which 
interact with dynamin and other SV proteins, may also participate in dynamin-
associated mechanisms in epileptogenesis. Inhibition of syndapin I using syndapin 
antibodies resulted in strong impairment of inhibitory postsynaptic currents at high 
frequency stimulation (Andersson et al., 2008). Studies of protein expression in rat 
model of epilepsy as well as patients with temporal lobe epilepsy revealed an 
upregulation of DYN1. Inhibition of DYN1 using the DYN1 inhibitor, dynasore, 
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resulted in decreased frequency and severity of seizures (Li et al., 2015). Genetic 
studies have indicated that a missense ftfl (fitful) mutation in the DYN1a isoform 
results in recurrent seizures, severe ataxia and neurosensory deficits by altering 
developmental expression and self-assembly of DYN1 in mice (Boumil et al., 2010). 
There is also increasing evidence of epileptogenesis caused by DYN1 mutations in 
humans, as many clinical studies have now identified several de novo mutations in 
genes coding for DYN1 to be responsible for human epileptic encephalopathy 
(Consortium et al., 2014, Nakashima et al., 2016). These defects in dynamin I and 
syndapin I give evidence to severe impairment of neurotransmission during sustained 
high levels of neuronal activity, providing insight to a possible novel mechanism in 
the generation of seizures.  
Genetic ablation of amphiphysin I led to severely reduced expression of amphiphysin 
II and defective assembly of endocytic protein complexes, resulting in a smaller 
functional SV recycling pool size, slower recycling kinetics or delayed vesicle 
priming. These cell biological defects potentially underlie the occurrence of rare 
spontaneous seizures observed in amphiphysin I knockout mice (Di Paolo et al., 
2002). Synaptojanin I deficient mice progressively developed weakness, ataxia and 
displayed general convulsions until death within 2-3 weeks of birth. Reduced 
phosphoinositide activity led to a defect in vesicle uncoating and an accumulation of 
clathrin-coated SVs in the cytomatrix-rich area surrounding nerve terminals. 
Prolonged high frequency stimulation of hippocampal slices obtained from 
synaptojanin I deficient mice revealed enhanced synaptic depression followed by 
delayed recovery (Cremona et al., 1999).  Studies on mice lacking the central region 
of the presynaptic active zone protein Bassoon demonstrated that the loss of Bassoon 
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led to inactivation of a significant fraction of glutamatergic synapses, resulting in 
reduction in normal synaptic transmission and spontaneous epileptic seizures 
(Altrock et al., 2003). Analysis of genome mutations in four unrelated individuals 
with early infantile epileptic encephalopathy revealed the existence of heterozygous 
missense mutations in the gene encoding for syntaxin binding protein 1 (STXBP1, 
also known as MUNC18-1). STXBP1 is an evolutionally conserved neuronal protein 
that is essential in SV fusion in several species, and functional studies indicated that 
the mutations in STXBP1 impaired binding to the SV protein syntaxin (Saitsu et al., 
2008). Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin 
family of growth factors that binds with high affinity to the receptor tyrosine protein 
kinase B (TrKB), may also be involved in epileptogenesis. In various animal seizure 
models, the seizures caused a prominent increase in the expression of BDNF in the 
brain, particularly in the hippocampus [see review: (Casillas-Espinosa et al., 2012)]. 
The acute administration of BDNF into the CA3 region of the hippocampus, the 
dentate gyrus and medial entorhinal cortex produces neuronal hyperexcitability 
(Messaoudi et al., 1998). BDNF has been suggested to regulate synaptic transmission 
by a variety of mechanisms including increasing excitatory NMDA currents (Xu et 
al., 2006) and attenuating inhibition on GABAergic postsynaptic cells by down-
regulating chloride transport (Huang et al., 2012), thus possibly impacting on the 
very same mechanistic pathways implicated in the onset of epileptic seizures. 
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4.1.3 – SV2A and Epilepsy 
Synaptic vesicle protein 2A (SV2A) is a SV glycoprotein which has been previously 
discussed to play a key role in SV trafficking and exocytosis. In 2004, SV2A was 
demonstrated to be the binding partner for the popular anti-epileptic drug 
levetiracetam (LEV) (Lynch et al., 2004). This discovery provided a platform for 
SV2A being a valid and novel target for further anti-epileptic drug discovery 
research and its role in epilepsy. In support of this, the correlation between LEV-
SV2A binding affinity and anti-seizure potency was later confirmed in an audiogenic 
seizure model and extended to other models of epilepsy (Kaminski et al., 2008). 
Mice that harboured a 50 percent reduction in SV2A also displayed reduced anti-
seizure activity when administered with LEV compared with wild-type animals 
(Kaminski et al., 2009).  
Gorter et al. initially demonstrated that SV2A gene expression was downregulated in 
the endorhinal cortex of rats in which epilepsy was induced by sustained electrical 
stimulation (Gorter et al., 2006). Later studies showed that SV2A was also decreased 
in the hippocampus of chronic epileptic rats, resembling the decrease in SV2A that 
was observed in human patients with temporal lobe epilepsy (van Vliet et al., 2009). 
Hippocampal SV2A mRNA and protein expression were also found to be lower in 
phenytoin-resistant epileptic rats compared with normal anti-epileptic drug 
responding controls, suggesting a role for SV2A in the mechanism that underlies 
pharmacoresistant epilepsy (Wang et al., 2014). In support of this, previous findings 
have shown that SV2A expression was reduced by 30 to 50 percent in the anterior 
temporal neocortex of adult patients with temporal lobe epilepsy (Feng et al., 2009). 
Malformations that cause intractable epilepsy, such as focal cortical dysplasia and 
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tuberous sclerosis complex, also show significantly reduced SV2A expression in 
immunocytochemistry studies. Cortical tissue of patients with dysplasia displayed 
decreased SV2A immunoreactivity compared to tissue obtained from normal 
patients. This decrease was similarly observed in Western blot analyses of protein 
samples obtained from tissue from patients with both focal cortical dysplasia and 
tuberous sclerosis complex (Toering et al., 2009). These results suggest that 
decreased SV2A expression may contribute to the instability of neuronal networks 
and therefore to the progression of epilepsy. Recently, a homozygous mutation was 
discovered in the SV2A gene of a patient with intractable epilepsy, providing the 
first line of evidence that an SV2A mutation can cause epilepsy in humans. Exome 
sequencing identified a homozygous arginine to glutamine mutation in amino acid 
residue 383 (R383Q) in exon 5 of the SV2A gene. Both parents were carriers for the 
R383Q variant, suggesting that R383Q is a recessive mutation. No other candidate 
alterations in the exome were found that could otherwise explain the phenotype 
observed in the patient (Serajee and Huq, 2015). A missense leucine to glutamine 
mutation in amino acid residue 174 (L174Q) in rat models showed an increased 
susceptibility to induced seizures compared to control animals. Microdialysis studies 
also revealed that presence of the L174Q mutation preferentially reduced GABA 
release in the amygdala after depolarisation with elevated levels of K+, indicating 
that dysfunction of SV2A leading to disruption of synaptic GABA release in the 
amygdala may play a crucial role in epileptogenesis (Tokudome et al., 2016). 
It is tempting to speculate that epileptogenesis may be mediated by associated 
changes in the conformation and/or trafficking of SV2A that may occur after the first 
seizure episode. SV2A knockout mice via targeted gene disruption appear normal at 
   
140 
 
birth, but fail to grow normally and experience severe seizures before dying within 
three weeks of birth. Electrophysiological studies of hippocampal cells in the CA3 
region revealed that loss of SV2A led to a reduction in action potential-dependent 
GABA-ergic neurotransmission, but action potential-independent neurotransmission 
was normal. Analysis of synapse structure suggested that the altered inhibitory 
neurotransmission was not caused by changes in synapse density or 
morphology(Crowder et al., 1999). Neurones lacking both SV2A and SV2B 
experienced sustained increases in Ca2+-dependent synaptic transmission when two 
or more action potentials were triggered in succession. The increased synaptic 
transmission could be reversed by the calcium chelator ethylene glycol tetraacetic 
acetoxymethyl ester (EGTA-AM), which confirms the calcium dependence of the 
observed phenotype (Janz et al., 1999). This finding indicated that the absence of 
SV2 led to presynaptic Ca2+ accumulation during consecutive action potentials that 
led to abnormal increases in neurotransmitter release that may destabilise synaptic 
circuits and induce epilepsy.  
 
  
   
141 
 
4.1.4 – Aims and Objectives 
SV2A is the binding site of the anti-epileptic drug, levetiracetam, and is currently the 
only known SV target for pharmacological treatment of epilepsy. There has been just 
a single identification of a pathogenic mutation in the gene coding for SV2A in 
humans to date. Exome sequencing has identified a homozygous arginine to 
glutamine mutation at residue 383 (R383Q) in the cytosolic loop of SV2A which 
leads to intractable epilepsy, involuntary movements, microcephaly, developmental 
and growth retardation in a five-year old female patient (Serajee and Huq, 2015). The 
R383Q change is not observed in known healthy cohorts, exome databases, or the 
Database of Single Nucleotide Polymorphisms, which supports the argument that 
there is a clear pathogenic role for the mutation. The mechanism by which the 
R383Q mutation affects SV2A normal function remains unclear. As it is currently 
known that SV2A and SYT1 are intrinsic trafficking partners, a random mutation in 
SV2A may lead to protein dysfunction and downstream effects of SYT1 recycling 
during compensatory endocytosis. I hypothesise that presence of the R383Q mutation 
disrupts the normal function of SV2A in neurones, eventually leading to a defect in 
SYT1 trafficking during SV recycling. This R383Q mutation may occur in a region 
that is critical to the maintenance of normal SV2A function, therefore resulting in a 
loss of protein-protein interactions with other known SV proteins. In this chapter, I 
aim to elucidate possible presynaptic mechanisms underlying the causes for the onset 
of epilepsy in patients carrying the R383Q SV2A mutation.   
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The primary objectives of the research in this chapter are: 
1) To validate the knockdown of wild type SV2A by use of a small hairpin RNA 
(shRNA) sequence and subsequent rescue of SV2A expression with wild type 
(WT) or R383QA SV2A 
 
2) To characterise the effect of R383Q SV2A on the surface expression of SYT1 
at the plasma membrane and its localisation to presynaptic terminals 
 
3)  To characterise the effect of R383Q SV2A on the rate of SYT1 retrieval 
from the plasma membrane during compensatory endocytosis 
 
4) To establish the SYT1 specificity of defects in SV recycling which are caused 
by R383Q SV2A 
 
5) To compare and contrast between the mechanism of R383Q SV2A action of 
SYT1 trafficking at the presynapse and currently known mechanistic 
pathways which alter the SV2A-SYT1 interaction and result in defective 
SYT1 retrieval from the plasma membrane 
 
6) To characterise the protein-protein interactions of R383Q SV2A in presence 
of mouse brain lysate and discriminate between any loss or gain of protein 
interaction which may lead to defective SYT1 recycling 
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4.2. – Results of Studies Using R383Q SV2A 
Several lines of evidence implicate the SV2A gene in neuronal excitability and 
epilepsy. Homozygous SV2A mice appear normal at birth, but develop severe 
seizures and die within 3 weeks of birth (Crowder et al., 1999). The over-expression 
of SV2A in neurones was demonstrated to display a phenotype that was similar to 
that observed in neurones obtained from SV2A knockout mice (Nowack et al., 2011). 
Moreover, SV2A expression was significantly decreased in the hippocampus of 
patients diagnosed with temporal lobe epilepsy (van Vliet et al., 2009). The study 
conducted by Serajee et al. identified an arginine to glutamine mutation at residue 
383 in SV2A (R383Q SV2A) in the cytosolic loop of the protein that led to the onset 
of intractable epilepsy, developmental and growth retardation. This was the first 
reported example of a pathogenic mutation in SV2A in humans that led to the onset 
of epilepsy. In this chapter, I aimed to characterise the effect of SV2A R383Q 
mutation on: 1) surface fraction and localisation of SYT1 and 2) rate of retrieval of 
SYT1 during SV endocytosis. I then proceeded to compare and evaluate the 
mechanism of R383Q SV2A action of SYT1 with other known mechanisms by 
which SYT1 trafficking dysfunction may be caused (e.g. mutation of the AP-2 
binding motif, see chapter 3; mutation of the SV2A/SYT1 binding motif, see Zhang 
2015). Finally, I characterised the protein-protein interactions of the SV2A cytosolic 
loop, which contained the R383Q SV2A mutation in an effort to discriminate 
between any loss (or gain) of protein interaction which may lead to defective SYT1 
recycling. 
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Key research findings of this chapter: 
• R383Q SV2A leads to the acceleration of SYT1 retrieval kinetics, increased 
surface expression and mislocalisation of SYT1 on the plasma membrane. 
• The Y46A, R383Q and T84A SV2A mutations all perturb the same 
mechanistic pathway at the presynapse, suggesting a function for the R383Q 
SV2A mutation to affect SV2A-dependent retrieval of SYT1 by AP-2. 
• Residue charge mutation at R383 affects SV2A interactions with actin, 
tubulin and V-ATPase, suggesting roles for these proteins in modulating 
SV2A/SYT1 retrieval. 
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4.2.1 – Expression of R383Q SV2A-mCer Successfully Rescues Defects in SV2A 
Expression Levels Caused By shRNA-mediated Knockdown 
Initial experiments aimed to validate and quantify the effectiveness of the efficiency 
of exogeneously expressed R383Q SV2A-mCer vector in rescuing SV2A depletion 
in neurones caused by short hairpin RNA (shRNA)-mediated knockdown. Primary 
cultures of mice hippocampal cells were co-transfected with: 1) a SYT1-pHluorin 
plasmid also containing a shRNA sequence for SV2A (SV2A shRNA/SYT1-
pHluorin) to simultaneously deplete SV2A levels and express SYT1-pHluorin in 
neurones; 2) plasmids containing either wild-type SV2A-mCer (WT SV2A) or 
R383Q SV2A-mCer (R383Q SV2A) to rescue SV2A expression after shRNA-
mediated knockdown. Final SV2A expression levels in the cultures after transfection 
were detected by immunofluorescence (Figure 4.1 A).  
The co-transfection of the SV2A shRNA plasmid with either wild-type (WT) or 
R383 SV2A plasmids resulted in a complete rescue of SV2A expression when 
compared to SV2A expression levels of non-transfected neurones in the same field of 
view [Ratio of SV2A expression in transfected neurones/untransfected neurones = 
0.521 ± 0.039 (mCer), 1.062 ± 0.077 (WT SV2A), 1.028 ± 0.044 (R383Q SV2A); p 
< 0.0001 (WT vs mCer, R383Q vs mCer), one-way ANOVA, Bonferroni’s post-hoc, 
P < 0.0001, F = 29.1] (Figure 4.1 B).  
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In agreement with previous results, these experiments show that depletion of SV2A 
expression in neurones was achieved by transfection with a previously described 
combined SV2A shRNA/SYT1-pHluorin plasmid and normal SV2A expression was 
subsequently rescued by co-transfection of the neurones with a plasmid that 
expressed either exogeneous WT SV2A or R383Q SV2A.  
  




Figure 4.1: Expression of R383Q SV2A-mCer rescues deficits in SV2A Expression caused by shRNA-
mediated knockdown: A) Images of cultures co-transfected with SV2A shRNA–Syt1–pHluorin vector 
and either empty rescue (mCer), wild-type (WT) SV2A or R383Q SV2A-mCer. Grayscale panels 
highlight transfected neurones (GFP), whereas false colour panels display exogeneous SV2A revealed 
by immunofluorescence staining. Arrows highlight nerve terminals. Scale bar = 10 μM.  B) Bar graph 
shows levels of rescue of SV2A expression. The background-corrected SV2A immunofluorescence 
obtained from transfected neurones was normalised to the SV2A immunofluorescence obtained 
from non-transfected neurones within the same field of view [n=10 mCer empty, purple; n=10 WT 
SV2A-mCer, blue; n=10 R383Q SV2A-mCer, red; ****p<0.0001 (mCer vs WT, mCer vs R383Q); one-
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4.2.2 – R383Q SV2A Results in Increased but Delocalised Surface Expression of 
SYT1 
The R383Q mutation in SV2A has only recently been documented to play a role in 
the onset of intractable epilepsy and developmental growth in humans (Serajee and 
Huq, 2015). As such, there has been no published literature of on the characterisation 
of the effects of this particular mutation on presynaptic activity and SV recycling. As 
previously described, SV2A is known to be the intrinsic trafficking partner for SYT1 
at the presynapse. Therefore, any defect in SV2A function caused by a mutation may 
lead to downstream abnormalities in presynaptic activity because of defects in SYT1 
trafficking. These specific defects in SV2A/SYT1 trafficking at the presynapse may 
provide unexplored insight into the mechanisms of certain forms of epileptogenesis.   
In order to characterise a potential effect of the R383Q mutation in SV2A on 
presynaptic activity, I first proceeded to investigate the effect of the R383Q SV2A 
mutation on the surface expression and localisation of SYT1 to synaptic terminals. 
As in the above experiments, SV2A shRNA/SYT1-pHluorin was transfected into 
primary cultures to knockdown SV2A expression and co-express the SYT1-pHluorin 
reporter. Neuronal SV2A expression was rescued by co-transfection of either WT or 
R383Q SV2A-mCer plasmid (Figure 4.2 A).  
In order to investigate surface expression of SYT1 after perturbation of SV2A levels, 
the fraction of surface-expressed SYT1-pHluorin in transfected neurones was 
compared to the total SYT1-pHluorin pool in the neurone. Surface fraction 
experiments revealed that knockdown of SV2A in neurones and rescue using an 
empty plasmid resulted in a significant increase of surface-expressed SYT1-pHluorin 
compared to control rescue experiments using WT SV2A, in consistency with 
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previously reported results. The knockdown of SV2A in neurones and rescue with 
R383Q SV2A plasmid also resulted in a significant increase in the percentage of 
surface-expressed SYT1-pHluorin when compared to control rescue experiments 
using WT SV2A [Surface expression of SYT1-pHluorin (% of total SYT1 pool) = 
16.2 ± 4.8 (WT SV2A), 38.1 ± 4.5 (mCer), 50.8 ± 5.2 (R383Q SV2A); p < 0.0001 
(R383Q vs WT), p < 0.05 (mCer vs WT), one-way ANOVA, Bonferroni’s post-hoc, 
P = 0.0006, F = 14.6] (Figure 4.2 B). These results demonstrate that depletion of 
SV2A in neurones leads to increased expression of SYT1 at the plasma membrane 
surface. Rescue with R383Q SV2A fails to rescue the abnormality in SYT1 surface 
expression despite successful rescue of SV2A expression in the neurones. These 
observations suggest that like the Y46A mutation, the R383Q mutation also plays a 
crucial role in the internalisation of SYT1 from the plasma membrane. 
In order to investigate the effect of R383Q SV2A on the localisation of SYT1 to 
synaptic terminals, an analysis of the coefficient of variation (CV) for SYT1-
pHluorin fluorescence was performed. CV analysis of the expression of the total 
SYT1-pHluorin pool in a 50-µm length of neurite in SV2A knockdown cultures co-
expressing a mCer empty plasmid revealed a significantly decreased coefficient of 
variation compared to control rescue experiments using WT SV2A. In SV2A 
knockdown cultures co-expressing the R383Q SV2A plasmid, CV analysis of SYT1-
expression in a 50-µm length of neurite revealed similarly decreased CVs compared 
to control rescue experiments using WT SV2A [Mean CV = 42.1 ± 8.0 (WT SV2A), 
22.0 ± 1.7 (mCer), 19.8 ± 2.3 (R383Q SV2A); p < 0.05 (mCer vs WT, R383Q vs 
WT), one-way ANOVA, Bonferroni’s post-hoc, P = 0.0136, F = 6.29] (Figure 4.2 
C). 
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These experiments demonstrate that R383Q mutation in SV2A leads to increased 
diffuseness of SYT1 expression across the neurite, suggesting a role for the R383 
residue in the targeting SYT1 to presynaptic terminals during SV recycling. A 
similar phenotype is observed when the AP-2 binding motif in SV2A is mutated 
(Y46A), suggesting that the R383 residue in the cytosolic loop of SV2A may play a 
role in regulating the ability of SV2A to target SYT1 efficiently to synaptic 
terminals. 
  




Figure 4.2: R383Q SV2A results in increased but delocalised surface expression of SYT1. A) 
Hippocampal neurones were co-transfected with an SV2A shRNA-SYT1-pHluorin plasmid and either 
wild-type (WT) or R383Q SV2A-mCer. Representative greyscale images show that rescue with R383Q 
SV2A-mCer resulted in less localisation to nerve terminals compared to WT SV2A-mCer rescue. Scale 
bar = 10 μM. B) Surface expression of SYT1–pHluorin after rescue with SV2A-mCer variants displayed 
as a percentage of total SYT1-pHluorin pool ± SEM [n=5 mCerN1 empty, purple; n=5 WT SV2A-mCer, 
blue; n=5 R383Q SV2A-mCer, orange; ***p<0.001 (R383Q vs WT); *p<0.05 (mCer vs WT); one-way 
ANOVA, Bonferroni’s post-hoc, P=0.0006, F=14.6]. C) Bar graph displays the mean coefficient of 
variation of SYT1-pHluorin fluorescence along axons of neurones in alkaline buffer. Data are 
presented as ± SEM [n=5 mCerN1 empty, purple; n=5 WT SV2A-mCer, blue; n=5 R383Q SV2A-mCer, 
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4.2.3 – R383Q SV2A Fails to Rescue the Acceleration of SYT1 Retrieval Caused by 
Knockdown of SV2A 
The discovery that the R383Q mutation in SV2A led to increased diffuseness of 
SYT1 expression at the plasma membrane in neurones has presented novel insight 
into how the cytosolic loop of SV2A may play a key role in the regulation of normal 
SV2A function. In order to characterise further the role of SV2A R383 in regulating 
normal SYT1 trafficking, I proceeded to investigate the effect of the SV2A R383Q 
mutation on the rate of SYT1 retrieval and the proportion of externalised SYT1 
(compared to the total available SYT1 pool) during compensatory SV endocytosis.  
The shRNA-mediated knockdown of SV2A in neurones and rescue with an empty 
plasmid resulted in an acceleration of SYT1 retrieval compared with control rescue 
experiments using WT SV2A, consistent with previous results [p < 0.05 (mCer vs 
WT), two-way ANOVA of traces normalised to peak at stimulation]. Knockdown of 
SV2A and rescue with R383Q SV2A in neurones resulted in a failure to rescue 
SYT1 retrieval kinetics to WT levels, mimicking the SYT1 pHluorin recycling 
phenotype seen in SV2A-deficient neurones and in neurones where the AP-2 binding 
site was mutated [p < 0.05 (R383Q vs WT), two-way ANOVA of traces normalised 
to the peak at stimulation] (Figure 4.3 A). Knockdown of SV2A and rescue with the 
R383Q mutant resulted in a significantly increased proportion of SYT1 
externalisation during stimulation [Max ΔF/F0 (as a fraction of the total pHluorin 
pool) = 0.347 ± 0.023 (WT SV2A), 0.395 ± 0.040 (mCer), 0.510 ± 0.061 (R383Q 
SV2A); p < 0.05 (R383Q vs WT), one-way ANOVA, Bonferroni’s post-hoc, P = 
0.0316, F = 4.12] (Figure 4.3 B).  Quantification of the average time constant for 
retrieval (tau) of the evoked SYT1-pHluorin response previously revealed that the 
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rate of SYT1 retrieval during compensatory endocytosis is accelerated when SV2A 
levels are depleted in neurones. In agreement with the analysis of the average time 
traces in part A, the knockdown of SV2A in neurones and rescue using either empty 
vector or R383Q SV2A resulted in significantly decreased taus of SYT1-pHluorin 
retrieval compared to control rescue experiments using WT SV2A. [Tau (s) = 60.8 ± 
4.4 (WT SV2A), 43.4 ± 3.1 (mCer), 43.4 ± 2.6 (R383Q SV2A); p < 0.01 (R383Q vs 
WT), p < 0.05 (mCer vs WT), one-way ANOVA, Bonferroni’s post-hoc, P = 0.0038, 
F = 7.45] (Figure 4.3 C). The phenotype observed with the R383Q SV2A rescue 
experiments was similar to that observed when SV2A was depleted. 
These experiments indicate that the R383Q mutation in SV2A results in the faster 
retrieval of SYT1 during endocytosis compared to WT SV2A. Interestingly, this 
dysfunction of SV2A is highly similar to previous observations when SV2A is 
depleted in neurones or when the AP-2 binding site in SV2A is mutated (Y46A) and 
will be discussed later. Unlike the Y46A SV2A mutation, the R383Q SV2A mutation 
significantly increased SYT1 trafficking to the membrane during exocytosis. 
 
  




Figure 4.3: R383Q SV2A fails to rescue the acceleration of SYT1 retrieval caused by knockdown of 
SV2A. A) Hippocampal neurones were co-transfected with an SV2A shRNA-SYT1-pHluorin vector and 
either mCerulean (mCer) empty vector or SV2A-mCer variants. Cultures were stimulated using a train 
of 300 action potentials (Aps, 10 Hz, indicated by bar). After 200 seconds of recovery, the total 
recycling synaptic vesicle (SV) pool was revealed with a NH4Cl pulse. Graph displays the mean ΔF/F0 
time course for SYT1–pHluorin ± SEM normalized to the peak of stimulation [n=5 mCer empty, 
purple; n=10 wild-type (WT) SV2AmCer, blue; n=8 R383Q SV2AmCer, orange; *p<0.05 (Y46A vs WT), 
two-way ANOVA, Bonferroni’s post-hoc (over times indicated by solid lines)]. B) Mean maximum 
evoked SYT1-pHluorin response (ΔF/F0) expressed as a fraction of the total SV pool [*p<0.05 (R383Q 
vs WT); one-way ANOVA, Bonferroni’s posthoc, P=0.0316, F=4.12]. C) Graph shows quantification of 
the average time constant (Tau) ± SEM of the evoked SYT1-pH response [**p<0.01 (R383Q vs WT); 
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4.2.4 – R383Q SV2A Does Not Affect SYP Retrieval or Surface Expression 
Previous experiments have revealed that residue 383 in SV2A plays a role in 
regulating normal SV2A function. When residue 383 is mutated from arginine to 
glutamine, it results in defects in the localisation and trafficking of SYT1 at the 
synaptic terminal in a similar manner to that observed when SV2A is depleted in the 
neurone or when its own trafficking is disrupted (Y46A SV2A). However, this 
observed phenomenon could be a result of a general defect in global SV recycling 
caused by SV2A dysfunction rather than a specific effect on SYT1 trafficking. In 
order to discount the possibility of R383Q SV2A having a global effect on SV 
recycling, I investigated the effect of R383Q SV2A on the localisation of 
synaptophysin (SYP) and the rate of SYP retrieval from the plasma membrane. In 
these experiments, neuronal cultures were transfected with three constructs: 1) SV2A 
shRNA to knockdown SV2A expression in neurones; 2) synaptophysin-pHluorin 
(SYP-pHluorin) as a reporter for SYP expression and retrieval in neurones during 
compensatory endocytosis; 3) either WT or R383Q SV2A-mCer for the purposes of 
rescuing SV2A expression after knockdown. 
The shRNA-mediated knockdown of SV2A in neurones and rescue using R383Q 
SV2A did not affect the rate of SYP-pHluorin retrieval compared to control rescue 
experiments using WT SV2A (ns, two-way ANOVA of traces normalised to peak at 
stimulation) (Figure 4.4 A). Knockdown of SV2A and rescue using either an empty 
vector or R383Q SV2A also did not have an effect on the amount of SYP-pHluorin 
externalisation during stimulation when compared to control rescue experiments with 
WT SV2A [Max ΔF/F0 (as a fraction of the total pHluorin pool) = 0.277 ± 0.024 
(WT SV2A), 0.285 ± 0.028 (mCer), 0.320 ± 0.023 (R383Q SV2A); ns, one-way 
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ANOVA, P = 0.452, F = 0.841] (Figure 4.4 B). In agreement with the analysis of the 
average time traces, the quantification of the retrieval time constants for SYP-
pHluorin in SV2A knockdown neurones rescued with R383Q SV2A revealed no 
significant effect compared to control rescue experiments using WT SV2A [Tau (s) = 
43.0 ± 5.8 (WT SV2A), 41.7 ± 4.0 (mCer), 40.2 ± 3.2 (R383Q SV2A); ns, one-way 
ANOVA, P = 0.905, F = 0.101] (Figure 4.4 C). Surface fraction experiments 
revealed that knockdown of SV2A in neurones and rescue using an empty plasmid 
did not affect the expression of SYP-pHluorin compared to control rescue 
experiments using WT SV2A. Likewise, the rescue of SV2A expression using 
R383Q SV2A did not affect the surface expression of SYP-pHluorin [Surface 
expression of SYP-pHluorin (% of total SYP-pHluorin pool) = 22.7 ± 3.0 (WT 
SV2A), 23.9 ± 2.6 (mCer), 20.8 ± 0.9 (R383Q SV2A); ns, one-way ANOVA, P = 
0.665, F = 0.422] (Figure 4.4 D). 
This set of results provides evidence to support the hypothesis suggesting that the 
R383Q mutation in SV2A does not have an effect on the rate of SYP trafficking 
during endocytosis and exocytosis as well as the surface expression of SYP. 
Therefore, the findings from previous observations made using SYT1-pHluorin as a 
reporter can be attributed to a specific effect on the trafficking of SYT at the synaptic 
terminal and not a global effect on SV recycling. 
  




Figure 4.4: R383Q SV2A does not affect SYP retrieval or surface expression. A) Hippocampal 
neurones were co-transfected with SV2AshRNA, SYP-pHluorin and mCer or SV2AmCer variants. 
Cultures were stimulated using a train of 300 APs (10 Hz, indicated by bar) and the total recycling 
synaptic vesicle (SV) pool was revealed with a NH4Cl pulse at the end of the experiment. Graph 
displays the mean ΔF/F0 time course for SYP–pHluorin ± SEM normalized to the peak of stimulation 
(n=6 mCerN1 empty, purple; n=6 wild type (WT) SV2A-mCer, blue; n=5 R383Q SV2A-mCer, orange; 
ns, two-way ANOVA). B) Mean maximum evoked response (ΔF/F0) of SYP-pHluorin during 
stimulation expressed as a fraction of the total SV pool (ns, one-way ANOVA, P=0.452, F=0.841). C) 
Graph shows quantification of the average time constant (Tau) ± SEM of the evoked SYP-pH 
response (ns, one-way ANOVA, P=0.905, F=0.101). D) Surface expression of SYP–pHluorin after 
rescue with SV2AmCer variants displayed as a percentage of total releasable pHluorin pool ± SEM 
(n=5 mCerN1 empty, purple; n=5 WT SV2A-mCer, blue; n=5 R383Q SV2A-mCer, orange; ns, one-way 
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4.2.5 – T84A/R383Q SV2A Does Not Exacerbate Defects in SYT1 Recycling 
Mutation of the R383 residue in the cytosolic loop of SV2A has so far been shown to 
render SV2A incapable of localising SYT1 to synaptic terminals as well as incapable 
of retrieving SYT1 efficiently as its intrinsic trafficking partner during compensatory 
endocytosis. Similar loss-of function phenotypes were previously observed in similar 
experiments where the SV2A AP-2 binding motif was mutated (Y46A) and when the 
SV2A-SYT1 phosphorylation-dependent binding motif (T84A) was mutated (see 
chapter 3). These phenotypic defects are also believed to be dependent on the 
phosphorylation-mediated binding of SV2A to SYT1 at T84A as previously 
hypothesised, and therefore the combination of both T84A and R383Q SV2A 
mutations should not exacerbate the observed defects to SYT1 trafficking. Any 
exacerbation observed may be a direct indication of a separate SYT1 retrieval 
mechanism in action during endocytosis.  
In order to shed further light on the SYT1-binding dependency of R383Q SV2A-
induced defects in SYT1 trafficking, the T84A/R383Q SV2A double mutant was 
genetically engineered and used to rescue SV2A expression in SV2A knockdown 
neurones and the rate of SYT1 retrieval during endocytosis in these experiments was 
compared to results obtained from experiments using the individual single mutants to 
reveal any additive defects in SYT1 trafficking that may be present. The shRNA-
mediated knockdown of SV2A and rescue using the T84A/R383Q SV2A double 
mutant resulted in a failure to rescue normal SYT1 recycling behaviour compared to 
control rescue experiments using WT SV2A. The observed phenotype was consistent 
with the findings obtained from rescue experiments using the single mutants only. 
Comparison of the average SYT1-pHluorin traces obtained from experiments using 
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T84A/R383Q SV2A double mutant to experiments using the corresponding single 
mutants did not reveal any additive defects in SYT1 recycling (p < 0.05 
(T84A/R383Q vs WT), ns (T84/R383Q vs T84A or R383Q), two-way ANOVA of 
traces normalised to the peak at stimulation) (Figure 4.5 A). The proportion of SYT1 
externalisation in rescue experiments using the T84A/R383Q SV2A double mutant 
was increased when compared to rescue experiments using either WT or T84A 
SV2A single mutant, but not to the extent of increase seen with the R383Q SV2A 
single mutant rescue experiments. [Max ΔF/F0 (as a fraction of the total pHluorin 
pool) = 0.270 ± 0.040 (WT SV2A), 0.292 ± 0.066 (T84 SV2A), 0.511 ± 0.056 
(R383Q SV2A), 0.468 ± 0.060 (T84A/R383Q SV2A); p < 0.05 (R383Q vs WT), 
one-way ANOVA, Bonferroni’s post-hoc, P = 0.0126, F = 4.55] (Figure 4.5 B). The 
quantification of retrieval time constants for SYT1-pHluorin in SV2A knockdown 
neurones rescued with T84A/R383Q SV2A revealed a significant decrease in 
retrieval time compared to control rescue experiments using WT SV2A. No added 
disruption to retrieval was observed when analysis of the T84A/R383Q double 
mutant time constants was compared to T84A and R383Q SV2A single mutants [Tau 
(s) = 59.3 ± 3.2 (WT SV2A), 39.2 ± 2.3 (T84A SV2A), 38.7 ± 3.3 (R383Q SV2A), 
41.2 ± 2.1 (T84A/R383Q SV2A); p < 0.05 (T84A/R383Q vs WT), ns (T84A/R383Q 
vs T84A or R383Q), one-way ANOVA, Bonferroni’s post-hoc, P < 0.0001, F = 12.1] 
(Figure 4.5 C). 
These experiments indicate that mutation of both the R383 residue in SV2A and the 
SV2A/SYT1 binding motif results in faster retrieval of SYT1 during compensatory 
endocytosis. The presence of both mutations together in SV2A did not exacerbate the 
acceleration to SYT1 recycling and retrieval time constants compared to experiments 
   
160 
 
where only one mutation was present, suggesting that R383Q SV2A-induced defects 
were dependent on the SV2A-SYT1 interaction and that both mutations in SV2A are 
likely to disrupt targeting of SYT1 to presynaptic terminals via a similar mechanistic 
pathway.  The proportion of SYT1 externalisation during exocytosis was slightly 
increased (but non-significant) when both the T84A and R383Q mutations are 
present in SV2A when compared to control rescue experiments using WT SV2A. 
These results indicate that ablation of SV2A binding to SYT1 disrupts normal SYT1 
retrieval in a highly similar manner to that observed when binding to AP-2 is ablated, 
even though the binding motifs are located in different domains of the protein. This 
suggests an unknown interaction between the SV2A N-terminus domain and its 
cytosolic loop which has an overall effect on regulating SYT1 trafficking at the 
presynapse, which will be discussed further in later chapters. 
 
  




Figure 4.5: T84A/R383Q SV2A does not exacerbate defects in SYT1 recycling. A) Hippocampal 
neurones were co-transfected with SV2AshRNA-SYT1-pHluorin and mCer or SV2A-mCer variants. 
Cultures were stimulated using a train of 300 APs (10 Hz, indicated by bar) and the total releasable 
vesicle pool was revealed with a NH4Cl pulse at the end of the experiment. Graph displays the mean 
ΔF/F0 time course for SYT1–pHluorin ± SEM normalized to the peak of stimulation [n=6 wild type 
(WT) SV2A-mCer, blue; n=6 T84A SV2A-mCer, cyan; n=7 R383Q SV2A-mCer, orange; n=7 
T84A/R383Q SV2A-mCer, light brown]; *p<0.05 (T84A/R383Q vs WT), two-way ANOVA, Bonferroni’s 
post-hoc (over times indicated by solid lines)]. B) Mean maximum evoked response (ΔF/F0) of SYT1-
pHluorin during stimulation expressed as a fraction of the total releasable vesicle pool [*p<0.05 
(R383Q vs WT); one-way ANOVA, Bonferroni’s post-hoc, P=0.0126, F=4.55]. C) Graph shows 
quantification of the average time constant (Tau) ± SEM of the evoked SYT1-pH response 
[***p<0.001 (T84A/R383Q vs WT, T84A vs WT, R383Q vs WT); one-way ANOVA, Bonferroni’s post-
hoc, P<0.0001, F=12.1]. 
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4.2.6 – T84A/R383Q SV2A Does Not Exacerbate Defects in SYT1 Surface Expression 
and Localisation 
The presence of the T84A and R383Q double mutation in SV2A presented no 
significant additive effects on the time constant of SYT1 retrieval and its externalised 
proportion during evoked transmission. In order to ensure that this finding was not 
isolated to mechanisms specific to the retrieval of SYT1, I proceeded to investigate 
the effect of the T84A/R383Q SV2A double mutation on the fraction of surface-
expressed SYT1 and its localisation to presynaptic terminals in neurones. As in 
previous experiments, SV2A shRNA/SYT1-pHluorin was transfected into primary 
cultures to knockdown SV2A expression and co-express the SYT1-pHluorin 
reporter. Neuronal SV2A expression was rescued by co-transfection of WT, T84A, 
R383Q and T84A/R383Q SV2A-mCer plasmids (Figure 4.6 A). 
An investigation of the fraction of surface-expressed SYT1-pHluorin in SV2A 
knockdown neurones rescued with T84A/R383Q SV2A double mutant revealed a 
significant increase of surface fraction when compared to control rescue experiments 
using WT SV2A, consistent with previous results obtained from the single SV2A 
mutants. Comparison of results obtained from experiments using the T84A/R383Q 
double mutant to experiments using the corresponding single mutants revealed no 
additive defects in the fraction of SYT1 surface expression [Surface expression of 
SYT1-pHluorin (% of total SYT1-pHluorin pool) = 16.0 ± 0.9 (WT SV2A), 36.0 ± 
3.5 (mCer), 32.1 ± 3.0 (T84A SV2A), 45.9 ± 2.2 (R383Q SV2A), 40.0 ± 5.2 
(T84A/R383Q SV2A); p < 0.01 (T84A/R383Q SV2A vs WT), ns (T84A/R383Q 
SV2A vs T84A or R383Q SV2A), one-way ANOVA, Bonferroni’s post-hoc, P < 
0.0001, F = 11.6] (Figure 4.6 B). CV analysis of the expression of the total SYT1-
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pHluorin pool in a 50-µm length of neurite in SV2A knockdown cultures co-
expressing the T84A/R383Q SV2A double mutant revealed a significantly decreased 
coefficient compared to control rescue experiments using WT SV2A. Comparison of 
results obtained from experiments using the T84A/R383Q double mutant to 
experiments using the corresponding single mutants revealed no additive effects to 
the CV [Mean CV = 29.3 ± 3.0 (WT SV2A), 11.7 ± 0.9 (mCer), 16.2 ± 1.9 (T84A 
SV2A), 19.8 ± 2.3 (R383Q SV2A), 14.9 ± 0.5 (T84A/R383Q SV2A); p < 0.001 
(T84A/R383Q SV2A vs WT), ns (T84A/R383Q SV2A vs T84A or R383Q SV2A), 
one-way ANOVA, Bonferroni’s post-hoc, P < 0.0001, F = 12.0] (Figure 4.6 C).  
These experiments demonstrate that the presence of both the T84A and R383Q 
mutations in SV2A lead to increased surfaced expression and increased diffuseness 
of SYT1 expression across the neurite, but these effects were not exacerbated 
compared to those observed in experiments with just a single SV2A mutation. These 
results are in agreement with the previous experiments demonstrating the lack of an 
exacerbated effect on the retrieval kinetics of SYT1 in the presence of the 
T84A/R383Q SV2A double mutant. 
  




Figure 4.6: T84A/R383Q SV2A does not exacerbate defects to SYT1 surface expression and 
localisation. A) Hippocampal neurones were co-transfected with an SV2A shRNA-SYT1-pHluorin 
plasmid and either wild-type (WT) or SV2A-mCer variants. Representative greyscale images show 
that rescue with T84A/R383Q SV2A-mCer resulted in less localisation to nerve terminals compared 
to WT SV2A-mCer rescue. Scale bar = 10 μM. B) Surface expression of SYT1–pHluorin after rescue 
with SV2A-mCer variants displayed as a percentage of total SYT1-pHluorin pool ± SEM [n=5 mCerN1 
empty, purple; n=5 WT SV2A-mCer, blue; n=5 T84A SV2A-mCer, cyan; n=5 R383Q SV2A-mCer, 
orange; n=5 T84A/R383Q SV2A-mCer, gold; ****p<0.0001 (R383Q vs WT); **p<0.01 (mCer vs WT, 
T84A/R383Q vs WT); *p<0.05 (T84A vs WT); one-way ANOVA, Bonferroni’s post-hoc, P<0.0001, 
F=11.6]. C) Bar graph displays the mean coefficient of variation of SYT1-pHluorin fluorescence along 
axons of neurones in alkaline buffer. Data are presented as ± SEM (n=5 mCerN1 empty, purple; n=5 
WT SV2A-mCer, blue; n=5 T84A SV2A-mCer, cyan; n=5 R383Q SV2A-mCer, orange; n=5 T84A/R383Q 
SV2A-mCer, gold; ****p<0.05 (mCer vs WT); ***p<0.001 (T84A/R383Q vs WT); **p<0.01 (T84A vs 
WT); *p<0.05 (mCer vs WT); one-way ANOVA, Bonferroni’s post-hoc, P<0.0001, F=12.0). 
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4.2.7 – Y46A/R383Q SV2A Does Not Exacerbate Defects in SYT1 Recycling 
Previous experiments have ascertained that the T84A/R383Q double mutation in 
SV2A resulted in no exacerbation of defects to the localisation of SYT1 to synaptic 
terminals as well as the rate of SYT1 retrieval from the plasma membrane during 
compensatory endocytosis. The next step was to probe the AP-2 binding dependency 
of the observed SYT1 trafficking defects due to R383Q SV2A. If this phenotype was 
dependent on AP-2 binding, then the presence of the Y46A mutation together with 
the R383Q mutation should not exacerbate any defects already observed in the 
experiments with only the single mutant. 
In order to shed further light on the AP-2 binding dependency of R383Q SV2A-
induced defects in SYT1 trafficking, the Y46A/R383Q SV2A double mutant was 
genetically engineered and used to rescue SV2A expression in SV2A knockdown 
neurones. The rate of SYT1 retrieval during endocytosis in these neurones was 
compared to the rates obtained from rescue using the individual single mutants to 
reveal any additive defects in SYT1 trafficking which may have been present due to 
the double mutation. The shRNA-mediated knockdown of SV2A and rescue using 
the Y46A/R383Q SV2A double mutant resulted in a failure to rescue normal SYT1 
recycling behaviour compared to control rescue experiments using WT SV2A. The 
observed phenotype was consistent with the findings obtained from rescue 
experiments using the single mutants only. Comparison of the average SYT1-
pHluorin traces obtained from experiments using the Y46A/R383Q SV2A double 
mutant to experiments using the corresponding single mutants did not reveal any 
additive defects in SYT1 recycling (p < 0.05 (Y46A/R383Q vs WT), ns 
(Y46A/R383Q vs Y46A or R383Q), two-way ANOVA of traces normalised to the 
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peak at stimulation) (Figure 4.7 A). The proportion of SYT1 externalisation in rescue 
experiments using the Y46A/R383Q SV2A double mutant was increased when 
compared to rescue experiments using the WT SV2A single mutant, but not to the 
extent of increase seen with the Y46A and R383Q SV2A single mutant rescue 
experiments. [Max ΔF/F0 (as a fraction of the total pHluorin pool) = 0.352 ± 0.028 
(WT SV2A), 0.472 ± 0.041 (Y46A SV2A), 0.521 ± 0.036 (R383Q SV2A), 0.421 ± 
0.038 (Y46A/R383Q SV2A); p < 0.05 (R383Q vs WT), one-way ANOVA, 
Bonferroni’s post-hoc, P = 0.0207, F = 3.87] (Figure 4.7 B). The quantification of 
retrieval time constants for SYT1-pHluorin in SV2A knockdown neurones rescued 
with Y46A/R383Q SV2A revealed a significant decrease in retrieval time compared 
to control rescue experiments using WT SV2A. No additive disruption to SYT1 
retrieval was observed when analysis of the Y46A/R383Q double mutant time 
constants was compared to Y46A and R383Q SV2A single mutants [Tau (s) = 70.6 ± 
9.3 (WT SV2A), 47.7 ± 4.3 (Y46A SV2A), 45.4 ± 3.1 (R383Q SV2A), 45.1 ± 3.8 
(Y46A/R383Q SV2A); p < 0.05 (Y46A/R383Q vs WT), ns (Y46A/R383Q vs Y46A 
or R383Q), one-way ANOVA, Bonferroni’s post-hoc, P = 0.0075, F = 4.96] (Figure 
4.7 C). 
These experiments indicate that the presence of both Y46A and R383Q mutations in 
SV2A did not exacerbate the acceleration of SYT1 recycling and retrieval time 
constants compared to experiments where only a single mutation was present, 
suggesting that R383Q-induced defects in SYT1 trafficking are dependent on the 
AP-2-SV2A interaction. The proportion of SYT1 externalisation during exocytosis 
was increased (but non-significant) when both the Y46A and R383Q mutations are 
present in SV2A when compared to control rescue experiments using WT SV2A. 




Figure 4.7: Y46A/R383Q SV2A does not exacerbate defects in SYT1 recycling. A) Hippocampal 
neurones were co-transfected with SV2AshRNA-SYT1-pHluorin and mCer or SV2A-mCer variants. 
Cultures were stimulated using a train of 300 APs (10 Hz, indicated by bar) and the total releasable 
vesicle pool was revealed with a NH4Cl pulse at the end of the experiment. Graph displays the mean 
ΔF/F0 time course for SYT1–pHluorin ± SEM normalized to the peak of stimulation [n=7 wild type 
(WT) SV2A-mCer, blue; n=7 Y46A SV2A-mCer, red; n=8 R383Q SV2A-mCer, orange; n=8 Y46A/R383Q 
SV2A-mCer, pink; *p<0.05 (Y46A/R383Q vs WT), two-way ANOVA, Bonferroni’s post-hoc (over times 
indicated by solid lines)]. B) Mean maximum evoked response (ΔF/F0) of SYT1-pHluorin during 
stimulation expressed as a fraction of the total releasable vesicle pool [*p<0.05 (R383Q vs WT); one-
way ANOVA, Bonferroni’s post-hoc, P=0.0207, F=3.87]. C) Graph shows quantification of the average 
time constant (Tau) ± SEM of the evoked SYT1-pH response [*p<0.05 (Y46A/R383Q vs WT, Y46A vs 
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4.2.8 – Y46A/R383Q SV2A Does Not Exacerbate Defects to SYT1 Surface 
Expression and Localisation 
The Y46A/R383Q double mutation in SV2A presented no significant additive 
defects on the time constant of SYT1 retrieval and its externalised proportion during 
evoked transmission compared with the respective SV2A single mutations. In order 
to ensure that this finding was not isolated to mechanisms specific to the retrieval of 
SYT1, I proceeded to investigate the effect of the Y46A/R383Q SV2A double 
mutation on the fraction of surface-expressed SYT1 and its localisation to 
presynaptic terminals in neurones. As in previous experiments, SV2A shRNA/SYT1-
pHluorin was transfected into primary cultures to knockdown SV2A expression and 
co-express the SYT1-pHluorin reporter. Neuronal SV2A expression was rescued by 
co-transfection of WT, Y46A, R383Q and Y46A/R383Q SV2A-mCer plasmids 
(Figure 4.8 A). 
An investigation of the fraction of surface-expressed SYT1-pHluorin in SV2A 
knockdown neurones rescued with Y46A/R383Q SV2A double mutant revealed a 
significant increase of surface fraction when compared to control rescue experiments 
using WT SV2A, consistent with previous results obtained from the single SV2A 
mutants. Comparison of results obtained from experiments rescued with the 
Y46A/R383Q double mutant to experiments rescued with the corresponding single 
mutants revealed no additive defects in the fraction of SYT1 surface expression 
[Surface expression of SYT1-pHluorin (% of total SYT1-pHluorin pool) = 16.0 ± 0.9 
(WT SV2A), 36.0 ± 3.5 (mCer), 44.5 ± 3.3 (Y46A SV2A), 45.9 ± 2.2 (R383Q 
SV2A), 48.5 ± 3.6 (Y46A/R383Q SV2A); p < 0.0001 (Y46A/R383Q SV2A vs WT), 
ns (Y46A/R383Q SV2A vs Y46A or R383Q SV2A), one-way ANOVA, 
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Bonferroni’s post-hoc, P < 0.0001, F = 20.1] (Figure 4.8 B). CV analysis of the 
expression of the total SYT1-pHluorin pool in a 50-µm length of neurite in SV2A 
knockdown cultures co-expressing the Y46A/R383Q SV2A double mutant revealed 
a significantly decreased coefficient compared to control rescue experiments using 
WT SV2A. Comparison of results from rescue experiments with the Y46A/R383Q 
double mutant to rescue experiments with the corresponding single mutants revealed 
no additive effects to the CV [Mean CV = 29.3 ± 3.0 (WT SV2A), 11.7 ± 0.9 
(mCer), 14.8 ± 0.9 (Y46A SV2A), 19.8 ± 2.3 (R383Q SV2A), 14.6 ± 1.4 
(Y46A/R383Q SV2A); p < 0.001 (Y46A/R383Q SV2A vs WT), ns (Y46A/R383Q 
SV2A vs Y46A or R383Q SV2A), one-way ANOVA, Bonferroni’s post-hoc, P < 
0.0001, F = 13.5] (Figure 4.8 C).  
These experiments demonstrate that the presence of both the Y46A and R383Q 
mutations in SV2A lead to increased surfaced expression and increased diffuseness 
of SYT1 expression across the neurite, but with no additive effects compared to 
those observed in experiments with just a single SV2A mutation. These results are in 
agreement with the previous experiments demonstrating the lack of an exacerbated 
effect on the retrieval kinetics of SYT1 in the presence of the Y46A/R383Q SV2A 
double mutant. 
  




Figure 4.8: Y46A/R383Q SV2A does not result in additive defects to SYT1 surface expression and 
localisation. A) Hippocampal neurones were co-transfected with an SV2A shRNA-SYT1-pHluorin 
plasmid and either wild-type (WT) or SV2A-mCer variants. Representative greyscale images show 
that rescue with Y46A/R383Q SV2A-mCer resulted in less localisation to nerve terminals compared 
to WT SV2A-mCer rescue. Scale bar = 10 μM. B) Surface expression of SYT1–pHluorin after rescue 
with SV2A-mCer variants displayed as a percentage of total SYT1-pHluorin pool ± SEM [n=5 mCerN1 
empty, purple; n=5 WT SV2A-mCer, blue; n=5 Y46A SV2A-mCer, red; n=5 R383Q SV2A-mCer, orange; 
n=5 Y46A/R383Q SV2A-mCer, light purple; ****p<0.0001 (Y46A vs WT, R383Q vs WT, Y46A/R383Q 
vs WT); ***p<0.001 (mCer vs WT); one-way ANOVA, Bonferroni’s post-hoc, P<0.0001, F=20.1]. C) Bar 
graph displays the mean coefficient of variation of SYT1-pHluorin fluorescence along axons of 
neurones in alkaline buffer. Data are presented as ± SEM (n=5 mCerN1 empty, purple; n=5 WT 
SV2AmCer, blue; n=5 Y46A SV2A-mCer, red; n=5 R383Q SV2A-mCer, orange; n=5 Y46A/R383Q SV2A-
mCer, light purple; ****p<0.05 (mCer vs WT); ***p<0.001 (Y46A vs WT, Y46A/R383Q vs WT); 
*p<0.05 (R383Q vs WT);  one-way ANOVA, Bonferroni’s post-hoc, P<0.0001, F=13.5). 
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4.2.9 – R383 Mutations in the SV2A Cytosolic Loop Results in Altered Interactions 
with Actin and V-ATPase V1B1. The SV2A Cytosolic Loop Does Not Interact with 
SYP, SYT1 or SV2A 
Previous experiments investigating the effects on a point mutation in the cytosolic 
loop of SV2A (R383Q) have indicated that this mutation altered the normal SYT1 
recycling phenotype. The R383Q mutation in SV2A resulted in defects in SYT1 
expression and localisation to synaptic terminals, as well as an accelerated retrieval 
of SYT1 during compensatory endocytosis compared to normal WT SV2A controls. 
Although strong evidence was provided for this phenotypic result, the driving 
mechanism responsible for this change in phenotype remained unclear from prior 
results. It was predicted that the amino acid charges may have played a significant 
role in changing SV2A protein interactions, since the R383Q mutation results in a 
change from arginine (a polar positively charged amino acid residue) to glutamine (a 
polar neutral amino acid residue).  
In order to investigate the effect of changing the amino acid charge at residue 383 on 
selective binding partners for the SV2A cytosolic loop (residues 356-447) in brain 
lysate, pull-down experiments were performed using recombinant GST fusion 
proteins containing the WT SV2A cytosolic loop (positively charged at residue 383), 
the R383Q SV2A cytosolic loop (neutral at residue 383) and the R383E (negatively 
charged at residue 383). GST bound binding partners were extracted from 
synaptosomes and separated using gel electrophoresis. The R383Q SV2A cytosolic 
loop displayed a highly similar protein interaction profile to WT SV2A, but with a 
few discernible differences. The associations of three proteins, with molecular 
masses of 53, 45 and 41 kilodaltons (kDa), were altered when the R383Q mutation 
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was introduced into the GST-fusion protein (Figure 4.9). Gel electrophoresis bands 
corresponding to these proteins were excised from the gel and sent for identification 
using ESI-QUAD-TOF mass spectrometry (data not shown).  Mass spectrometry 
results identified the proteins as vesicular ATP-ase subunit V1B1 (V-ATPase V1B1, 
53 kDa), β-III tubulin (45 kDa) and β-actin (41 kDa) and confirmed by western 
blotting (Figure 4.10 A). Further western blotting experiments provided no evidence 
of any interaction between the SV2A cytosolic loop and full-length SV2A, SYT1 or 
SYP (Figure 4.10 B). Quantification of protein association with various GST-SV2A 
fusion proteins show that the interaction with β-actin was increased ~3-5 fold when 
the R383Q mutation was present (p < 0.001, two-way ANOVA, Bonferroni’s post-
hoc), and reduced to ~ 0.4-0.5 fold when the R383E mutation was present (p < 0.01, 
two-way ANOVA, Bonferroni’s post-hoc). Associations between β-III tubulin, V-
ATPase V1B1 and V-ATPase V1E1 and the SV2A cytosolic loop were decreased, 
though not significantly, when the R383Q mutation was present. When the R383E 
SV2A mutation was present, a significant increase was observed in the binding of the 
SV2A loop to V-ATPase V1B1 (p < 0.01, two-way ANOVA, Bonferroni’s post-hoc) 
(Figure 4.10 C). 
 
  





Figure 4.9: Mutation of R383 in the SV2A cytosolic loop results in altered interactions with SV 
proteins. Pulldown experiments using GST-SV2A cytosolic loop domains containing WT, R383Q and 
R383E SV2A from whole rat brain lysate. A synaptosome extract was used to isolate binding proteins 
for each GST-SV2A cytosolic loop domain in the order indicated. Results are shown in duplicate. 
Control pull-down experiments were performed with media in the absence of brain lysate. Bands at 
53, 45 and 41 kDa (marked by red rectangles) were excised from the gel and identified by ESI-QUAD-
TOF mass spectrometry. Results from mass spectrometry identified the bands as vesicular ATP-ase 
subunit V1B1, βIII-tubulin and β-actin respectively and band identities were confirmed by western 
blotting (Figure 4.10 A). 
 
  




Figure 4.10: Mutation of R383 in the SV2A cytosolic loop results in altered interactions with actin 
and V-ATPase V1B1. The SV2A cytosolic loop does not interact with SYP, SYT1 or SV2A. A) 
Associated proteins from GST-SV2A pull-down experiments were extracted, separated using SDS gel 
electrophoresis and transferred to nitrocellulose membranes. Representative western blots for β-
actin, βIII-tubulin, v-ATPase V1B1 and v-ATPase V1E1 are shown. B) Associated proteins from GST-
SV2A pull-down experiments were extracted, separated using SDS gel electrophoresis and 
transferred to nitrocellulose membranes. Representative western blots for full-length SV2A, 
synaptotagmin I and synaptophysin are shown. C) Graph shows quantification of protein association 
with various GST-SV2A cytosolic loop fusion proteins, normalised to WT SV2A association. 
Interactions with β-actin were increased ~3-5 fold when the R383Q mutation was present, and 
reduced to ~ 0.4-0.5 fold when the R383E mutation was present. Association of β-III tubulin, V-
ATPase V1B1 and V-ATPase V1E1 with the SV2A cytosolic loop was decreased, though not 
significantly, when the R383Q mutation was present. Data are presented as ± SEM [GST only, red; 
WT SV2A loop, blue; R383Q SV2A loop, orange; R383E SV2A loop, cyan; ***p < 0.001 (Actin – R383Q 
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4.3. – Discussion on the Presynaptic Effects of R383Q SV2A 
Recent studies have shown that a homozygous arginine to glutamine mutation at 
residue 383 (R383Q) in the cytosolic loop of SV2A which leads to intractable 
epilepsy, involuntary movements, microcephaly, developmental and growth 
retardation in a five-year old female patient (Serajee and Huq, 2015). The molecular 
mechanism by which the R383Q mutation affects SV2A normal function remains 
unclear. SV2 is a key SV protein that has a role in the maintenance of both excitatory 
and inhibitory neurotransmission (Crowder et al., 1999) and plays a role in the 
trafficking of SYT1 as its intrinsic trafficking partner (see chapter 3). Therefore, the 
R383Q mutation in SV2A may represent an underlying factor in the onset of epilepsy 
symptoms through impairment of presynaptic function. This work aimed to 
characterise the effect of the R383Q SV2A mutation on SV and SYT1 recycling at 
the presynapse, as well as to determine the molecular mechanisms underlying any 
observations of synaptic malfunction. 
 
4.3.1 – ShRNA-mediated Knockdown of SV2A Expression in Neurones Can Be 
Successfully Rescued by Use of Exogeneously Transfected R383Q SV2A DNA 
Knockdown of endogeneous SV2A was achieved using a short hairpin DNA 
sequence and successfully reduced expression of SV2A to about 50% of its original 
level, consistent with the previous experimental results observed with the Y46A 
SV2A rescue. As previously discussed, this observation is slightly lower than in 
previously reported data (>75%) (Zhang et al., 2015) and discrepancies may have 
arisen from the selection of nerve terminals for analysis, which is a highly subjective 
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process and may inevitably lead to differences when reporting data. In comparison 
with internal controls, there was still significant reduction in average SV2A levels. 
As previously discussed, SV2A is known to have a relatively low copy number on 
SVs at the nerve terminal (around 2-12 per SV) compared to other intergral SV 
proteins, therefore it is also expected that a 50% reduction in expression levels in 
these experiments would exhibit a large effect on the sorting of SV2A and its related 
cargo. SV2A expression in these knockdown cells was then rescued by the 
transfection of exogenous DNA that codes for either full length WT SV2A or full 
length R383Q SV2A. The R383Q SV2A mutant was shown to rescue SV2A 
expression to similar levels to that seen when WT SV2A is used. Expression levels 
were similar to those observed in rescue experiments using Y46A SV2A. Therefore, 
any observable phenotype due to the use of these constructs is attributed to an effect 
resulting from the presence of the R383Q mutation and not due to an experimental 
failure to rescue SV2A expression in the cell. 
 
4.3.2 – R383Q SV2A Leads to Acceleration of SYT1 Retrieval Kinetics and Increased 
Surface Expression and Mislocalisation of SYT1 
The presence of R383Q SV2A in hippocampal neurones resulted in an acceleration 
of SYT1 retrieval during compensatory endocytosis, mimicking the phenotype 
observed when there is a deficiency of SV2A, or the presence of the Y46A mutation, 
at the synaptic terminal. This was not a general acceleration of endocytosis, as other 
SV cargos such as synaptophysin were not affected in a similar manner by the 
presence of the R383Q mutation. The presence of the R383Q SV2A mutation led to 
an increased fraction of SYT1 expression on the membrane surface as well as 
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defective localisation of SYT1 to synaptic terminals. This phenotype is highly 
similar to that previously observed with the Y46A mutation. Presence of the R383Q 
mutation also resulted in a significant increase of externalised SYT1 during SV 
exocytosis, suggesting that SV2A may have a role in the regulation of SV release 
through modulation of the Ca2+-sensing function of SYT1. There are several pieces 
of evidence in support of this hypothesis: 1) SV2 has previously been shown to have 
an effect downstream of SV priming but upstream of the Ca2+ triggering of release 
(Chang and Südhof, 2009), possibly through enhancement of the responsiveness of 
SYT1 to Ca2+ influx; 2) SV2 plays a role in regulating the concentration of resting 
and evoked presynaptic Ca2+ levels, indicating a role in the regulation of exocytosis 
(Wan et al., 2010). 
The acceleration of SYT1 retrieval caused by R383Q SV2A is an interesting 
phenomenon, since the R383Q mutation lies in the cytosolic loop region far away 
from the known SV2A-SYT1 binding region. Recent knockdown and rescue 
experiments within SV2A-depleted neurones have revealed rescue of SV2A 
expression with R383Q SV2A did not result in defects in SV2A retrieval during 
compensatory endocytosis compared to rescue with WT SV2A, suggesting that the 
R383 residue does not play a key role in the retrieval of SV2A during compensatory 
endocytosis. The presence of the R383Q mutation however did result in an increased 
fraction of SV2A expression on the membrane surface similar to the phenotype seen 
with SYT1, indicating that R383Q is involved in the correct localisation of SV2A to 
synaptic terminals (Dr. Callista Harper, personal communication, data not shown). 
These results suggest that the R383 residue in SV2A plays a key role in the 
localisation of both SV2A and SYT1 at the synaptic terminal as well as the retrieval 
   
178 
 
of SYT1 from the plasma membrane, but does not affect the trafficking of SV2A 
itself. 
 
4.3.2.1 – How Might R383Q SV2A Mutation Affect SYT1 Retrieval? 
The SV2A-SYT1 interaction is regulated by the phosphorylation of the T84 residue 
in SV2A by tau–tubulin protein kinases 1 and 2 (TTBK 1 and 2) (Zhang et al., 2015). 
The SYT1-binding pocket is located on residues 81-90 of SV2A in the N-terminus 
region, fairly close to the tyrosine-based AP-2 binding YSRF motif located on 
residues 46-49.  The R383 residue lies in the cytosolic loop of SV2A, located 
between the sixth and seventh transmembrane region of the protein. This residue is 
distally located from the SV2A-SYT1 binding region and therefore the manner in 
which it may affect SYT1 trafficking is more complex. There are however, two 
possible explanations for the SYT1 trafficking phenotype observed in the presence of 
R383Q SV2A. 
Firstly, SV2A is known to contain signature motifs that are linked to the major 
facilitator superfamily (MFS) of transporters. The MFS family of transporters 
contain nucleotide-binding sites and their transporter activity is regulated by ATP-
binding in some cases e.g. ATP inhibition of glucose transport (Levine et al., 2002). 
Biochemical binding affinity studies have confirmed that SV2A does indeed have 
has a particular high binding affinity to adenine nucleotides, and further gene 
mapping studies have indicated that SV2A contains two nucleotide-binding sites in 
the cytoplasmic regions of the protein. The first site is located between residues 59-
162 preceding the first transmembrane domain, while the second site is located at 
residues 382-439 preceding the seventh transmembrane domain (Yao and Bajjalieh, 
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2008). Interestingly, the R383 residue resides exactly in the adenine nucleotide-
binding region preceding the seventh transmembrane domain. This suggests that 
adenine nucleotide binding to SV2A at the cytosolic loop region may play a crucial 
role in regulating the influence of SV2A on SYT1 trafficking during SV recycling, 
leading to the observed impairments in SYT1 surface expression, localisation and 
retrieval kinetics during compensatory endocytosis. In support of this, previous 
immunodetection studies have demonstrated that SV2 forms the core of the intra-
vesicular matrix and is responsible for immobilisation and release of ATP (Reigada 
et al., 2003). It has been previously reported that maintenance of the SV cycle is the 
primary source of activity-driven metabolic demand at the presynapse, and that 
interruptions in presynaptic ATP synthesis and hydrolysis resulted in severe 
impairments in presynaptic function (Rangaraju et al., 2014). Interestingly, 
preliminary GST pulldown studies to probe the mechanism of R383Q SV2A action 
have indicated that presence of the R383Q mutation reduces the interaction of SV2A 
with the V1B1 sub-unit of the SV proton pump V-ATPase (Figure 4.10). It is noted 
however, that this study identified only severe impairments to SYT1 trafficking 
without affecting general SV function. Future protein-crosslinking experiments using 
photo-reactive ATP to probe the ATP-binding affinity of R383Q SV2A compared to 
WT SV2A may provide further insight into the degree modulation of ATP-SV2A 
binding afforded by the R383Q mutation. 
Another possible reason which may explain how the R383Q mutation may regulate 
SYT1 trafficking is through altered protein interactions caused by a change in the 
amino acid charge. Arginine (R) is an amino acid with a positively charged side 
chain, whereas glutamine (Q) is an amino acid with a neutral side chain. This may 
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lead to partial misfolding of the protein in crucial areas, leading to altered 
intramolecular protein interactions. It is noted that both the R383 residue and the 
SYT1 binding domain of SV2A reside in the cytoplasmic regions of the protein. 
Changes in the interaction between the two cytoplasmic regions may therefore lead 
to an alteration of SYT1 binding affinity to N-terminus region of SV2A, leading to 
possible defects in the trafficking and function of SYT1. Preliminary GST pulldown 
studies with the SV2A cytoplasmic loop region containing mutations with differently 
charged amino acids at residue 383 (Q – neutral, E – negatively charged) have 
indicated significantly altered protein interactions with several structural and 
functional SV proteins. Unsurprisingly, the cytoplasmic region did not directly bind 
to SYT1. Future protein pulldown investigations between full-length R383Q/E 
SV2A and SYT1 and shed further light on the possibility that residue 383 may have a 
role in regulating binding of SV2A to SYT1. 
 
4.3.3 – The R383Q and T84A SV2A Mutations Affect the Same Mechanistic 
Pathway 
While the R383Q single mutation resulted in the acceleration of SYT1 retrieval and 
severe defects in its localisation and expression, the next experimental step looked to 
probe if the phenotype observed is dependent on SV2A binding to SYT1. It is 
reported here that ablation of the phosphorylation-dependent SV2A-SYT1 
interaction together with R383Q SV2A resulted in no additive defects being 
observed in the surface expression, localisation and retrieval kinetics of SYT1 during 
compensatory endocytosis. This indicates that the defects in SYT1 retrieval observed 
with the R383Q mutation is dependent of SYT1-binding to SV2A and gives evidence 
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that both mutations therefore play a role in the same SYT1 retrieval mechanistic 
pathway. The affected pathway is likely to be the one involving the formation of a 
complex between AP-2-SV2A-SYT1 during compensatory endocytosis whereby 
SV2A, together with AP-2, plays a role in the correct sorting of SYT1 to SVs. The 
manner in which the R383Q mutation may play a role in regulating the mechanism in 
which AP-2 and SV2A retrieve SYT1 has already been discussed previously, 
however the absences of additive defects in the presence of both mutations also 
suggest that the retrieval of SYT1 by stonin-2, which operates via a different 
mechanistic pathway, remains unaffected by the presence of the R383Q mutation. As 
before, it should be noted that the lack of observed effects in experiments using the 
T84A/R383Q double mutant could also be attributed to the lack of a dominant 
negative effect over remaining expressed WT SV2A, since depletion of SV2A using 
shRNA does not result in 100% ablation of WT protein expression. 
The presence of both T84A and R383Q mutations resulted in a slight reduction in the 
total amount of externalised SYT1 during SV exocytosis. However, the level 
observed with the double remain greatly elevated over the levels observed when only 
the single mutants were used, suggesting that increased SYT1 externalisation during 
exocytosis was most likely still present and that the T84A mutation did not largely 
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4.3.4 – The R383Q/Y46A SV2A Double Mutation Does Not Exacerbate Defects in 
SYT1 Retrieval 
Upon determination that the R383Q SV2A-induced defects in SYT1 trafficking was 
dependent upon binding of SV2A to SYT1, subsequent experiments proceeded to 
investigate the whether the R383Q SV2A-induced defects in SYT1 trafficking are 
dependent on binding of SV2A to AP-2. Previous experiments have demonstrated 
ablation of SV2A-AP-2 interaction by the Y46A mutation led to defects in the 
expression and localisation of SYT1 and accelerated retrieval during SV endocytosis. 
This phenotype is completely mirrored when the R383Q mutation is present in 
SV2A, indicating that both mutations exert an effect on the trafficking of SYT1 via 
the same mechanistic pathway. The presence of both Y46A and R383Q SV2A 
mutations resulted in no additive defects being observed in SYT1 expression, 
localisation and trafficking during SV recycling compared to the single mutant, 
suggesting that the effects of the R383Q SV2A as seen in previous experiments is 
dependent upon the binding of SV2A to AP-2. Taken together with the previous 
experimental results, this provides another layer of evidence to support the 
hypothesis that the R383Q mutation exerts an effect on the capability of SV2A to 
mediate formation of the AP-2-SV2A-SYT1 complex during SV cargo sorting, 
therefore resulting the observed SYT1 trafficking defects. 
 
4.3.5 – Mutation at R383 Affects SV2A Interactions with Actin, Tubulin and V-
ATPase 
The discovery that use of the R383Q SV2A mutant resulted in defective SYT1 
surface expression, localisation and trafficking similar to that observed with the 
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Y46A SV2A mutant presented an interesting point of debate, since the R383Q SV2A 
mutation resides in a sequential and structurally distinct region from  the Y46A 
mutation. In order to probe the mechanisms underlying these defects, GST pulldown 
experiments were conducted to probe the protein interactions between the cytosolic 
loop region (between residues 356-447) of WT, R383Q and R383E SV2A and 
proteins present in rat brain lysate. The residue selection at 383 was important, since 
the R383Q mutation represented a change in the residue charge from positive to 
neutral. In these experiments, we also used the R383E SV2A mutation to investigate 
the effect of significant changes in protein charge on SV2A protein-protein 
interactions.  
Preliminary GST pulldown/western blotting experiments demonstrate that the 
cytosolic loop of SV2A does not bind to full length SV2A or SYT1, providing 
evidence the cytosolic loop of SV2A does not directly affect SV2A-SYT1 binding by 
acting as a competitive binding partner for either protein during the formation of the 
AP-2-SV2A-SYT1 recycling complex. The experiments also show that interactions 
of the cytosolic loop of SV2A with β-actin were significantly increased ~3-5 fold 
when the R383Q mutation was present, and reduced to ~0.4-0.5 fold when the 
R383E mutation was present, suggesting a key role of the charge at residue 383 in 
mediating β-actin-SV2A interactions. The associations between β-III tubulin, V-
ATPase V1B1 and V-ATPase V1E1 and the SV2A cytosolic loop were decreased, 
though not significantly, when the R383Q mutation was present. However, 
subsequent repeats of these experiments have since indicated significance differences 
in the changes in the interactions between β-III tubulin/V-ATPase V1B1 and the 
cytosolic loop of SV2A (Dr. Karen Smillie, personal communication, data not 
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shown). It is noted that the initial experiments that were conducted used a high 
loading of fusion protein in order to provide the best chance of identifying all 
potential binding partners, resulting in limitations in obtaining reliable protein 
quantification data. The repeat experiments used a reduced loading of GST-fusion 
protein and therefore provided a much more accurate result.   
How do actin, tubulin and V-ATPase potentially alter presynaptic function and in 
particular the trafficking of SYT1? Actin filaments and tubulin-derived microtubules 
are major components of the neuronal cytoskeleton, which has a key role in ensuring 
the maintenance of neuronal polarity, morphology and integrity (Kapitein and 
Hoogenraad, 2011), cell migration (Katsuno et al., 2015), and molecular scaffolding 
of the exocytosis-endocytosis proteins to the SV release sites in the active zone 
(Haucke et al., 2011). Actin and myosin, together with syndapin and dynamin I, have 
been documented to play a part in the scission of SVs from the plasma membrane in 
SV endocytosis in chromaffin cells (Gormal et al., 2015). The exact mechanisms 
underpinning the link between the actin, SV2A and SYT1 function at the presynapse 
currently remains unclear, since SV2A is not known to be a major interaction partner 
for actin. ATP is bound to actin monomers and its hydrolysis is required for 
polymerisation of actin, thus it is probable that the observed binding of actin to the 
R383Q SV2A loop in this study may be a result of f-actin-ATP conjugates binding to 
the SV2A adenine nucleotide-binding site. Disruption of ATP binding to the SV2A 
loop due to the R383Q mutation would result in decreased binding to ATP and 
therefore actin, though it is unlikely that perturbation of this minor interaction would 
directly relate in large defects in SYT1 trafficking and may just be an artefact of the 
pulldown process. It is noted that there is increasing amounts of evidence for the role 
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of actin in the regulation of synaptic function in mammalian central synapses (Rust 
and Maritzen, 2015). In addition to its structural function, actin (together with n-
cofilin) has been shown to play a role in the recruitment and positioning of SVs as 
well as regulation of SV exocytosis in mouse hippocampal synapses (Wolf et al., 
2015). The activity-dependent assembly of actin filaments, facilitated by the active 
zone protein Piccolo, has been shown to be involved in the regulation of 
neurotransmitter release in mouse hippocampal synapses (Waites et al., 2011). 
A role for tubulin in regulating presynaptic function is less evidenced. There are 
several lines of evidence implicating the microtubule stabilising and bundling protein 
MAP1 in synaptic function. Interference of the interaction between MAP1A/MAP1B 
and voltage-gated calcium channel 2.2 resulted in reduced calcium uptake into the 
presynapse and impaired uptake of the FM4-64 dye (Leenders et al., 2008, Gandini 
et al., 2014). Interestingly, immunohistochemistry experiments using hippocampal 
tissue in pentylenetetrazole-induced epileptic rats shown an increased expression of 
MAP1B (Popa-Wagner et al., 1997), providing evidence for a causal link between 
epileptogenesis and dysfunction of tubulin-binding proteins. Tau-tubulin protein 
kinases 1 and 2 (TTBK1/2), which primarily phosphorylate microtubule associated 
tau and tubulin, has been reported to play an integral role in mediating the 
phosphorylation-dependent binding of SV2A to SYT1 at the N-terminus (Zhang et 
al., 2015). However, it is noted that the previous studies did not identify any 
phosphorylation sites in the cytosolic loop of SV2A, thus TTBK is unlikely to be 
responsible for the binding of SV2A to tubulin in this case. The observed binding of 
the SV2A cytosolic loop with both actin and tubulin in this study suggests that the 
cytosolic loop of SV2A may interact with the neuronal cytoskeleton in an unknown 
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capacity. The neuronal cytoskeleton has been proposed to be confer directionality to 
the process of clearing the active zone of excess SV cargo, thus preventing a 
functional block of the of the previously used release site (Haucke et al., 2011), 
however it is unclear how this may affect the specific trafficking of SYT1 in the 
presence of all SV proteins. Future experiments to probe SYT1 trafficking in the 
presence of disruption of the neuronal cytoskeleton may serve to provide greater 
insight into this phenomenon. 
Lastly, the interaction between the R383Q SV2A cytosolic loop and the V-ATPase 
V1 subunits presents evidence supporting the hypothesis that SV2A may be involved 
in normal ATP activity at the presynapse by interacting with presynaptic ATP at the 
adenine-binding site. V-ATPase is primarily responsible for SV re-acidification 
during endocytosis, although it has been shown to have a role in neurotransmitter 
release through direct interaction with the V-SNARE protein SYB2 (Di Giovanni et 
al., 2010). The cytosolic V1 units in V-ATPase contains the ATP catalytic site 
(Nelson et al., 2000), which suggests that the adenine-binding site of SV2A may play 
a role in mediating binding of ATP to V-ATPase for ATP hydrolysis. It is unclear 
whether the SV2A cytosolic loop simply acts as a carrier for ATP during SV 
endocytosis, or if it plays a more complex role in the regulation of SV re-
acidification and thus neurotransmitter release. However, it is noted that R383Q 
SV2A rescue experiments using a SYP-pHluorin reporter showed no defects in SV 
recycling or SV re-acidification, suggesting that the latter explanation is unlikely. 
The manner in which the ATP-SV2A interaction may affect SYT1-trafficking again 
remains unclear. It is possible that that ATP-SV2A binding is coupled with the 
phosphorylation-dependent SV2A-SYT1 binding. Disruption of normal presynaptic 
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ATP activity caused by the R383Q mutation may lead to downstream effects in the 
local availability of inorganic phosphates for the phosphorylation of SV2A, thus 
leading to defective SYT1 binding. Future biochemical experiments probing the 
ATP-dependency of the SV2A-SYT1 binding, together with SYT1-pHluorin 
experiments using mOrange as a better reporter for SV re-acidification (Egashira et 
al., 2015), may provide further insight into the mechanisms in which V-ATPase, 
SV2A and SYT1 interact with each other to maintain normal presynaptic function. 
 
4.3.6 – Technical Limitations of the Study 
As previously discussed in chapter 3, the caveats for using pHluorins as a tool for 
determining the effects of R383Q on SYT1 trafficking must also be considered. 
Analysis of the data is based on the assumption that SV re-acidification takes place 
on a much faster timescale compared to SV endocytosis, and thus all data obtained 
can be directly related to the rate of SYT1 retrieval during compensatory 
endocytosis. It is also unknown if the R383Q mutation has a direct effect on SV re-
acidification, since GST pulldown/western blot experiments have revealed that the 
cytosolic loop of R383Q SV2A has an altered interactions with the V1B1 and V1E1 
subunits of the SV proton pump V-ATPase (see below). Similar to previous 
experiments, all of the above pHluorin investigations were compared against control 
experiments using GFP-fused WT SV2A, which should eliminate any intrinsic 
trafficking differences between exogeneous and endogeneously expressed protein. 
The presence of a phenotype with the R383Q SV2A mutant also suggests that it does 
exert a dominant negative effect over WT SV2A in these studies; however, the exact 
nature of the double mutants used remains unclear. 







5.0 –The Effects of Levetiracetam on 
SYT1 Trafficking at the Presynapse 
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5.1. – Introduction to the Treatment of Seizures Associated with Epilepsy 
The mainstay of epilepsy therapy is the use of anti-epileptic drugs (AEDs) which 
provide symptomatic treatment of spontaneously recurrent seizures that occur in 
epilepsy. In order to exhibit anti-epileptic properties, a drug must act on one or more 
target molecules in the brain. AED action can usually be categorised into three 
categories: 1) modulation of voltage-gated ion channels; 2) enhancement of synaptic 
inhibition and 3) inhibition of synaptic excitation (Rogawski and Löscher, 2004). 
Therefore, AEDs targets usually include ion channels, neurotransmitter transporters 
and neurotransmitter metabolic enzymes. The ultimate goal of AED interaction is to 
modify the burst firing properties of neurones and to reduce the synchronisation of 
localised neuronal sub-groups. For example, generalised absence seizures are 
believed to result from thalamocortical synchronisation (Gigout et al., 2013). In order 
to abort such seizures, it is necessary to interfere with the rhythm-generating 
mechanisms that underlie the synchronised activity. Voltage-gated ion channels 
(including sodium, calcium and potassium channels) allow neurones to fire action 
potentials and define the threshold of neuronal activity. In addition, voltage-gated ion 
channels regulate the response of the presynapse to action potentials and are crucial 
to neurotransmitter release. Consequently, they are key targets for AEDs that can 
inhibit epileptic bursting, synchronisation and spread of seizures after status 
epilepticus. Synaptic inhibition and excitation are mediated by neurotransmitter-
regulated channels, which permit synchronisation of local synaptic activity. 
Therefore, AEDs that modify excitatory and inhibitory neurotransmission can also 
suppress burst firing of neurones and can have prominent effects on seizure spread 
(Rogawski and Löscher, 2004). 
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5.1.1 – Molecular Targets of Anti-Epileptic Drug Action 
The first generation of anti-epileptic drugs (AED) used to treat generalised and 
partial seizures, such as phenytoin and sodium valproate, function through inhibition 
of voltage-gated sodium channel activity (Van den Berg et al., 1993, Kuo and Bean, 
1994). Voltage-gated sodium channels in the brain can rapidly cycle through the 
resting, open and inactivated states, allowing neurones to fire high-frequency trains 
of action potentials (Bagal et al., 2015). Drugs that target sodium channels are able to 
block high-frequency repetitive burst firing, which is believed to occur during the 
spread of seizure activity, without affecting normal neural activity. This provides the 
basis for their ability to protect against seizures without causing a generalised 
impairment of brain function. Sodium channel inhibitors may also function via a 
channel inactivation mechanism. Phenytoin does not alter the conductance of the 
open state of sodium channels, but rather induces a non-conducting state in the 
channel that is akin to channel inactivation. Recovery from drug block of the channel 
therefore occurs more slowly than that which completely blocks the channel, 
therefore partly accounting for phenytoin’s selective ability to block high-frequency 
firing (Kuo and Bean, 1994). Sodium channel inhibitors, however, produces severe 
side effects in patients. Although the spread of seizure activity was reduced in 
patients taking the medication, both phenytoin and valproate have been associated 
with detrimental effects of cognitive and behaviour (Aldenkamp et al., 1994, Meador 
et al., 2009). 
Aside from voltage-gated sodium channels, AEDs can also target voltage-gated 
calcium channels. Voltage-gated calcium channels permit the flux of calcium ions 
when they are activated by membrane depolarisation. Calcium channels are broadly 
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grouped into two categories, high voltage-activated (HVA) and low voltage-activated 
(LVA) calcium channels. HVA calcium channels require strong membrane 
depolarisation to initiate gating activity and are responsible for the regulation of 
calcium entry and thus neurotransmitter release at the presynaptic terminal. Blocking 
HVA calcium channels inhibit neurotransmitter release, thus they are potentially 
good targets for AED action. Gabapentin, a drug originally synthesised to be a 
GABA receptor agonist, binds to the α2δ-1 and α2δ-2 auxiliary subunits of calcium 
channels with high affinity (Marais et al., 2001). The α2δ-binding affinities of 
gabapentin and its analogues such as pregabalin in rat cortical slices correlate with 
their antiepileptic potency, thus strongly implicating these subunits as a relevant 
target for AED action (Dooley et al., 2002). The mechanism by which gabapentin 
binding to α2δ-1 and α2δ-2 subunits of calcium channels produces anti-seizure 
effects are still not fully defined. Studies on dorsal root ganglion neurones have 
demonstrated that gabapentin produces small inhibitions in HVA calcium currents in 
a dose-dependent matter at clinically relevant concentrations (~10-100 μM) (Martin 
et al., 2002). Gabapentin has also been shown to inhibit potassium-evoked glutamate 
release in rat hippocampal slices (Dooley et al., 2000) and suppress excitatory 
postsynaptic currents in the dorsal horn of the rat spinal cord (Shimoyama et al., 
2000). Taken together, these studies suggest that inhibition of HVA calcium currents 
by gabapentin may translate to a reduction in excitatory transmission. 
Second and third generation AEDs have since been developed, many of which are 
demonstrated to be effective in improving symptoms of epilepsy thorough 
modulation of neurotransmitter release. The potentiation of inhibitory GABA-
mediated neurotransmission represents a key mechanism for modern AED action. 
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Although inhibitory neurones that utilise GABA only represent a small fraction of 
neurones that are pivotal to epileptic activity such as the cortex, hippocampus and 
amygdala, these neuronal connections are vital in restraining the positive feedback 
which causes recurrently connected excitatory neurones to develop synchronised 
epileptiform bursts (Miles and Wong, 1987). GABA acts through fast chloride-
permeable ionotropic GABAA receptors and through slower metabotropic G-protein-
coupled GABAB receptors. Drugs that block GABAA receptors, such as bicuculline 
and pentylenetetrazole, reduce the efficacy of synaptic inhibition mediated by 
GABAA receptors and can lead to seizures. Conversely, the pharmacological 
enhancement of GABAA receptor-mediated inhibition can therefore be an effective 
anti-epileptic approach. Many modern AEDs influence GABAA receptor inhibition 
either by interacting with GABAA receptors or by modifying the activity of enzymes 
and transporters, which alters the dynamics of GABA release and recycling. 
Benzodiazepines and barbiturates act as positive allosteric modulators of GABAA 
receptors. Benzodiazepines potentiated GABAA receptor function, prolonged the 
duration of mini inhibitory postsynaptic currents (IPSCs) and increased tonic current 
amplitude in cultured neurones (Bai et al., 2001). The AED vigabatrin increases 
inhibitory GABA activity through inhibition of GABA transaminase, which is the 
enzyme responsible for breakdown of GABA. Administration of vigabatrin has led to 
large elevations in GABA levels in rat brain regions (Löscher and Hörstermann, 
1994). The action of GABA at the synapse can also be terminated by rapid retrieval 
into presynaptic terminals and reuptake into the surrounding glia mediated by high 
affinity plasma membrane GABA transporters. The AED tiagabine is a potent and 
selective competitive inhibitor of the GABA transporter GAT1. Tiagabine bound  
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with high affinity to GAT1 and slowed the reuptake of synaptically released GABA, 
therefore prolonging inhibitory postsynaptic potentials in rat hippocampal slices 
(Jackson et al., 1999). 
Ionotropic glutamate receptors mediate the bulk of fast excitatory neurotransmission 
in the central nervous system. Ionotropic glutamate receptors can be subdivided into 
three groups: 1) N-methyl-D-aspartate (NMDA) receptors; 2) α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors and 3) kainate receptors. 
Despite many efforts, clinical trials with selective NMDA/AMPA antagonists in the 
chronic treatment of epilepsy have been largely disappointing. However, there are a 
few examples of drugs that exhibit potential in their use for the treatment of status 
epilepticus. One of these drugs is topiramate, which has multiple modes of action 
that includes the blockade of kainate and AMPA receptors (Perucca, 1996). 
Topiramate is well established as an effective AED for partial-onset seizures, but it is 
associated with some significant adverse effects that include renal stones and word-
finding difficulties (Aldenkamp et al., 2000). 
 
5.1.2– Levetiracetam as a Treatment for Generalised Seizures in Epilepsy 
Levetiracetam (LEV) [(S)-α-ethyl-2-oxo-1-pyrrolidineacetamide, also known as 
Keppra™] is an anti-convulsant medication manufactured by UCB Pharmaceuticals 
Ltd. Early pre-clinical development showed LEV to be an orally active, safe and 
broad-spectrum anti-convulsant agent that was effective against audiogenic seizures 
in mice (Gower et al., 1992). The use of LEV is associated with a minor side effect 
profile that included: rashes, itches, mood swings, irritability, lethargy, tiredness and 
   
194 
 
asthenia. However, it is generally well-tolerated in comparison to older AEDs such 
as phenytoin (Fuller et al., 2013). 
Electrophysiological studies of cultured rat neocortical neurones showed that LEV 
did not exhibit any specific effects on neuronal voltage-gated Na+ channels and 
voltage-gated Ca2+ channels (Zona et al., 2001). LEV also did not have an effect on 
inhibitory GABA-ergic transmission or the affinity of GABA or glutamatergic 
receptors for their respective neurotransmitter molecules (Klitgaard, 2001). These 
studies represent the most common modes of action for the vast majority of anti-
epileptic drugs, with LEV seemingly excluded from any of these cases. A common 
idea that LEV may function via a mechanism that desynchronises excessive neuronal 
firing remains unsupported by evidence. There is currently a large research focus on 
the elucidation of molecular mechanisms of action that makes LEV a potent drug for 
the treatment of epilepsy.  
 
5.1.3 – Mechanisms of Levetiracetam Action 
Over the last decade, multiple studies have been conducted with the aim of obtaining 
further insight into LEV’s mode of action. Although LEV does not affect inhibitory 
neurotransmission directly, it has been suggested to have several indirect effects at 
synaptic terminals. LEV-induced modifications of the enzymes involved in the 
synthesis and degradation of GABA, glutamic acid decarboxylase (GAD) and GABA 
aminotransferase in the striatum resulted in decreased spontaneous neural activity in 
discrete areas of the brain of anaesthetised rats (Löscher et al., 1996). Treatment of 
hippocampal neurones with LEV also produced a decrease in glutamate-mediated 
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excitatory transmission by preventing Zn2+-induced presynaptic GABAA inhibition 
(Wakita et al., 2014). Addition of LEV also results in a significant reduction in the 
levels of the amino acid taurine, a low affinity agonist for GABAA receptors (Tong 
and Patsalos, 2001). These experiments have provided evidence that modulation of 
the inhibitory neuronal network could be a potential mechanism by which LEV 
operates. 
The modulation of intracellular Ca2+ levels may also provide a possible candidate 
mechanism for LEV’s antiepileptic activity. Ca2+ plays a large role in a multitude of 
neurological functions, in particular neuronal excitability and SV recycling (Sudhof, 
2004). LEV has been reported to significantly depress neuronal high voltage 
activated Ca2+ current at clinically relevant conditions in rat hippocampal slices 
(Niespodziany et al., 2001), as well as inhibit voltage-dependent Ca2+ channels in 
superior cervical ganglion neurones through an intracellular pathway that is specific 
to a single enantiomer of the drug, leading to reduced neuronal excitability (Vogl et 
al., 2012). LEV has also been reported to inhibit the ryanodine and inositol 1,4,5-
triphosphate receptors, both of which are implicated in the control of Ca2+ influx 
from extracellular space as well as output from intracellular Ca2+ stores (Fukuyama 
et al., 2012). LEV’s effect on Ca2+ homeostasis could also limit epileptogenesis, 
since the inhibition of Ca2+ influx after an initial seizure have shown anti-
epileptogenic effects (Nagarkatti et al., 2008). 
  
   
196 
 
5.1.4 – SV2A Mediates Entry of Levetiracetam into the Presynapse 
The anticonvulsant properties of various SV2A ligands, including LEV, were 
initially demonstrated to correlate strongly with its in vitro binding affinity to SV2A 
in rat cerebral cortex (Noyer et al., 1995). Later studies incorporating photo-affinity 
labelling techniques on purified SVs from SV2A knockout mice brain membranes 
demonstrated no LEV binding, whereas experiments using wild type mice brain 
membranes exhibited a strong LEV binding affinity to purified SVs, suggesting 
SV2A is indeed the binding partner for LEV. No binding was observed to the related 
isoforms SV2B and SV2C in these experiments. The study also showed that a strong 
correlation existed between the binding affinity for a compound for SV2A and its 
protective effect against seizures (Lynch et al., 2004). Binding characteristics of LEV 
to SV2A was corroborated by further experiments using human brain samples and 
human recombinant SV2A expressed in Chinese hamster ovary cells (Gillard et al., 
2006). Elucidation of the racetam binding site in SV2A remains highly debated, 
though it is becoming increasing clear that racetams are likely to function by binding 
onto multiple residues within SV2A rather than just a single residue. In an early 
biochemical study, Shi et al. identified three residues in the putative tenth 
transmembrane helix of SV2A (F658, G659 and V661) that altered binding of LEV 
and related racetam derivatives to SV2A when they are mutated (Shi et al., 2011). 
These residues aligned with critical functional residues with the major facilitator 
superfamily (MFS) protein lactose permease found in E.Coli. As SV2A is part of the 
MFS of transporter proteins, this suggests that LEV may play a role modulating key 
structural motifs within SV2A that may play critical role in the protection against 
seizures. More recently, a molecular dynamics simulation approach in silico has been 
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successful in building a complete model of SV2A protein with LEV, as well as other 
effective racetams, docked into the protein (Correa-Basurto et al., 2015). Although 
the simulations were performed on a relatively short timescale, the studies support 
the putative binding pocket previously observed by Shi et al. and identified five 
putative binding sites (T456, S665, W666, D670 and L689) with additional 
hydrophobic and hydrogen bond interactions that were important for racetam binding 
within the transmembrane hydrophilic core of SV2A. 
With the knowledge that SV2A is a principal binding site for LEV, great efforts have 
been made recently to elucidate the effects of the drug at the presynapse. Incubation 
of rat hippocampal slices in 100 µM LEV for up to 3 hours resulted in a significant 
reversal of paired-pulse facilitation that is normally produced by repetitive 
stimulation. There was also a reduction of the rate of vesicle fusion, suggesting that 
LEV had an influence on the rate of neurotransmitter release (Yang et al., 2007). In 
other electrophysiological studies, rat hippocampal slices incubated in LEV for three 
hours revealed a dose-dependent decrease in excitatory postsynaptic currents 
(EPSCs) and a reduction of the readily releasable pool of vesicles. The same study 
also found that synaptic activity during LEV incubation significantly decreased the 
time at which the effect of LEV was observed, as well as its magnitude. 
Traditionally, studies on the mechanisms of LEV on neurones only reveal an effect 
after incubation times of at least 1 to 3 hours. Interestingly, either the use of 4-
aminopyridine (4-AP) to increase spontaneous activity of neurones or induction of 
low frequency stimulation during LEV incubation (180 action potentials, 0.2 Hz) 
revealed an early LEV effect on EPSCs after an incubation period of only 30 minutes 
(Meehan et al., 2011). Further studies by the same research group also demonstrated 
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that LEV reduced IPSCs in a frequency-dependent manner, with the largest effect 
observed in later IPSCs in high-frequency stimulation trains in rat hippocampal 
slices. However, in contrast to their observations with EPSCs, a LEV effect was 
observed in IPSCs after only 30 minutes of LEV incubation compared to 3 hours of 
LEV incubation required to reveal an effect on EPSCs. Silencing of neuronal 
spontaneous activity by use of CNQX/APV ablated the early onset of the LEV effect 
on IPSCs (Meehan et al., 2012). These lines of evidence demonstrate a requirement 
for synaptic activity to reveal a LEV effect, perhaps as a means to mediate entry of 
the drug into the synaptic terminal. Differences in the level of spontaneous activity 
may also affect the probability of observing a LEV effect, since excitatory and 
inhibitory nerve terminals require significantly different LEV incubation times for an 
effect to be revealed. 
LEV may also play a role in modulating synaptic protein levels that will have direct 
downstream effects on the SV recycling pathway. Overexpression of SV2A in 
autaptic hippocampal neurones increased the levels of synaptotagmin in tandem at 
the synapse and reduced EPSC amplitude. Treatment with 100 µM LEV for a period 
of 6 to 10 hours restored normal levels of SV2A and synaptotagmin as well as 
rescued normal neurotransmission, indicating that LEV may play a role in 
modulating SV2A protein interactions that may affect its expression and thus impact 
directly upon neurotransmission (Nowack et al., 2011). 
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5.1.5 – Levetiracetam in the Prevention of Epilepsy 
A major goal of contemporary epilepsy research is the identification of therapies to 
prevent the development of recurrent seizures in individuals at risk. The first 
evidence that LEV may exhibit anti-epileptogenic properties came from a study on 
rats using the kindled model for epilepsy. Treatment of the rats with LEV suppressed 
the increase of seizure severity and duration in a dose-dependent manner. After 
termination of the treatment, the duration of the seizures remained significantly 
shorter than vehicle controls, which suggest that LEV did not simply have an anti-
seizure effect but also exerted a true disease-modifying effect concomitantly 
(Löscher et al., 1998). In another study, chronic treatment with LEV in a dose-
dependent manner counteracted the long-term effects of pilocarpine-induced status 
epilepticus in rats such as increased amplitude of neuronal spikes in the dentate gyrus 
and reduced paired-pulse inhibition in the CA1 region of the hippocampus, 
suggesting that LEV completely inhibits the development of hippocampal 
hyperexcitability following pilocarpine-induced status epilepticus (Margineanu et al., 
2008). Treatment of rats with LEV also significantly decreased the mean duration of 
spontaneous seizures 58 days after treatment. LEV also prevented a status 
epilepticus-induced increase in the number of ectopic granule cells by suppressing 
neuronal proliferation in the dentate sub-granular zone and abnormal migration of 
nascent neurones from this zone (Sugaya et al., 2010). There is also evidence that 
suggests that LEV is able to exert long-term molecular effects at the synapse, which 
may be crucial in describing the mechanisms by which LEV may prevent the onset 
of epilepsy. The process of kindling is associated with an upregulation of 
hippocampal BDNF and neuropeptide Y mRNA levels and the downregulation of 
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neuropeptide Y1 and Y5-like receptors. Pre-treatment with LEV delayed the 
progression of kindling in rats by abolishing the kindling-induced rise in BDNF and 
neuropeptide Y mRNA and preventing a decrease in levels of neuropeptide Y1- and 
Y5-like receptors in the hippocampus (Husum et al., 2004). LEV treatment also 
prevented kindling-induced accumulation of SV2 as well as kindling-induced 
accumulation of 7S SNARE complexes in the ipsilateral hippocampus of rats 
(Matveeva et al., 2008). 
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5.1.6 – Aims and Objectives 
It was previously reported that SV2A mediates the entry of LEV into vesicles via 
several putative racetam binding sites (T456, S665, W666, D670 and L689) but no 
evidence of a LEV effect on the trafficking and recycling of any SV proteins has 
been published to date. I hypothesise that LEV has a mode of action at the 
presynaptic terminal that involves modulation of the trafficking behaviour of SV 
proteins, in particular SV2A and its intrinsic trafficking partner SYT1. A 
perturbation of SYT1 recycling may lead to alterations in SV priming, docking and 
exocytosis behaviour, which may play a key role in the treatment of seizures 
associated with epilepsy. The aim of this study is to determine the effects of LEV on 
the trafficking behaviour of various common synaptic vesicle proteins in the vesicle 
recycling process.  
 
The primary objectives of this project are: 
1) To determine whether LEV exhibits any effect on SV recycling in mouse 
hippocampal neurones.  
 
2) To determine the level of synaptic activity required to mediate LEV entry into 
nerve terminals in mouse hippocampal neurones. 
 
3) To elucidate a possible mechanism for LEV action at the presynapse, by 
determining the effect of LEV on important SV proteins in the SV recycling 
pathway. 
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5.2. – Results of Studies on the Effect of Levetiracetam on SV and SYT1 Recycling 
Prior studies on the effect of LEV at synaptic terminals have shown that synaptic 
activity is required to reveal a LEV effect. Incubation of the drug for an extended 
period of time (6 hrs or more) is usually required to reveal the effect of the drug on 
synaptic activity, however it has recently been demonstrated that the use of a low 
level loading stimulation, either with 4-aminopyridine or a low frequency electrical 
activity (180AP, 0.2 Hz), allowed a LEV-mediated effect to be observed within 30 
min (Meehan et al., 2011). In inhibitory nerve terminals, defects in synaptic 
transmission were observed within 30 min of LEV application. This early LEV effect 
can be abolished with by use of the synaptic activity blockers CNQX/APV (Meehan 
et al., 2012). These lines of evidence suggest a need for synaptic activity as a loading 
mechanism for mediating LEV uptake into nerve terminals.  
Key research findings of this chapter: 
• Treatment of neurones with LEV under strong/mild synaptic stimulation does 
not affect recycling of SYP or VGLUT1. 
• Treatment of neurones with LEV under strong/mild synaptic stimulation does 
not affect recycling of SYT1. 
• Protocols designed to provide neurones with strong/mild synaptic stimulation 
were tested and verified for purpose to ensure reliability of results. 
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5.2.1 – Application of LEV in the Absence of Mild Synaptic Stimulation Does Not 
Affect SV Recycling 
The requirement for synaptic activity to mediate LEV uptake into presynaptic nerve 
terminals was first investigated. Initial investigations were focused on whether a 
short incubation with LEV could affect SV recycling without prior neuronal activity 
to accumulate the drug. Synaptophysin-pHluorin (SYP-pHluorin) was used as a 
reporter for synaptic vesicle recycling (see Materials and Methods) in dissociated 
primary cultures of mouse hippocampal cells. Imaging of the SYP-pHluorin response 
was undertaken in the presence of the activity blockers CNQX/APV as per previous 
experiments (Figure 5.1 A). Incubation of cells in 100 and 300 µM LEV in the 
absence of a low-level stimulation to drive the loading of LEV into the synapses did 
not affect the rate of SYP-pHluorin retrieval (ns, two-way ANOVA of traces 
normalised to peak at evoked transmission) (Figure 5.1 B) or the total amount of 
SYP-pHluorin externalisation as a fraction of the total pHlurin pool during evoked 
transmission compared to controls [Max ΔF/F0 (as a fraction of the total pHluorin 
pool) = 0.323 ± 0.025 (No LEV), 0.338 ± 0.032 (100 µM LEV), 0.302 ± 0.033 (300 
µM LEV); ns, one-way ANOVA, P = 0.705, F = 0.357] (Figure 5.1 C).  
In order to ensure that the absence of an observed LEV effect was not due to a 
specific effect on SYP-pHluorin recycling, vesicle glutamate transporter 1-pHluorin 
(VGLUT1-pHluorin) was used in replicate experiments. Incubation of the cells with 
100-300 µM LEV without a low-level loading stimulation did not have an effect on 
either the rate of VGLUT1-pHluorin retrieval (ns, two-way ANOVA of traces 
normalised to peak at evoked transmission) (Figure 5.1 D) or the total amount of 
externalised VGLUT1-pHluorin during evoked transmission [Max ΔF/F0 (as a 
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fraction of the total pHluorin pool) = 0.439 ± 0.037 (No LEV), 0.466 ± 0.046 (100 
µM LEV), 0.415 ± 0.044 (300 µM LEV); ns, one-way ANOVA, P = 0.751, F = 
0.294] (Figure 5.1 E). The lack of a LEV effect seen with either SYP-pHluorin or 
VGLUT1-pHluorin demonstrated that the absence of use of a loading stimulation 
resulted in a failure to reveal any effect of LEV at the presynapse, most likely due to 
the failure of uptake of the drug into the cell within a short space of time. 
  




Figure 5.1: Application of levetiracetam in the absence of mild synaptic stimulation does not affect 
SV recycling.  A) Experimental scheme. Hippocampal neurones were incubated with levetiracetam 
(LEV, 0, 100 or 300 μM) for 30 min prior to stimulation with a train of 300 action potentials (APs, 
10Hz). After 200 seconds of recovery, the total recycling synaptic vesicle (SV) pool was revealed with 
an NH4Cl buffer pulse. B,C) SYP-pHluorin-transfected neurones were incubated with LEV at the 
indicated concentrations and stimulated with a train of 300 APs (10 Hz, indicated by bar). B) Graph 
displays the mean ΔF/F0 time course for SYP–pHluorin ± SEM normalized to the peak of stimulation 
[n=6 0 μM LEV, blue; n=7 100 μM LEV, green; n=7 300 μM LEV, purple; ns, two-way ANOVA]. C) 
Mean maximum evoked SYP-pHluorin response (ΔF/F0 ± SEM) expressed as a fraction of the total SV 
pool (ns, one-way ANOVA, P=0.705, F=0.357). D,E) VGLUT1-pHluorin-transfected neurones were 
incubated with LEV at the indicated concentrations and stimulated with a train of 300 APs (10 Hz). D) 
Graph displays the mean ΔF/F0 time course for VGLUT1–pHluorin ± SEM normalized to the peak of 
stimulation [n=6 0 μM LEV, blue; n=3 100 μM LEV, green; n=4 300 μM LEV, purple; ns, two-way 
ANOVA]. E) Mean maximum evoked VGLUT1-pHluorin response (ΔF/F0 ± SEM) expressed as a 
fraction of the total SV pool (ns, one-way ANOVA, P=0.751, F=0.294).  
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5.2.2 – Application of LEV in the Presence of Intense Synaptic Stimulation Does 
Not Affect SV Recycling 
The use of intense synaptic activity as a loading mechanism for LEV into synaptic 
terminals in order to reveal a LEV effect on SV recycling was next investigated. 
Exposure to high KCl concentrations maintains the cells in a membrane-depolarised 
state, mimicking cellular stress conditions experienced during high levels of synaptic 
activity. SYP-pHluorin transfected neurones were stimulated with an elevated KCl 
buffer (50 mM KCl added, with 50 mM NaCl removed to maintain osmolarity) 
containing 100 µM LEV. After depolarisation, the neurones were allowed to recover 
in standard imaging buffer containing 100 µM LEV before being challenged by a 
train of action potentials (300 APs, 10Hz) 30 minutes later (Figure 5.3 A). 
Application of 100 µM LEV in the presence of 50 mM KCl-induced synaptic activity 
did not affect either the subsequent rate of SYP-pHluorin trafficking (ns, two-way 
ANOVA of traces normalised to peak at evoked transmission) (Figure 5.3 B) or the 
total amount of SYP-pHluorin externalisation during evoked transmission compared 
to controls. The use of prior KCl in the absence of LEV as a positive control resulted 
in a reduction in post-stimulation SV recycling, indicating that resting synaptic 
activity was increased by the presence of KCl. [Max ΔF/F0 (as a fraction of the total 
pHluorin pool) = 0.385 ± 0.022 (No LEV), 0.371 ± 0.003 (100 µM LEV), 0.247 ± 
0.019 (No LEV + KCl), 0.306 ± 0.035 (100 µM + KCl); p < 0.01 (0 µM LEV vs 50 
mM KCl + 0 µM LEV), ns (No LEV + KCl vs 100 µM LEV + KCl), one-way 
ANOVA, Bonferroni’s post-hoc, P = 0.0053, F = 8.57] (Figure 5.2 C). 
In order to see whether the system could be altered by higher concentrations of the 
drug, the experiments were replicated using of a higher dose of 300 µM LEV (Figure 
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5.3 A). In agreement with previous results, the application of 300 µM LEV in the 
presence of 50 mM KCl-induced synaptic activity did not affect either the rate of 
SYP-pHluorin trafficking (ns, two-way ANOVA of traces normalised to peak at 
evoked transmission) (Figure 5.3 B) or the total amount of SYP-pHluorin 
externalisation during evoked transmission compared to controls [Max ΔF/F0 (as a 
fraction of the total pHluorin pool) = 0.456 ± 0.037 (No LEV), 0.394 ± 0.049 (300 
µM LEV), 0.360 ± 0.035 (No LEV + KCl), 0.394 ± 0.037 (300 µM + KCl); ns, one-
way ANOVA, P = 0.327, F = 1.24] (Figure 5.3 C).  
In order to ensure that the lack of observed effect was not specific to SYP-pHluorin, 
the experiments were replicated with VGLUT1-pHluorin. In agreement with results 
obtained with SYP-pHluorin, application of 300 µM LEV in the presence of 50 mM 
KCl-induced synaptic activity did not affect either the rate of VGLUT1-pHluorin 
trafficking (ns, two-way ANOVA of traces normalised to peak at evoked 
transmission) (Figure 5.3 D) or the total amount of VGLUT1-pHluorin 
externalisation during evoked transmission compared to controls [Max ΔF/F0 (as a 
fraction of the total pHluorin pool) = 0.511 ± 0.036 (No LEV), 0.440 ± 0.019 (300 
µM LEV), 0.442 ± 0.041 (No LEV + KCl), 0.385 ± 0.025 (300 µM + KCl); ns, one-
way ANOVA, P = 0.101, F = 2.31]   (Figure 5.3 E).  
 
  




Figure 5.2: Application of 100 μM LEV in the presence of intense synaptic stimulation does not 
affect SV recycling.  A) Experimental scheme. Hippocampal neurones were clamped in a membrane 
depolarised state with 50 mM KCl in the presence of levetiracetam (LEV, 100 μM) for 30 s and then 
incubated in LEV for 30 min prior to stimulation with a train of 300 action potentials (APs, 10Hz). 
After 200 seconds of recovery, the total recycling synaptic vesicle (SV) pool was revealed with a 
NH4Cl buffer pulse. B,C) SYP-pHluorin-transfected neurones were incubated with LEV (100μM) after 
50 mM KCl induced loading and stimulated with a train of 300 APs (10 Hz, indicated by bar). B) Graph 
displays the mean ΔF/F0 time course for SYP–pHluorin ± SEM normalized to the peak of stimulation 
[n=3 0 μM LEV, dark blue; n=3 100 μM LEV, dark green; n=4 50 mM KCl+ 100 μM LEV, blue; n=3 50 
mM KCl + 100 uM LEV, cyan; ns, two-way ANOVA]. C) Mean maximum evoked SYP-pHluorin 
response (ΔF/F0) expressed as a fraction of the total SV pool [**p<0.01 (0 µM LEV vs 50 mM KCl + 0 
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Figure 5.3: Application of 300 μM LEV in the presence intense synaptic stimulation does not affect 
SV recycling.  A) Experimental scheme. Hippocampal neurones were clamped in a membrane 
depolarised state with 50 mM KCl in the presence of levetiracetam (LEV, 300 μM) and then 
incubated in LEV for 30 min prior to stimulation with a train of 300 action potentials (APs, 10Hz). 
After 200 seconds of recovery, the total recycling synaptic vesicle (SV) pool was revealed with a 
NH4Cl buffer pulse. B,C,D,E) SYP-pHluorin-transfected (B,C) and VGLUT1-pHluorin-transfected (D,E) 
neurones were incubated with LEV (300 μM) after 50 mM KCl induced loading and stimulated with a 
train of 300 APs (10 Hz, indicated by bar). B,D) Graph displays the mean ΔF/F0 time course for SYP–
pHluorin (B) ± SEM normalized to the peak of stimulation [n=6 0 μM LEV, dark blue; n=4 300 μM LEV, 
dark purple; n=6 50 mM KCl+300 μM LEV, blue; n=4 50 mM KCl+100 uM LEV, purple; ns, two-way 
ANOVA] and VGLUT1-pHluorin (D) ± SEM normalized to the peak of stimulation [n=7 0 μM LEV, dark 
blue; n=7 300 μM LEV, dark purple; n=6 50 mM KCl+300 μM LEV, blue; n=4 50 mM KCl+100 uM LEV, 
purple; ns, two-way ANOVA]. C,E) Mean maximum evoked SYP-pHluorin (C) and VGLUT1-pHluorin (E) 
response (ΔF/F0) expressed as a fraction of the total SV pool (ns, one-way ANOVA). 
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5.2.3 – Application of LEV in the Presence of Mild Synaptic Stimulation Does Not 
Affect SV Recycling 
Previous work from Meehan demonstrated that a faster LEV effect was generated 
when mild synaptic activity was used to drive loading of the drug, and that use of 
intense synaptic stimulation resulted in a failure to reveal any drug effects. In light of 
previous results where the use of intense synaptic activity to drive LEV loading 
revealed no observed drug effect, LEV loading was next performed in the presence 
of mild synaptic activity. In initial attempts to utilise mild synaptic activity to 
mediate a LEV effect, 4-aminopyridine (4-AP) was used as a mild enhancer of non-
evoked synaptic transmission by enhancing spontaneous neurotransmitter release in 
both excitatory and inhibitory synapses (Buckle and Haas, 1982). SYP-pHluorin 
transfected neurones were incubated with 100 µM LEV in the presence of 50 µM 4-
AP before being challenged by a train of action potentials (300 AP, 10 Hz) (Figure 
5.4 A). Application of LEV in the presence of 50 µM 4-AP did not significantly 
affect either the rate of SYP-pHluorin trafficking (ns, two-way ANOVA of traces 
normalised to peak at evoked transmission) (Figure 5.4 B) or the total amount of 
externalised SYP-pHluorin during evoked transmission compared to control [Max 
ΔF/F0 (as a fraction of the total pHluorin pool) = 0.321 ± 0.039 (No LEV + 4-AP), 
0.406 ± 0.024 (100 µM LEV + 4-AP); ns, two-tailed t-test]   (Figure 5.4 C).  
In an effort to ensure that the lack of an observed LEV effect was not due to SYP-
pHluorin specific interactions, VGLUT1-pHluorin was again used in replicate 
experiments. In agreement with results obtained using SYP-pHluorin, the use of 4-
AP did not significantly affect either the rate of VGLUT1-pHluorin trafficking (ns, 
two-way ANOVA of traces normalised to peak at evoked transmission) (Figure 5.4 
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D) or the total amount of externalised VGLUT1-pHluorin during evoked 
transmission compared to control [Max ΔF/F0 (as a fraction of the total pHluorin 
pool) = 0.534 ± 0.054 (No LEV + 4-AP), 0.562 ± 0.044 (100 µM LEV + 4-AP); ns, 
two-tailed t-test] (Figure 5.4 E). 
The lack of an observed LEV effect using 4-AP as a mild synaptic activity enhancer 
did not corroborate with previous results published by Meehan et al. (Meehan et al., 
2011). In order to ensure that the LEV effect was not masked by any off-target 
effects due to the use of a second drug, the cells were subjected to weak electrical 
stimulation (180 AP, 0.2 Hz) as a means for generating mild synaptic activity 
required to mediate uptake of LEV into neurones. SYP-pHluorin transfected 
neurones were exposed to mild electrical  stimulation (180 AP, 0.2 Hz) in the 
presence of 100 µM LEV before being challenged by a train of action potentials (300 
AP, 10 Hz) (Figure 5.5 A). Application of LEV in the presence of mild electrical 
stimulation did not significantly affect either the rate of SYP-pHluorin trafficking 
(ns, two-way ANOVA of traces normalised to peak at evoked transmission) (Figure 
5.5 B) or the total amount of externalised SYP-pHluorin during evoked transmission 
compared to controls [Max ΔF/F0 (as a fraction of the total pHluorin pool) = 0.442 ± 
0.057 (No LEV + 4-AP), 0.391 ± 0.051 (100 µM LEV + 4-AP); ns, two-tailed t-test] 
(Figure 5.5 C). The lack of any observable LEV effect despite the change of loading 
method suggests that it is unlikely that an effect of LEV was masked due to off-target 
effects in the cell due to use of 4-AP. 
These experiments indicate the presence of LEV at the presynapse did not have any 
effect on SV recycling despite a reduction in synaptic stimulation used to load the 
drug. 




Figure 5.4: Application of 100 μM LEV in the presence of 4-AP induced activity does not affect SV 
recycling.  A) Experimental scheme. Hippocampal neurones were incubated with levetiracetam (LEV, 
100 μM) in the presence of 50 µM 4-AP for 30 min prior to stimulation with a train of 300 action 
potentials (APs, 10Hz). After 200 seconds of recovery, the total recycling synaptic vesicle (SV) pool 
was revealed with a NH4Cl buffer pulse. B,C) SYP-pHluorin-transfected neurones were incubated with 
LEV (100 μM) in the presence of 50 µM 4-AP and stimulated with a train of 300 APs (10 Hz, indicated 
by bar). B) Graph displays the mean ΔF/F0 time course for SYP–pHluorin ± SEM normalized to the 
peak of stimulation [n=4 0 μM LEV, blue; n=3 100 μM LEV, green; ns, two-way ANOVA]. C) Mean 
maximum evoked SYP-pHluorin response (ΔF/F0) expressed as a fraction of the total SV pool (ns, 
two-tailed t-test). D,E) VGLUT1-pHluorin-transfected neurones were incubated with LEV (100 uM) in 
the presence of 4-AP and stimulated with a train of 300 APs (10 Hz). D) Graph displays the mean 
ΔF/F0 time course for VGLUT1–pHluorin ± SEM normalized to the peak of stimulation [n=3 0 μM LEV, 
blue; n=4 (100 μM LEV, green; ns, two-way ANOVA]. E) Mean maximum evoked VGLUT1-pHluorin 
response (ΔF/F0) expressed as a fraction of the total SV pool (ns, two-tailed t-test). 
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Figure 5.5: Application of 100 μM LEV in the presence of low-frequency electrical activity does not 
affect SV recycling.  A) Experimental scheme. Hippocampal neurones were incubated with 
levetiracetam (LEV, 100 μM) in the presence of 180 AP (0.2Hz) prior to stimulation with a train of 300 
action potentials (APs, 10Hz). After 200 seconds of recovery, the total recycling synaptic vesicle (SV) 
pool was revealed with a NH4Cl buffer pulse. B,C) SYP-pHluorin-transfected neurones were 
incubated with LEV (100 μM) in the presence of 180 APs (0.2 Hz) and stimulated with a train of 300 
APs (10 Hz, indicated by bar). B) Graph displays the mean ΔF/F0 time course for SYP–pHluorin ± SEM 
normalized to the peak of stimulation [n = 5 0 μM LEV, blue; n=5 100 μM LEV, green; ns, two-way 
ANOVA] C) Mean maximum evoked SYP-pHluorin response (ΔF/F0) expressed as a fraction of the 
total SV pool (ns, two-tailed t-test). 
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5.2.4 – Application of LEV in the Presence of Both Mild and Intense Synaptic 
Activity Does Not Affect SYT1 Trafficking 
As SV2A is well documented to be the binding partner for both LEV and SYT1 (see 
chapter 3), there exists a potential mechanism for a presynaptic LEV effect that could 
be mediated through this SV2A-SYT1 interaction. Therefore, the hypothesis that 
LEV may specifically alter the trafficking of SYT1 through binding to SV2A was 
investigated. In order to investigate if LEV had an effect on SYT1-trafficking, 
SYT1-pHluorin transfected neurones were stimulated with an elevated KCl buffer 
containing 100 µM LEV. After depolarisation, the neurones were allowed to recover 
in normal buffer containing 100 µM LEV before being challenged by a train of 
action potentials (300 APs, 10Hz) (Figure 5.6 A). Application of LEV in the 
presence of 50 mM KCl-induced synaptic activity did not significantly affect either 
the rate of SYT1-pHluorin trafficking (ns, two-way ANOVA of traces normalised to 
peak at evoked transmission) (Figure 5.6 B) or the total amount of externalised 
SYT1-pHluorin during evoked transmission compared to controls [Max ΔF/F0 (as a 
fraction of the total pHluorin pool) = 0.331 ± 0.043 (100 µM LEV), 0.296 ± 0.015 
(No LEV+ KCl), 0.270 ± 0.017 (100 µM LEV+KCl); ns, one-way ANOVA, P = 
0.349, F = 1.19] (Figure 5.6 C).  
In order to preclude the possibility that intense stimulation might be disrupting any 
weak LEV effect, previous experiments were replicated with the use of 4-AP as a 
mild enhancer of non-evoked synaptic activity. SYT1-pHluorin transfected neurones 
were incubated in 100 µM LEV, in the presence of 4-AP, before being challenged by 
a train of action potentials (300 AP, 10 Hz) (Figure 5.7 A). Application of LEV in 
the presence of 4-AP-induced synaptic activity did not significantly affect either the 
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rate of SYT1-pHluorin trafficking (ns, two-way ANOVA of traces normalised to 
peak at evoked transmission) (Figure 5.7 B) or the total amount of externalised 
SYT1-pHluorin during evoked transmission compared to controls [Max ΔF/F0 (as a 
fraction of the total pHluorin pool) = 0.410 ± 0.055 (100 µM LEV), 0.450 ± 0.039 
(No LEV + KCl), 0.469 ± 0.015 (100 µM LEV+KCl); ns, one-way ANOVA, P = 
0.469, F = 0.786] (Figure 5.7 C).  
These experiments indicate that the use of LEV in the presence of either intense or 








Figure 5.6: Application of 100 μM LEV in the presence of 50 mM KCl-induced activity does not 
affect SYT1 recycling.  A) Experimental scheme. Hippocampal neurones were clamped in a 
membrane depolarised state with 50 mM KCl in the presence of levetiracetam (LEV, 100 μM) and 
then incubated in LEV for 30 min prior to stimulation with a train of 300 action potentials (APs, 
10Hz). After 200 seconds of recovery, the total recycling synaptic vesicle (SV) pool was revealed with 
a NH4Cl buffer pulse. B,C) SYT1-pHluorin-transfected neurones were incubated with LEV (100μM) 
after 50 mM KCl induced loading and stimulated with a train of 300 APs (10 Hz, indicated by bar). B) 
Graph displays the mean ΔF/F0 time course for SYT1–pHluorin ± SEM normalized to the peak of 
stimulation [n=4 100 μM LEV, green; n=4 0 μM LEV+50 mM KCl, blue; n=4 100 μM+50mM KCl, cyan; 
ns, two-way ANOVA]. C) Mean maximum evoked SYT1-pHluorin response (ΔF/F0) expressed as a 
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Figure 5.7: Application of 100 μM LEV in the presence of 4-AP-induced activity does not affect SYT1 
recycling.  A) Experimental scheme. Hippocampal neurones were incubated with levetiracetam (LEV, 
100 μM) in the presence of 50 uM 4-AP for 30 min prior to stimulation with a train of 300 action 
potentials (APs, 10Hz). After 200 seconds of recovery, the total recycling synaptic vesicle (SV) pool 
was revealed with a NH4Cl buffer pulse. B,C) SYT1-pHluorin-transfected neurones were incubated 
with LEV (100 uM) in the presence of 4AP and stimulated with a train of 300 APs (10 Hz). B) Graph 
displays the mean ΔF/F0 time course for SYT1–pHluorin ± SEM normalized to the peak of stimulation 
[n=6 100 μM LEV, green; n=7 0 μM LEV+50mM KCl, blue; n=9 100 μM LEV+50mM KCl, cyan; ns, two-
way ANOVA]. C) Mean maximum evoked SYT1-pHluorin response (ΔF/F0) expressed as a fraction of 
the total SV pool (ns, one-way ANOVA, P=0.469, F=0.786). 
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5.2.5 – Verification of Effects of KCl and 4-AP on Synaptic Activity 
The lack of any LEV effect observed with the previous experiments did not 
corroborate with published data indicating a mechanism of LEV action at the 
presynapse (Nowack et al., 2011, Meehan et al., 2011, Meehan et al., 2012). To 
ensure that this lack of effect was not due to a failure in the protocols to stimulate  
synaptic activity, the effect of 50 mM KCl and 50 µM 4-AP on synaptic Ca2+ 
responses was visualised by use of the fluorescent calcium reporter Fluo-3 AM. To 
verify the protocol for stimulating intense synaptic activity, hippocampal neurones 
that were loaded with Fluo-3 AM were stimulated with an elevated KCl buffer (50 
mM). The cells were allowed to recover before being challenged by a train of action 
potentials (300 AP, 10 Hz) to act as a positive control for the experiment (Figure 5.8 
A). Application of elevated KCl buffer to the neurones led to a significant transient 
increase in the level of intracellular free calcium to nearly two-fold the level 
observed under electrical stimulation (p < 0.05, two-way ANOVA of traces 
normalised to peak of calcium response at evoked transmission) (Figure 5.8 C).  
To verify the protocol for stimulating mild synaptic activity, hippocampal neurones 
loaded with Fluo-3 AM were stimulated with 50 µM 4-AP. The cells were allowed to 
recover before being challenged by a train of action potentials (300 AP, 10 Hz) 
(Figure 5.8 B).  Application of 50 µM 4-AP to the neurones led to significant long 
lasting increase in levels of intracellular free calcium of about 0.2 fold the level 
observed under electrical stimulation (p < 0.05, two-way ANOVA of traces 
normalised to peak of calcium activity at evoked transmission) (Figure 5.8 D).  
These experiments verified that the protocols alteredpresynaptic activity as predicted 
and that the lack an experimental LEV effectwas not due to protocol failures. 




Figure 5.8: Verification of the effects of KCl and 4-AP on synaptic activity. A) Experimental scheme. 
Hippocampal neurones were incubated with 10 µM Fluo-3 AM for 30 min prior to a 30 s stimulation 
with 50 mM KCl. The neurones were allowed to recover being challenged with a train of 300 action 
potentials (APs, 10Hz). B) Experimental scheme. Hippocampal neurones were incubated with 10 µM 
Fluo-3 AM for 30 min prior to a 120 s stimulation with 50 µM 4-AP. The neurones were allowed to 
recover being challenged with a train of 300 action potentials (APs, 10Hz). C) Neurones were 
incubated in 50 mM KCl for 30 s before being stimulated with a train of 300 action potentials (AP, 10 
Hz). Graph displays the mean ΔF/F0 time course for Fluo-3 AM ± SEM normalized to the peak of 
electrical stimulation [n=3 0 mM KCl, blue; n=4 50 mM KCl, pink; *p<0.05, two-way ANOVA, 
Bonferroni’s post-hoc (over times indicated by the solid lines)]. D) Neurones were incubated in 50 
µM 4-AP for 120 s before being stimulated with a train of 300 action potentials (AP, 10 Hz). Graph 
displays the mean ΔF/F0 time course for Fluo-3 AM ± SEM normalized to the peak of electrical 
stimulation [n=3 0 µM 4-AP, blue; n=3 50 µM 4-AP, pink; *p<0.05, two-way ANOVA, Bonferroni’s 
post-hoc (over times indicated by the solid lines)]. 
  
A
10 Hz 300 AP
10 uM Fluo-3 
50 mM KCl





10 Hz 300 AP
10 uM Fluo-3 
50 µM 4-AP































































1 .2 1 0  H z
0  u M  4 A P
(3 )
(3 )
5 0  u M  4 A P
*
*
   
220 
 
5.3. – Discussion on the Effects of LEV on SV and SYT1 Recycling 
The exact mechanism by which LEV functions in the treatment of generalised 
seizures remains unknown, even though it is one of the most popular anti-epileptic 
drugs available on the market. The SV protein SV2A was has been shown to mediate 
LEV entry into the neurone via SV recycling at the presynapse (Lynch et al., 2004). 
Several electrophysiological studies (previously described in chapter 5.1) have 
demonstrated that LEV has a mechanism of action at the post-synapse (Yang et al., 
2007, Meehan et al., 2011, Meehan et al., 2012). Immunohistochemistry experiments 
have also indicated possible modulation of key SV protein levels at the presynapse 
(Nowack et al., 2011), however studies that investigate the real-time trafficking of 
key SV proteins during synaptic activity, under the influence of LEV action, has not 
been documented. 
 
5.3.1 – Treatment of Neurones with LEV under Mild/Strong Synaptic Simulation 
Does Not Affect Recycling of SYP or VGLUT1 
Previous experiments have demonstrated that long incubation times of greater than 3 
hrs are required to evoke a LEV effect on mammalian hippocampal tissue slices 
(Meehan et al., 2011). In agreement with this finding, it has been also shown that 
incubation with LEV for up to 6-10 hours is necessary for revealing a LEV effect on 
regulating SYT1 and SV2A expression levels at the presynapse in primary 
hippocampal cell cultures (Nowack et al., 2011). In my initial experiments, it was 
observed that the acute application of 100-300 µM LEV onto hippocampal cell 
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cultures revealed no effect on the recycling of key SV proteins synaptophysin (SYP) 
and VGLUT1. This is in agreement with previously published literature.  
An early LEV effect was achieved in hippocampal slices by increasing synaptic 
activity upon application of the drug by use of 4-aminopyridine [4-AP, a potassium 
channel blocker that is known to increase spontaneous ESPC frequency and 
amplitude (Buckle and Haas, 1982)] as well as low-frequency electrical stimulation 
(0.2 Hz). These actions presumably increase the rate of internalisation of LEV 
molecules into the neurone, resulting in accelerated action. Interestingly, the same 
study revealed that the use of higher intensity stimulation (10 Hz compared to 0.2 
Hz) abolished any observed LEV effects in hippocampal slices (Meehan et al., 2011). 
A possible explanation for this observation is that LEV is still taken up by SVs, but is 
immediately released again due to the higher intensity of stimulation, thus negating 
the uptake overall. In my experiments, the use of a high KCl solution (50 mM) to 
clamp neurones in a membrane-depolarised state during incubation with LEV 
resulted in no observable drug effect on the recycling of SYP and VGLUT1. This 
result indicates that clamping the membrane potential in a depolarised state does not 
promote a LEV effect on the general SV recycling, which is in agreement with 
previously published data. Another possible reason for the lack of a LEV effect 
under elevated KCl conditions is the uptake of LEV by ADBE into bulk endosomes, 
since ADBE is the dominant mode of endocytosis under these conditions (Clayton et 
al., 2008). 
Interestingly, the use of 4-AP to increase spontaneous neuronal network activity 
during incubation of the neurones with LEV resulted in no significant effect on 
general SV recycling. Stimulation of the cells using low frequency electrical 
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stimulation (0.2 Hz) during incubation of neurones with LEV also revealed no 
significant LEV effect on general SV recycling. This is in contrast to previous 
observations by Meehan et.al where LEV was shown to have a modulating effect on 
synaptic activity in hippocampal slices. The lack of an observed drug effect cannot 
be attributed to a fault in the protocol for the generation of synaptic activity during 
LEV incubation, as control experiments showed that the use of 50 mM KCl and 75 
µM 4-AP in solution resulted in an observable increase in baseline neuronal activity, 
using intracellular free calcium as a reporter. There are several possible explanations 
for these observations: Firstly, although LEV has previously been documented to 
enter the synapse via binding to SV2A in SVs, there has been no clear evidence that 
the drug has a mode of action that alters SV recycling. If SV2A does play a part in 
the immobilisation and liberation of neurotransmitter as previously been suggested 
(Reigada et al., 2003), then LEV could alter the efficiency of neurotransmitter 
refilling in SVs. If SVs do not refill themselves efficiently, this may have an effect 
on the release probability of SVs. In support of this, recent optogenetic studies have 
suggested that incompletely filled SVs exhibit a lower release probability compared 
to full SVs (Rost et al., 2015). If this mode of action is true, it could be revealed by 
investigating on the effect of LEV on the frequency of spontaneous EPSCs in cell 
electrophysiological studies. Secondly, LEV may act specifically on inhibitory 
neurones with minimal effect on excitatory neurones. As hippocampal cell cultures 
contain a higher proportion of excitatory neurones, any potential LEV effect 
mediated by inhibitory neurones may be masked. Studies using SV2A L174Q 
missense mutant animals have demonstrated that dysfunction of SV2A preferentially 
disrupts action potential-induced GABA, but not glutamate, release in the limbic 
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regions of the brain (e.g. hippocampus) and greatly facilitates kindling 
epileptogenesis (Tokudome et al., 2016). This evidence suggests that the SV2A-
GABAergic system may play a crucial role in modulating epileptogenesis. If LEV 
has a mode of action at inhibitory neurones, future experiments to investigate SV 
recycling in inhibitory neurones by use of fluorescent anti-VGAT C antibodies to 
label cellular VGAT in vivo (Martens et al., 2008) may prove fruitful. Lastly, the 
previous experiments by Meehan demonstrated that the LEV effect was only 
observable when the concentrations of LEV used were significantly higher (300 µM) 
than the known clinically relevant concentrations used in treatment of epilepsy in 
humans [70-140 µM, (Leppik, 2002)]. When a lower LEV concentration was used in 
the key experiments of this study (100 µM), no significant LEV effect was observed. 
While it is clear that incubation of mammalian tissue with high concentrations of 
LEV revealed a drug effect on synaptic transmission within a shortened timeframe, 
more work needs to be done to affirm that this effect can be observed when LEV is 
used at clinically relevant doses. 
 
5.3.2 – Treatment of Neurones with LEV under Mild/Strong Synaptic Stimulation 
Does Not Affect Recycling of SYT1 
As SV2A has been previously shown to be an intrinsic trafficking partner for SYT1 
(chapter 3) as well as a binding partner for LEV, it is possible that LEV may have a 
role in modulating the recycling of SYT1, which is a key SV protein involved in the 
docking and fusion of vesicles at the presynapse. In experiments designed to probe 
the effect of LEV on SYT1 recycling, the use of 4-AP to increase spontaneous 
neuronal network activity during incubation of the neurones with LEV resulted in no 
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significant observed effect on SYT1 recycling. This is consistent with the results 
discussed above where LEV displayed no effect on general SV recycling. There are 
several explanations for the observed results. Firstly, it is possible that synaptic 
activity is a key factor in determining the onset of LEV’s anti-epileptic action in vivo. 
Previous pharmacokinetic research has indicated that concentration levels of LEV in 
cerebrospinal fluid reaches its peak within a few hours after initial oral 
administration, yet the onset of LEV’s anti-convulsant effect can take up to two days 
after treatment initiation (Stefan et al., 2006). This delayed onset of drug action could 
be explained by the requirement of synaptic activity to “load” LEV into presynaptic 
terminals, most likely by binding of LEV to SV2A and internalisation during SV 
recycling. Secondly, LEV may have a function in altering protein synthesis or 
protein degradation at the presynapse. This phenomenon would not have been 
observed using the assays used in this study. Future experiments probing the effect of 
LEV on protein translation and transport from the soma as well as the effect of LEV 
on classical endocytosis and protein ubiquitination in central synapses may shed 
further light on these hypotheses.  
 
5.3.3 – Implications of SV2A in Promoting a LEV Effect at the Presynapse 
If LEV exhibits no effect on general SV recycling or specific SYT1 recycling at the 
presynapse, then the role that SV2A plays in mediating LEV entry into the synaptic 
terminal must be further discussed. SV2A contains several putative LEV binding 
sites, thus there is a high possibility that SV2A may simply act as a carrier for the 
drug into the synapse and that LEV has a mode of action that is largely disconnected 
from SV recycling. The question remains: Is the LEV effect on synapses dependent 
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on the normal SV2A function? There is evidence to show that LEV has the ability to 
rescue deficits in SV2A and SYT1 expression and presynaptic localisation when 
SV2A is overexpressed, however no literature has been published which documents 
the effect of LEV on neurones where SV2A expression is ablated or SV2A function 
has been altered. Further immunofluorescence studies using LEV in SV2A 
knockdown cell cultures may provide further insight to the effects of LEV at the 
presynapse. If LEV does indeed rescue the expression of SV2A in an SV2A 
knockdown neurone, then it can be ascertained that the drug has a modulating effect 
on SV2A expression levels in neurones. Mechanisms of SV2A action can then be 
probed through further immunofluorescence loss-of-function experiments where 
SV2A knockdown is subsequently rescued using either SV2A mutants that exhibit 
defects in SV protein trafficking (e.g. Y46A, T84A), or  SV2A mutants where the 
LEV-binding site (W666) is mutated and ablated.  
Another question that remains unanswered is whether LEV has an effect on the 
recycling behaviour of SV2A itself. If SV2A is the intrinsic trafficking partner for 
SYT1 at the presynapse, then it follows that SYT1 recycling will be closely coupled 
to SV2A recycling. Since these results demonstrate that LEV has no observable 
effect on SYT1 recycling, it can be predicted that the drug would also exert no 
observable effects on the recycling of SV2A. Future live-cell, epifluorescence 
experiments in the presence of LEV using SV2A-pHluorin as a tool for observing 
SV2A trafficking will provide the platform for answering this key question. 
It is also possible that LEV has a mode of action on SV2A at inhibitory synapses 
rather than excitatory synapses. Traditional hippocampal culture preparations consist 
of predominantly excitatory synapses, with only around 6% of the total number of 
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cultured synapses being inhibitory (Benson et al., 1994). As a result, any presynaptic 
LEV effect at inhibitory synapses may not be revealed by the techniques used in this 
study. Further studies of a potential LEV effect on SV2A function in inhibitory 
synapse-enriched hippocampal cell cultures is required to provide a full picture. In 
conclusion, live-cell epifluorescence studies after 30-minute incubation with LEV 
have shown that there is no drug effect on the general SV and SYT1 recycling.  
  








6.0 – Final Discussion 
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6.1 – Final Discussion of Studies 
The sorting and retrieval of SV cargo from the presynaptic plasma membrane is a 
highly complex process with specific monomeric adaptor proteins such as AP-2 
playing a key role (Kelly and Owen, 2011). There is, however, evidence which 
indicates that certain SV proteins, such as SYP and SYB2, are intrinsically coupled 
and recycled as a complex during compensatory endocytosis (Gordon et al., 2011). 
The investigations in this thesis have provided evidence of a similar trafficking 
relationship between SV2A and SYT1 at the presynapse, and there is further 
evidence to indicate that defects in the trafficking of the SV2A/SYT1 complex 
caused by a point mutation may serve as an underlying mechanism for the cause of 
generalised epilepsy in humans. 
 
6.2 – SV2A and SYT1 are Intrinsic Trafficking Partners at the Presynapse 
The retrieval of SV2A during SV endocytosis is predominantly governed by the 
adaptor protein AP-2, whilst SYT1 is retrieved by the monomeric adaptor stonin-2 
(which itself binds to AP-2) during SV endocytosis. The experiments in this study 
have shown that the trafficking of SYT1 is greatly dependent on SV2A binding to 
both AP-2 and SYT1, since the defects in AP-2 SV2A binding led to increased 
surface expression, mislocalisation and accelerated retrieval of SYT1 during 
compensatory endocytosis. In agreement with this, the loss of stonin-2 at the synaptic 
terminal also results in increased surface expression and accelerated retrieval of 
SYT1 (Kononenko et al., 2013). These data suggest that the trafficking of SYT1 at 
the presynapse is tightly regulated by not just one specific adaptor protein, but 
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instead a synergistic effort between several key proteins. It is proposed that SYT1 
trafficking at the presynapse is dependent on two key factors: 1) the phosphorylation-
mediated binding of SYT1 to SV2A at residues at the C2B domain and 2) the 
binding of SYT1 to stonin-2 at the C2A domain. Since both stonin-2 and SV2A 
cargo are directed and sorted by AP-2 during SV endocytosis, it is likely that AP-2 
indirectly influences the endocytic sorting of SYT1 through its interactions with both 
SV2A and stonin-2. It is proposed that two different complexes are formed during 
SV CME that internalises SYT1 via two different mechanisms: 1) an AP-2-SV2A-
SYT1 complex which is dependent on the phosphorylation-mediated SV2A-SYT1 
interaction and 2) an AP-2-stonin-2-SYT1 complex which is independent of 
phosphorylation. Disruption of either pathway is therefore insufficient to cause total 
ablation of SYT1 trafficking, as the other sorting pathway is altered to maintain 
sufficient SYT1 retrieval for normal neurotransmission. In agreement with this, the 
Y46A SV2A mutation did not affect the retrieval of SYP in this study and the loss of 
stonin-2 also revealed no effect on endocytic sorting of SYP in earlier mentioned 
studies. In both cases, SYT1 retrieval is accelerated when their respective pathways 
were disrupted as opposed to retardation of retrieval normally observed when 
endocytic sorting mechanisms are disrupted. The lack of normal function in either 
SV2A or stonin-2 may trigger a cellular rescue mechanism by which SYT1 is 
retrieved by faster, clathrin-independent endocytic pathway such as ADBE or 
ultrafast endocytosis. On the bulk endosome that is formed, SV cargo sorting is 
predominantly mediated by AP-1 and AP-3, rather than AP-2, and thus a steady 
supply of SYT1 is maintained for presynaptic function. In support of this, electron 
micrographs and immunofluorescence experiments of stonin-2 deficient mice 
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hippocampal tissue has revealed profound decrease in the number and size of 
endosomal structures and a significant up-regulation of AP-1 at the synaptic boutons 
(Kononenko et al., 2013). 
 
6.3 – The Epilepsy-related R383Q SV2A Mutation Perturbs the AP-2-SV2A-SYT1 
CME Pathway 
The initial discovery of the homozygous R383Q mutation in SV2A leading to 
intractable epilepsy and involuntary movements in a five-year old South East Asian 
girl presented the first indication that SV2A dysfunction may play an underlying role 
in the onset of epileptogenesis (Serajee and Huq, 2015). Building on from earlier 
work, pHluorin imaging studies in this thesis has demonstrated that genetic 
knockdown and rescue of SV2A with a R383Q mutant variant led to an increased 
surface expression and mislocalisation of SYT1 at the synaptic terminal, an increased 
ratio of externalised SYT1 during SV exocytosis and an acceleration of its retrieval 
during SV endocytosis. This observed phenotype mimics those seen with the Y46A 
SV2A mutant as well as earlier data obtained from stonin-2 knockdown experiments, 
suggesting that the presence of the R383Q mutation in SV2A perturbs the 
abovementioned AP-2-SV2A-SYT1 retrieval pathway during CME.  
How the does R383Q mutation affect this CME pathway? One possibility that has 
already been discussed is that the R383 residue lies within known adenine-nucleotide 
binding sites of SV2A, suggesting that molecules such as ATP, ADP and AMP 
which are involved in cellular energy transfer may be transient binding partners for 
SV2A at the presynapse.  This is supported by observations that R383Q/E mutant 
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variants of the SV2A cytosolic loop resulted in altered protein interactions with 
certain subunits of V-ATPase. There is very currently little evidence to support the 
role of SV2A as a transporter protein in synaptic terminals, despite its highly 
conserved sequence homology with the MFS transporter family of proteins, thus it is 
unlikely that SV2A is solely responsible for the transport of ATP at the presynapse. 
The potential binding of adenine nucleotides to SV2A may however be critical for 
the retrieval of SYT1 during SV endocytosis, since the SV2A-SYT1 interaction is 
dependent upon the availability of inorganic phosphate carriers (such as ATP) for the 
phosphorylation of the T84A residue by TTBK 1/2 (Zhang et al., 2015). Disruption 
of the adenine nucleotide-binding site due to the R383Q mutation may therefore lead 
to defects in the phosphorylation of SV2A at T84 resulting in defective SYT1 
binding and therefore trafficking at the presynapse. In support of this, it has been 
previously documented that SV2A forms the core for an intra-vesicular matrix that is 
responsible for the immobilisation and release of ATP, thus regulating the 
availability of freely diffusible ATP (Reigada et al., 2003). The alteration of SV2A 
interaction with the cellular cytoskeleton may also be crucial to the localisation of 
SYT1 to synaptic terminals, since this study has shown that presence of the R383Q/E 
mutation leads to altered interactions with actin and tubulin, which are key 
cytoskeletal proteins. It is possible that the change in residue charge at 383 leads to 
localised protein misfolding, which may act to disrupt the ability of SV2A to bind to 
actin and tubulin thus leading to the mislocalisation of SV2A.  This theory is 
supported by recent unpublished SV2A-pHluorin studies revealing a significant 
increase in the surface expression of R383Q SV2A compared to WT SV2A (Dr. 
Callista Harper, Edinburgh, data not shown). 
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6.4 – There is a Lack of Evidence to Support a Mechanism for LEV Function via 
Modulation of the AP-2-SV2A-SYT1 CME Pathway 
SV2A is known to be a binding partner for the popular anti-epileptic drug, LEV, at 
the presynaptic terminal (Lynch et al., 2004), however it has not been determined 
whether SV2A dysfunction has an integral role in the onset of epilepsy-related 
symptoms or if it acts simply as a transporter of the drug into the presynapse.  It was 
initially hypothesised that the drug may have a mode of action at the AP-2-SV2A-
SYT1 CME pathway that is mediated by SV2A binding. The treatment of 
hippocampal cultures with LEV did not reveal any SV2A-mediated drug effects on 
the trafficking of SYT1 or SV recycling at the presynapse, suggesting that LEV does 
not have a mode of action mediated by the trafficking of the AP-2-SV2A-SYT1 
complex. This finding is in contrast with previously described work showing that 
LEV rescues normal levels of SV2A and SYT1 at the presynapse in SV2A knockout 
(Nowack et al., 2011), however this is likely explained by the differences in the 
incubation times and model systems used. Considering all evidence, it is most likely 
that entry of LEV into the synapse is mediated by SV2A binding and may have a 
significant effect on the expression and localisation of both SV2A and SYT1, 
however, it does not have a profound drug effect on the mechanisms involved in 
CME of SV2A and SYT1. 
 
6.5 – Model of SV2A-Mediated SYT1 Trafficking at the Presynaptic Terminal 
The trafficking of SV2A at the presynaptic terminal is mediated by binding to the 
adaptor protein AP-2 at residue Y46. SV2A itself binds to SYT1 and this interaction 
is mediated by phosphorylation of residue T84. It is proposed that these specific 
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interactions between SV2A, SYT1, stonin-2 and AP-2 at the synaptic terminal may 
aid the presentation of these SV cargos in the correct conformation needed for 
binding and clustering. This ensures maximum retrieval efficiency when all members 
are present and potential functional redundancy when one member is absent or 
mutated. The phosphorylation of SV2A may play a key regulatory role in this 
process, as it may mediate SYT1’s access to AP-2. Phosphorylated SV2A may bind 
to both the C2B domain of SYT1 as well as AP-2. This brings SYT1 and AP-2 to 
close proximity with each other and potentiates binding between AP-2 and the C2B 
domain of SYT1, facilitating the retrieval of SYT1 and SV endocytosis. Stonin-2 
continues to interact with the C2A and C2B domains of SYT1 as well as AP-2 in a 
separate mechanistic pathway to assist in SYT1 retrieval and endocytosis. The 
normal trafficking of SYT1 is dependent upon the fidelity of this process, and any 
perturbations to key interactions in the formation of this complex result in defective 
SYT1 expression and localisation at the plasma membrane and an acceleration of its 
retrieval during SV endocytosis. Disruption of the formation of the complex may be 
achieved either through ablation of any binding interactions between the three 
proteins (Y46, T84), or through disruption of key adenine-nucleotide binding motifs 
(R383) in SV2A. It is proposed that either arrestment of ATP binding at these sites in 
SV2A, or the misfolding of SV2A caused by the R383Q mutation, results in an 
inability of the protein to bind properly to SYT1. This causes downstream defects in 
SYT1 trafficking at the presynaptic terminal and may present an underlying 
mechanism in the onset of certain seizure phenotypes in humans. In support of this, 
previous clinical studies have demonstrated altered SYT1 expression in the temporal 
lobe tissue of patients with refractory epilepsy (Xiao et al., 2009). 





Figure 6.5: Model of SV2A-mediated SYT1 trafficking at the presynaptic terminal. The trafficking of 
SYT1 at the presynaptic terminal is partially mediated by formation of the AP-2-SV2A-SYT1 complex. 
Disruption of the formation of this complex via ablation of the AP-2-SV2A interaction (Y46A) or 
SV2A-SYT1 interaction (T84A) leads to aberrant localisation and expression of SYT1 at the plasma 
membrane and an acceleration of its retrieval during SV endocytosis. This acceleration may be 
explained by either an increased retrieval by other adaptor proteins such as stonin-2, or the retrieval 
of SYT1 by a faster alternative mechanism such as UFE/ADBE. The epilepsy-related R383Q SV2A 
mutation may perturb SYT1 retrieval through disruption of key adenine-nucleotide binding sites in 
SV2A, causing arrestment of ATP binding to SV2A that result in an inability of SV2A to bind properly 
to SYT1. SV2A protein misfolding caused by the R383Q mutation may also play a role in the 
disrupting normal SV2A-SYT1 interactions. 
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6.6 – Future Work 
There are a number of future studies that could be attempted in order to expand and 
clarify the mechanisms by which SV2A mediates the trafficking of SYT1 at the 
presynaptic terminal. 
 
6.6.1 – Retrieval of SYT1 by a Parallel Endocytic Mechanism When CME Pathway is 
Perturbed 
It has been proposed earlier that the acceleration of SYT1 retrieval due to defective 
SV2A binding may have due to the activation of a mode of endocytosis that operates 
on a faster timescale compared to CME. This mode of endocytosis may be ADBE or 
ultrafast endocytosis. Labelling of SYT1 during immunoelectron microscopy of 
hippocampal neurones after stimulation in the presence of Y46A SV2A or defective 
SYT1-binding stonin-2 may shed light on a possible increased accumulation of 
SYT1 on bulk endosomal structures compared to WT SV2A, thus providing 
evidence of ADBE as an alternative retrieval mechanism for SYT1 when CME is 
perturbed. In addition, a modified approach of the ‘flash-and-freeze’ cryo-electron 
microscopy technique (Watanabe et al., 2013b) to include SYT1 immunolabelling 
used on hippocampal tissue from Y46A SV2A or a stonin-2 knockout mice models 
may provide evidence of a role for ultrafast endocytosis in the retrieval of SYT1 
when CME is perturbed.  
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6.6.2 – The Dependency of SV2A-SYT1 Complex Formation on the Presence of ATP 
It has been proposed in this thesis that the R383Q mutation alters the AP-2-SV2A-
SYT1 complex. The R383 mutation lies within the adenine nucleotide binding region 
of SV2A, suggesting that ATP binding may play a key role in the maintenance of the 
AP-2-SV2A-SYT1 complex. Further SV2A/SYT1 affinity studies in the absence and 
presence of ATP may provide further insight on this hypothesis. In addition, 
biochemical experiments probing the capability of TTBK 1/2 to phosphorylate SV2A 
(Zhang et al., 2015) in the presence of the R383Q mutation would provide further 
support for the requirement of local presence of ATP for the formation of the SV2A-
SYT1 complex. If it were true that ATP is essential for the formation of the complex, 
then it would be interesting to determine the outcome when the second ATP binding 
site (residues 59-162) in SV2A is disrupted or ablated. Since this binding site is in far 
closer proximity to the SV2A-SYT1 binding site compared to the R383 site, it would 
be useful to probe if the two adenine-binding sites are have an equal influence on 
SV2A-SYT1 binding or if one site is dominant over the other. Experiments 
comparing the effect of double ablation of both binding sites compares to just a 
single ablation may provide further insight to the ablation of either adenine-binding 
site affects the same SYT1 retrieval pathway, or if the adenine-binding sites perform 
different roles for SV2A in SV recycling. Finally, it would be interesting to probe if 
the R383Q SV2A mutation activates parallel endocytic modes to aid in the retrieval 
of SYT1. Similar to experiments described above, SYT1-labelled immunoelectron 
microscopy or ‘flash-and-freeze’ experiments may reveal ADBE or ultrafast 
endocytosis as the primary mode of SYT1 retrieval when CME is perturbed. 
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6.6.3 – Probing the Involvement of the Neuronal Cytoskeleton on SYT1 Trafficking 
The discovery that the SV2A cytosolic loop interacts with actin and tubulin in 
pulldown experiments suggests that interaction between SV2A and the neuronal 
cytoskeleton may be a key step in the retrieval of SYT1 during SV endocytosis. It is 
possible that the neuronal cytoskeleton is involved in the siphoning of SYT1 and 
other SV cargo away from the active zone in preparation for its retrieval, thus 
clearing the release sites in preparation for the next round of SV fusion. A possible 
method to investigate this phenomenon would be the use of super-resolution imaging 
techniques such as stimulated emission depletion (STED) or photo-activated 
localization (PALM) microscopy that allows cell imaging at a resolution great 
enough to differentiate between the active and periactive zone. Quantification of the 
travelling distance between SYT1 and the active zone (using an active zone marker 
such as GFP-Piccolo) after stimulation in fixed hippocampal culture samples 
transfected with either WT SV2A or R383Q SV2A may provide further insight into 
the role of SV2A in the clearing of release site blockage at the active zone. Similar 
techniques probing the diffusional spread and confinement of exocytosed SV 
proteins using STED microscopy have been previously described (Gimber et al., 
2015). 
 
6.6.4 – A Possible Mode of LEV Action on SV Recycling in Inhibitory Neurones 
The lack of an observed LEV effect on SV recycling in this study may be attributable 
to a prevalent effect on inhibitory neurotransmission rather than excitatory. The viral 
transduction of the cells with an inhibitory synaptic marker such as GFP-fused (or its 
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coloured variants) versions of the vesicular GABA transporter (VGAT) or glutamate 
decarboxylase 1 (GAD1) in the presence of a GABA-ergic neurone-specific 
promoter (Rasmussen et al., 2007) may provide a means of identifying inhibitory 
synapses in prepared cultures of hippocampal neurones. SYT1-pHluorin imaging of 
these synapses will then provide further insight on a possible mode of LEV action on 
the inhibitory synaptic pathway.   
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